Piggybac transposase engineering
Hyperactive transposases with specific mutations and fusion proteins enable precise excision and targeting in human genomes, addressing the challenge of off-target effects and enhancing the safety and efficiency of gene therapy by allowing controlled transposition into specific genomic sites.
Patent Information
- Application Number
- PCT/US2024/027654
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-07
AI Technical Summary
Current transposon systems face challenges in efficiently targeting human genomes with reduced off-target effects, particularly in achieving precise excision without integration, which is crucial for generating induced pluripotent stem cells (iPSCs) without genetic changes.
Development of excision competent/integration defective (Exc+Int−) hyperactive transposases with specific mutations and fusion proteins like Cas9 or TALE DNA binding domains to enhance gene cleavage and targeting specificity, allowing for precise insertion of transgenes into genomic safe harbor sites.
The solution significantly reduces off-target effects and enhances the clinical safety of gene therapy by enabling precise and efficient transposition of therapeutic genes into specific genomic locations, minimizing mutagenic risks.
Smart Images

Figure US2024027654_07112024_PF_FP_ABST
Abstract
Description
[0001] PIGGYBAC TRANSPOSASE ENGINEERING FIELD The present disclosure relates to recombinant transposon systems and uses thereof. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No.63 / 500,139, filed on May 4, 2023, the entire content of which are hereby incorporated herein by reference in its entirety. SEQUENCE LISTING The instant application contains a sequence listing, which has been submitted in XML format via EFS-Web. The contents of the XML copy named “SAL-030PC_126933-5030_Sequence Listing,” which was created on May 3, 2024 and is 561,152 bytes in size, the contents of which are incorporated herein by reference in their entirety. BACKGROUND Transposable elements are genetic sequences that are found, with small exceptions, in all living organisms. Transposable elements, or transposons, have deep evolutionary origins and diversification, and have an astonishing variety of forms and shapes. A transposon movement to a new location in the human genome is performed by the action of a helper transposase enzyme that binds to an “end sequence” and inserts a donor DNA sequence at a specific DNA sequence such as the tetranucleotide, TTAA, by a “cut and paste” mechanism. The donor DNA is flanked by end sequences in living organisms such as insects (e.g., Trichnoplusia ni). Genomic DNA is excised by double strand cleavage at the hosts’ donor site and the donor DNA is integrated or inserted into a specific DNA sequence such as TTAA. A dual system that uses bioengineered transposons and transposases includes (1) a source of an active helper enzyme that “excises” a donor DNA flanked by the end recognition sequences and (2) inserts the donor sequence at a specific nucleotide sequence such as TTAA. Mobilization of the DNA sequences permits the intervening nucleic acid, or a transgene, to be inserted at the specific nucleotide sequence (i.e., TTAA) without a DNA footprint. The piggyBac transposon, from the looper moth, Trichnoplusa ni, is a bioengineered movable genetic element that transposes between vectors and human chromosomes through a “cut-and-paste” mechanism. Because it can excise precisely, a helper enzyme is especially useful if a transgene is only transiently required. To generate iPSCs without any genetic change, a helper enzyme mutant that promotes only excision (Exc+) and not integration (Int−), would be a useful tool. There is a need for compositions and methods that efficiently target human genomes with reduced risk of off-target effects. SUMMARY Accordingly, the present disclosure provides, inter alia, excision competent / integration defective (Exc+Int−) helper enzymes (hyperactive transposases) by introducing novel Exc+Int− mutations into a piggyBac helper enzyme and optionally an accompanying fusion protein with, e.g., a Cas9 protein devoid of nucleolytic activity or a TALE DNA binding domain or a zinc finger DNA binding domain. In embodiments, the helper enzymes are capable of specifically targeting to a location in the genome with or without being identified as Exc+Int-. The present disclosure, in embodiments, provides a composition comprising a recombinant transposase enzyme that has bioengineered enhanced gene cleavage [Excision (Exc+)] and / or integration deficient (Int-) and / or integration efficient (Int+) gene activity, and DNA binding domains (e.g., without limitation, a dCas9 or TALE or zinc finger) that guide donor insertion to specific genomic sites. In embodiments, there is provided a transposase enzyme or a nucleic acid encoding the enzyme, wherein the enzyme comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions N374X, K375X, R315X, L324X, N347X, R372X, S373X, R376X, E377X, K409X, and K412X of SEQ ID NO: 1, or a substitution at a position corresponding thereto. In embodiments, X is selected from a non-polar amino acid, optionally selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P), methionine (M), tryptophan (W), and phenylalanine (F), or a polar amino acid, optionally selected from serine (S), cysteine (C), asparagine (N), glutamine (Q), threonine (T), and tyrosine (Y), or a basic amino acid, optionally selected from arginine (R), and histidine (H), or an acidic amino acid, optionally selected from aspartic acid (D), and glutamic acid (E), or a positively charged hydrophilic amino acid, optionally selected from lysine (K), arginine (R), and histidine (H). In embodiments, the enzyme comprises one, or two, or three, or four, or five substitutions selected from N374A, K375A, R274A, R274S, R274K, R274D, R315A, R315K, R315S, R315E, R315Q, R315G, R315L, R315H, R315F, R315Y, L324A, D346A, N347A, N347D, R372A, R372K, R372H, R372S, R372Q, S373A, S373K, S373H, S373E, S373D, S373Q, S373G S373F, S373Y, S373L, S373R, N374S, N374K, N374H, N374E, N374Q, N374G, N374F, N374Y, N374L, N374W, K375S, K375Q, K375H, K375L, K375W, K375G, K375E, K375F, K375Y, R376A, R376K, R376E, R376S, R376Q, R376G, R376A, R376L, R376H, E377A, K409A, K409R, K409S, A411D, A411K, A411R, A411S, K412R, R459A, R459S, R459K, R459D, K460A, K460S, K460K, K460D, N462A, N462S, N462K, N462D, or substitutions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten substitutions at positions 374, 375, 30, 82, 103, 109, 165, 189, 191, 198, 201, 274, 282, 312, 313, 314, 315, 316, 321, 324, 346, 347, 362, 369, 370, 371, 372, 373, 376, 377, 378, 379, 380, 387, 388, 390, 400, 409, 411, 412, 425, 428, 450, 459, 460, 462, 500, 504, 509, 538, 571, and / or 591 or substitutions at positions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten, or eleven, or twelve substitutions selected from I30V, I82N, S103P, V109A, G165S, M282V, Y312A, D450N, S509G, N538K, N571S, and Q591R or substitutions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme comprises a substitution selected from Table 3, 4, and / or 13 or a substitution corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme further comprises a SV40 nuclear localization signal. In embodiments, the SV40 nuclear localization signal comprises an amino acid sequence of PKKKRKVYPYDVPDYAGS (SEQ ID NO: 656) or a variant thereof having a substitution or deletion. the SV40 nuclear localization signal is inserted immediately after residue M1 relative to SEQ ID NO: 1. In embodiments, the helper enzyme comprises a deletion of about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100 amino acids from an N-terminus or a C-terminus. In embodiments, the helper enzyme comprises a deletion of about 74 amino acids from the N-terminus. In embodiments, the helper enzyme comprises a deletion at positions about 1-35, or about 1-45, or about 1-55, or about 1-65, or about 1-75, or about 1-85, or about 1-95, or about 1-105 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1. In embodiments, the helper enzyme comprises a duplication of the C-terminal domain relative to SEQ ID NO:1. In embodiments, the C-terminal domain comprises residues 542-594 relative to SEQ ID NO: 1. In embodiments, the enzyme is able to cause excision of a nucleid acid. In embodiments, the enzyme has increased excision activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof. In embodiments, the enzyme has reduced or ablated integration activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof. In embodiments, the enzyme comprises a targeting element. In embodiments, the enzyme is capable of inserting a transposon, transgene and / or cargo nucleic acid comprising a transgene in a genomic safe harbor site (GSHS). In embodiments, the targeting element is able to direct a transposition machinery to the GSHS of a nucleic acid molecule in a mammalian cell. In embodiments, the GSHS is in an open chromatin location in a chromosome. In embodiments, the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus. In embodiments, the GSHS comprises one or more TTAA integration sites. In embodiments, the targeting element directs the helper enzyme to either one or more nucleic acid binding sites that are upstream and / or downstream of the TTAA integration sites or to the TTAA integration sites. In embodiments, the targeting element directs the helper enzyme to one or more nucleic acid binding sites that are upstream and / or downstream of the TTAA integration sites and within about 5 to about 30 base pairs of the TTAA integration sites or within about 11 to about 15 base pairs of the TTAA integration sites. In embodiments, the targeting element directs the helper enzyme to two nucleic acid binding sites of the TTAA integration sites, wherein a first site is upstream of TTAA and within about 5 to about 30 base pairs or about 11 to about 15 base pairs of the TTAA and a second site is downstream of TTAA and within about 5 to about 30 base pairs or about 11 to about 15 base pairs of the TTAA. In embodiments, the GSHS is an adeno-associated virus site 1 (AAVS1). In embodiments, the GSHS is a human Rosa26 locus. In embodiments, the GSHS is located on human chromosome 2, 4, 6, 10, 11, 17, or 22. In embodiments, the GSHS is selected from TALC1, TALC2, TALC3, TALC4, TALC5, TALC7, TALC8, AVS1, AVS2, AVS3, ROSA1, ROSA2, TALER1, TALER2, TALER3, TALER4, TALER5, SHCHR2-1, SHCHR2-2, SHCHR2-3, SHCHR2-4, SHCHR4-1, SHCHR4-2, SHCHR4-3, SHCHR6-1, SHCHR6-2, SHCHR6-3, SHCHR6-4, SHCHR10-1, SHCHR10-2, SHCHR10-3, SHCHR10-4, SHCHR10-5, SHCHR11-1, SHCHR11-2, SHCHR11-3, SHCHR17-1, SHCHR17-2, SHCHR17-3, and SHCHR17-4. In embodiments, the targeting element comprises one or more of a Cas enzyme, which is optionally catalytically inactive and which is optionally associated with a guide RNA (gRNA), transcription activator-like effector (TALE) DNA binding domain (DBD), Zinc finger, catalytically inactive transcription factor, catalytically inactive nickase, CRISPR / Cas enzymes (class I, class II), or their six subtypes (type I–VI), transcriptional activator, a transcriptional repressor, a recombinase, a DNA methyltransferase, a histone methyltransferase, or a paternally expressed gene 10 (PEG10). In embodiments, the targeting element comprises a Zinc finger. In embodiments, the Zinc finger comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 568 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 567 or a codon-optimized form thereof. In embodiments, the targeting element comprises a TALE DBD. In embodiments, the TALE DBD comprises one or more repeat sequences. In embodiments, the TALE DBD comprises about 14, or about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences. In embodiments, the repeat sequences each independently comprises about 33 or 34 amino acids. In embodiments, the repeat sequences each independently comprises a repeat variable di-residue (RVD) at residue 12 or 13 of the 33 or 34 amino acids, respectively. In embodiments, the RVD recognizes one base pair in a target nucleic acid sequence. In embodiments, the RVD recognizes a C residue in the target nucleic acid sequence and is selected from HD, N(gap), HA, ND, and HI. In embodiments, the RVD recognizes a G residue in the target nucleic acid sequence and is selected from NN, NH, NK, HN, and NA. In embodiments, the RVD recognizes an A residue in the target nucleic acid sequence and is selected from NI and NS. In embodiments, the RVD recognizes a T residue in the target nucleic acid sequence and is selected from NG, HG, H(gap), and IG. In embodiments, the targeting element comprises a Cas9 enzyme associated with a gRNA or a CasX enzyme associated with a gRNA. In embodiments, the Cas9 enzyme associated with a gRNA comprises a catalytically inactive dCas9 associated with a gRNA or the CasX enzyme associated with a gRNA comprises a catalytically inactive dCasX associated with a gRNA. In embodiments, the catalytically inactive dCas9 comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 9 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 10 or a codon-optimized form thereof. In embodiments, the targeting element comprises a CasX enzyme associated with a gRNA, optionally wherein the catalytic inactive dCasX. In embodiments, the targeting element comprises a Cas12 enzyme associated with a gRNA. In embodiments, the targeting element comprises a catalytically inactive Cas12 associated with a gRNA, optionally wherein the catalytically inactive Cas12 is dCas12j or dCas12a. In embodiments, the targeting element comprises a nucleic acid binding component of a gene-editing system. In embodiments, the composition comprises a linker connecting the enzyme and the targeting element. In embodiments, the linker is a covalent linker or a non-covalent linker. In embodiments, the linker is a flexible linker. In embodiments, the flexible linker is substantially comprised of glycine and serine residues, optionally wherein the flexible linker comprises (Gly4Ser)n, where n is an integer from 1-12. In embodiments, the flexible linker is a glycine-glycine linker. In embodiments, the flexible linker is of about 20, or about 30, or about 40, or about 50, or about 60 amino acid residues. In embodiments, the linker comprises an amino acid sequence of AKLAGGAPAVGGGPKAADKFAATGGS (SEQ ID NO: 3) or a variant thereof having a substitution or deletion. In embodiments, the linker connects the targeting element to the N-terminus of the helper enzyme or connects the targeting element within the helper enzyme. In embodiments, the linker is a non-covalent linker. In embodiments, the non-covalent linker comprises an epitope tag, optionally wherein the epitope tag comprises an ALFA tag. In embodiments, the ALFA tag further comprises recombinant variable domains of heavy-chain-only antibodies (VHH) (NANOBODY). In embodiments, the linker is inserted after a residue selected from V390, R315, T319, N320, G321, V322, P323, L324, R376, K383, N384, S385, R386, S387, R388, P389, G391, T392, S393, K407, P408, K409, P410, A411, K412, M413, or E428 relative to SEQ ID NO: 1. In embodiments, the enzyme is directly fused to the N-terminus of the dCas9 enzyme. In embodiments, the enzyme or variant thereof is able to directly or indirectly cause transposition of a target gene or nucleic acid cargo. In embodiments, the enzyme or variant thereof is able to directly or indirectly interact and / or form a complex with one or more proteins or nucleic acids. In embodiments, the composition further comprises a nucleic acid encoding a transposon or transgene to be integrated or inserted into a nucleic acid. In embodiments, the transposon, transgene and / or cargo nucleic acid comprises a cargo nucleic acid sequence and a first and a second transposon end sequences. In embodiments, the transposon, transgene and / or cargo nucleic acid is flanked by the first and the second transposon end sequences. In embodiments, the transposon end sequences are selected from nucleotide sequences of SEQ ID NO: 5 and / or SEQ ID NO: 6, or a nucleotide sequence having at least about 90% identity thereto. In embodiments, the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 5. In embodiments, the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 5 is positioned at the 5’ end of the transposon, transgene and / or nucleic acid. In embodiments, the end sequences can further include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 6. In embodiments, the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 6 is positioned at the 3’ end of the transposon, transgene and / or nucleic acid. In embodiments, the enzyme or variant thereof is incorporated into a vector or a vector-like particle. In embodiments, the vector or a vector-like particle comprises one or more expression cassettes. In embodiments, the vector or a vector- like particle comprises one expression cassette. In embodiments, the expression cassette further comprises the enzyme or variant thereof, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into one or more vectors or vector-like particles. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into a same vector or vector-like particle. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof is incorporated into different vectors vector-like particles. In embodiments, the vector or vector-like particle is nonviral. In embodiments, the composition comprises DNA, RNA, or both. In embodiments, the enzyme or variant thereof is in the form of RNA. In embodiments, the composition is a nucleic acid, optionally an RNA. In embodiments, the RNA is or comprises messenger RNA (mRNA). In embodiments, the mRNA is or comprises modified mRNA (mmRNA). In embodiments, the mRNA comprises one or more of a 5’-m7G cap (cap0, cap1, or cap2), a pseudouridine or n-methyl-pseudouridine substitution, and a poly-A tail of about 30, or of about 50, or of about 100, or of about 150 nucleotides in length. In embodiments, the transposon, transgene and / or nucleic acid is in the form of DNA. In embodiments, there is provided a host cel comprising the composition of the present disclosure. In embodiments, the composition is encapsulated in a lipid nanoparticle (LNP). In embodiments, the polynucleotide encoding the enzyme or variant thereof and the polynucleotide encoding the donor are in the form of the same LNP, optionally in a co-formulation. In embodiments, the LNP comprises one or more lipids selected from 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), a cationic cholesterol derivative mixed with dimethylaminoethane-carbamoyl (DC-Chol), phosphatidylcholine (PC), triolein (glyceryl trioleate), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol – 2000 (DMG-PEG 2K), and 1,2 distearol -sn-glycerol-3phosphocholine (DSPC) and / or comprising of one or more molecules selected from polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), and N-Acetylgalactosamine (GalNAc). In embodiments, there is provided a method for inserting a gene into the genome of a cell, comprising contacting a cell with the composition of the present disclosure or host cell of the present disclosure. In embodiments, the method of the present disclosure further comprises contacting the cell with a polynucleotide encoding a transposon, transgene, and / or nucleic acid. In embodiments, the transposon, transgene, and / or nucleic acid comprises a gene encoding a complete polypeptide. In embodiments, the transposon, transgene, and / or nucleic acid comprises a gene which is defective or substantially absent in a disease state. In embodiments, there is provided a method for treating a disease or disorder ex vivo, comprising contacting a cell with the composition of the present disclosure and administering the cell to a subject in need thereof. In embodiments, there is provided a method for treating a disease or disorder in vivo, comprising administering the composition of the present disclosure to a subject in need thereof. In embodiments, the present compositions and methods relate to or comprise one or more mutants or mutations of FIG.3, FIG.4, FIG.5, FIG.6, FIG.7, FIG.8, FIG.9, FIG.10, FIG.11, FIG.12, FIG.13, FIG.14, FIG.15, FIG.16, FIG. 17, FIG.18, FIG.19A, FIG.20, FIG.21, TABLE 3, TABLE 4, or TABLE 13 of SEQ ID NO: 1, or a substitution at a position corresponding thereto. In embodiments, the composition of the present disclosure comprises a transposase enzyme or a nucleic acid encoding the enzyme, wherein the enzyme comprises an amino acid sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 85% or a sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions shown in any one of FIG.3, FIG.4, FIG.5, FIG.6, FIG.7, FIG.8, FIG.9, FIG.10, FIG.11, FIG.12, FIG.13, FIG.14, FIG.15, FIG.16, FIG.17, FIG.18, FIG.19A, FIG.20, FIG.21, TABLE 3, TABLE 4, or TABLE 13 of SEQ ID NO: 1, or a substitution at a position corresponding thereto. BRIEF DESCRIPTION OF DRAWINGS FIG.1A and FIG.1B depict the effects of placing a zinc finger (ZnF) recognition site various distances on the right (R) and left (L) flanking a target TTAA. The gray arrow in FIG.1A points to the 9 bp spacing on either side of the target TTAA that results in the most enzyme activity. FIG.1B shows an example of the target sequence depicting the direction of the ZnF target sites and showing the spacing on either side of the target TTAA (bold). FIG.2 depicts a non-limiting proposed model whereby mutations (three asterisks) into the native DNA binding domain (DBD) reduce unwanted off-target integration. FIG.3 depicts a graph of DBD mutations that significantly reduce off-target insertion of targetable transposases. Bars with @ represent double ZnF target sites (double site), bars with # represent single ZnF target site (single site), and bars with $ represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 1 is mut 1 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R315A / R372A). FIG.4 depicts a 1.5% agarose gel with PCR amplicons that show specific targeting for DBD transposase mutants. The mutation numbers correspond to TABLE 13 (e.g., mut 1 is mut 1 in TABLE 13). “Double site” represents double ZnF target sites, and “neg” represents no ZnF target site. The mutation numbers correspond to TABLE 13 (e.g., mut 1 is mut 1 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. E2C right side 2x GGS linker represents GGS2linker placed on the right side of the Zinc finger. E2C flanking 4x GGS linker represents GGS4linkers placed on both sides of the Zinc finger. E2C flanking 6x GGS linker represents GGS6linkers placed on both sides of the Zinc finger. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A, R372A / R375A, and R315A / R372A). FIG.5 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 7 is mut 7 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A, R372A / R375A, and R315A / R372A). FIG.6 depicts a bar graph showing the results of site-specific integration into the human genome by a zinc finger (e.g., E2C)-pB fusion helper with DBD mutations using an artificial landing pad. First bar from the left represents no ZnF target site (neg), all other bars represent double ZnF target sites (dual site). The mutation numbers correspond to TABLE 13 (e.g., mut 7 is mut 7 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A, R372A / R375A, and R315A / R372A). FIG.7 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 7 is mut 7 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. Del74 represents deletion of the first 74 amino acid of the helper enzyme relative to SEQ ID NO: 1.2CD represents duplicating the C-terminal domain (residues 542-594 relative to SEQ ID NO: 1). LR2X represents two repeats of glycine-glycine-serine on both the left and right side of the ZnF. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A, R372A / R375A, and R315A / R372A). FIG.8 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 5 is mut 5 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.9 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 9 is mut 9 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A, R372A / R375A, and R315A / R372A). FIG.10 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 5 is mut 5 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A, R372A / R375A, and R315A / R372A). FIG.11 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 118 is mut 118 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. FIG.12 depicts a graph of DBD mutations that reduce off-target and increase on-target insertion. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 167 is mut 167 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. FIG.13 depicts a bar graph showing the results of site-specific integration into the human genome by a zinc finger (e.g., E2C)-pB fusion helper with DBD mutations using an artificial landing pad. Second bar from the left represents no ZnF target site (neg), all other bars represent double ZnF target sites (dual site). The mutation numbers correspond to TABLE 13 (e.g., mut 44 is mut 44 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.14 depicts a bar graph showing the results of site-specific integration into the human genome by a zinc finger (e.g., E2C)-pB fusion helper with del74 modifications using an artificial landing pad. Bars on the left of each DBD mutation represent double ZnF target sites (double site), bars on the right of each DBD mutation represent no ZnF target site (negative). The mutation numbers correspond to TABLE 13 (e.g., mut 17 is mut 17 in TABLE 13). E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. Del74 represents deletion of the first 74 amino acid of the helper enzyme relative to SEQ ID NO: 1.2CD represents duplicating the C-terminal domain (residues 542-594 relative to SEQ ID NO: 1). LR2X represents two repeats of glycine-glycine-serine on both the left and right side of the ZnF. LE RE represents standard left end and right end terminal repeats and LE LE represents two left end terminal repeats. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.15 depicts a bar graph showing the results of ZnF inserted into several piggyBac loop domains using reporter plasmids with the E2C target sequence at spacings of 7-11 bp from the target TTAA. For each condition, the bars from left to right represent 7 bp from the target TTAA (L7R7), 8 bp from the target TTAA (L8R8), 9 bp from the target TTAA (L9R9), 10 bp from the target TTAA (L10R10), 11 bp from the target TTAA (L11R11), and negative. E2C R315 represents insertion of the ZnF at residue R315 relative to SEQ ID NO: 1. E2C G321 represents insertion of the ZnF at residue G321 relative to SEQ ID NO: 1. E2C LR R376 represents insertion of the ZnF flanked by GGS4linkers on both the left side and right side of the ZnF at residue R376 relative to SEQ ID NO: 1. E2C K383 represents insertion of the ZnF at residue K383 relative to SEQ ID NO: 1. E2C S387 represents insertion of the ZnF at residue S387 relative to SEQ ID NO: 1. E2C V390 represents insertion of the ZnF at residue V390 relative to SEQ ID NO: 1. E2C S393 represents insertion of the ZnF at residue S393 relative to SEQ ID NO: 1. E2C LR K409 represents insertion of the ZnF flanked by GGS4linkers on both the left side and right side of the ZnF at residue K409 relative to SEQ ID NO: 1. E2C K409 represents insertion of the ZnF at residue K409 relative to SEQ ID NO: 1. E2C K412 represents insertion of the ZnF at residue K412 relative to SEQ ID NO: 1. E2C E428 represents insertion of the ZnF at residue E428 relative to SEQ ID NO: 1. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.16 depicts bar graphs showing the results of ZnF inserted into several piggyBac loop domains. For the bar graph on the left, in each condition, the bar on the left represent 9 bp from the target TTAA (L9R9) and the bar on the right represent no ZnF target site (negative). For the bar graph on the right, in each condition, the bars from left to right represent L9R9, L10R10, L11R11, 12 bp from the target TTAA (L12R12), 13 bp from the target TTAA (L13R13), 14 bp from the target TTAA (L14R14), 15 bp from the target TTAA (L15R15), and negative. E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. Hyper pB represents hyperactive piggyBac transposase. E2C LR R315 represents insertion of the ZnF flanked by GGS4linkers on both the left side and right side of the ZnF at residue R315 relative to SEQ ID NO: 1. E2C LR G321 represents insertion of the ZnF flanked by GGS4linkers on both the left side and right side of the ZnF at residue G321 relative to SEQ ID NO: 1. E2C K409 represents insertion of a zinc finger (e.g., E2C) after residue K409 corresponding to SEQ ID NO: 1. E2C LR K409 represents insertion of the ZnF flanked by GGS4linkers on both the left side and right side of the ZnF at residue K409 relative to SEQ ID NO: 1. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.17 depict a bar graph showing the results of ZnF inserted into positions K383-S393 of the piggyBac loop domain. For each condition, the bars from left to right represent 6 bp from the target TTAA (L6R6), L7R7, L8R8, L9R9, L10R10, L11R11, L12R12, and negative. Hyper pB represents hyperactive piggyBac transposase. E2C K383 represents insertion of a zinc finger (e.g., E2C) after residue K383 corresponding to SEQ ID NO: 1. E2C N384 represents insertion of a zinc finger (e.g., E2C) after residue N384 corresponding to SEQ ID NO: 1. E2C S385 represents insertion of a zinc finger (e.g., E2C) after residue S385 corresponding to SEQ ID NO: 1. E2C R386 represents insertion of a zinc finger (e.g., E2C) after residue R386 corresponding to SEQ ID NO: 1. E2C S387 represents insertion of a zinc finger (e.g., E2C) after residue S387 corresponding to SEQ ID NO: 1. E2C R388 represents insertion of a zinc finger (e.g., E2C) after residue R388 corresponding to SEQ ID NO: 1. E2C P389 represents insertion of a zinc finger (e.g., E2C) after residue P389 corresponding to SEQ ID NO: 1. E2C V390 represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. E2C G391 represents insertion of a zinc finger (e.g., E2C) after residue G391 corresponding to SEQ ID NO: 1. E2C T392 represents insertion of a zinc finger (e.g., E2C) after residue T392 corresponding to SEQ ID NO: 1. E2C S393 represents insertion of a zinc finger (e.g., E2C) after residue S393 corresponding to SEQ ID NO: 1. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.18 depict a bar graph showing the results of ZnF inserted into piggyBac loop domains wherein the ZnFs are connected using different linkers. For each condition, the bars from left to right represent L8R8, L9R9, L10R10, L11R11, L12R12, and negative. Hyper pB represents hyperactive piggyBac transposase. V390 E2C represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1. V390 GG E2C represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1, wherein a shorter GG linker connects the ZnF to the transposase. V390 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. G391 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue V390 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. T392 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue T392 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.19A – 19B depict results of E2C ZnF with a longer linker (e.g., 4x GGS linker on both the left and right side of the ZnF) was inserted at positions T319-V322 of the piggyBac loop domain. FIG.19A is a bar graph showing the results of ZnF inserted into piggyBac loop domain. For each condition, the bars from left to right represent L11R11, L12R12, L13R13, L14R14, L15R15 and negative. FIG.19B is a gel showing the results of ZnF with longer linkers inserted at positions N320, G321, and V322 of the piggyBac loop domain. Hyper pB represents hyperactive piggyBac transposase. T319 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue T319 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. N320 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue N320 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. G321 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue G321 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. V322 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue V322 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.20 depict a bar graph showing the results of ZnF with longer linkers inserted into positions G321-L324 of the piggyBac loop domain. For each condition, the bars from left to right represent L12R12, L13R13, L14R14, L15R15, L16R16 and negative. Hyper pB represents hyperactive piggyBac transposase. G321 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue G321 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. V322 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue V322 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. P323 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue P323 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. L324 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue L324 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). FIG.21 depict a bar graph showing the results of ZnF with longer linkers inserted into positions K407-M413 of the piggyBac loop domain. For each condition, the bars from left to right represent L8R8, L9R9, L11R11, L12R12, L13R13 and negative. Hyper pB represents hyperactive piggyBac transposase. K407 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue K407 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. P408 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue P408 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. K409 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue K409 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. P410 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue P410 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. A411 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue A411 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. K412 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue K412 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. M413 E2C LR represents insertion of a zinc finger (e.g., E2C) after residue M413 corresponding to SEQ ID NO: 1, wherein GGS4linkers connecting the ZnF to the transposase are placed on both the left and right side of the ZnF. All residue substitutions are relative to SEQ ID NO: 1 (e.g., R372A). DETAILED DESCRIPTION The present invention is based, in part, on the discovery of certain methods, compositions, and products for synthesizing a bioengineered pB transposase that target a TTAA tetranucleotide site in the human genome is a site- specific manner. The targeting methods in accordance with the present disclosure, in embodiments, find use in bioengineering a mutant (Exc+ / Int-) pB transposase with synthetic DNA binders that bind 9 bp from the target TTAA The described methods and compositions, in embodiments, employ transposition of therapeutic gene or gene product. The described methods and compositions, in embodiments, improve the clinical safety profile of human gene therapy by reducing off-target effects and their potential mutagenic or oncogenic effects in patients. In embodiments, the present disclosure provides a piggyBac with its N-terminus truncated, in whole or in part. In embodiments, a linking domain is fused to the N-terminal region of the present piggyBac. In embodiments, the linking domains are inserted into the flexible loop domains of the piggyBac. Without wishing to be bound by theory, the linking domains, e.g., fused to the N-terminus or inserted into the flexible loop domains, links the transposase to a separate linking domain fused to a DNA binding domain. In embodiments, the DNA binding domain is inserted into the flexible loop domains. In embodiments, the insertion of the linking domains into the loops of piggyBac is tolerated. In embodiments, excision activity is maintained after inserting the linking domains into the loops of piggyBac. In embodiments, the insertion of a ZNF directed to bind AAVS1 is provided. In embodiments, excision activity is maintained upon inserting a ZNF directed to bind AAVS1. In embodiments, the present disclosure provides a method to measure targeting events. In embodiments, a transposon that is targeted to a target sequence on a plasmid result in GFP expression. In embodiments, the present disclosure provides an assay that tests for successful targeting to a target sequence. In embodiments, the assay can be used to evaluate different targeting strategies. In embodiments, integration-negative mutant can target when the DNA binding domain is located within loops, when bound to the N-terminal, when separated by a linking domain at the N-terminal, and / or when separated by a linking domain inserted into a loop. In embodiments, the DNA binding domain is inserted into the N-terminal flexible region. In embodiments, the insertion of the DNA binding domain into the N-terminal flexible region can result in targeting. In embodiments, the N-terminal flexible region is positions at amino acids 24-128, or positions corresponding thereto, of SEQ ID NO: 1. In embodiments, the fusion of the DNA binding domain to the N-terminal truncation mutants that are integration- negative is suitable for targeting. In embodiments, direct fusions to the N-terminal truncation results in targeting. In embodiments, using a linking-domain results in targeting. In embodiments, when the DNA binding domain is omitted, no integration occurs. Without wishing to be bound by theory, the addition of the DNA binding domain rescues targeted integration. In embodiments, in the absence of the DNA binding domain, the integration negative mutant has minimal or no integration activity, as assessed by the targeting assay. In embodiments, the targeted integration is rescued when the DNA binding domain is fused to the N-terminal. In embodiments, the targeted integration is rescued when it is connected by a linking domain. In embodiments, the insertion of a zinc finger (e.g., E2C) into a loop domain promotes highly specific targeting. In embodiments, an exemplary loop domain is V390 (or a position corresponding thereto with reference to SEQ ID NO: 1). In embodiments, the off-target is reduced significantly for the V390 loop insert. In embodiments, most of the inserts occur near the zinc finger target sequence, e.g., as shown by PCR of the plasmid to plasmid. In embodiments, the products were sequenced to verify the location of the inserts. In aspects, there is provided a composition comprising an enzyme and a targeting element which directs the enzyme to a target site, optionally a genomic safe harbor site (GSHS), wherein the enzyme is a piggyBac transposase which comprises one or more mutations which cause decreased or ablated integration activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof. In embodiments, the piggyBac transposase comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions R315X, L324X, N347X, R372X, S373X, N374X, K375X, R376X, E377X, K409X, and K412X of SEQ ID NO: 1, or a substitution at a position corresponding thereto. In embodiments, X is selected from a non-polar amino acid, optionally selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P), methionine (M), tryptophan (W), and phenylalanine (F), or a polar amino acid, optionally selected from serine (S), cysteine (C), asparagine (N), glutamine (Q), threonine (T), and tyrosine (Y), or a basic amino acid, optionally selected from arginiI(R), and histidine (H), or an acidic amino acid, optionally selected from aspartic acid (D), and glutamic acI(E), or a positively charged hydrophilic amino acid, optionally selected from lysine (K), arginiI(R), and histidine (H). In embodiments, the piggyBac transposase comprises one, or two, or three, or four, or five substitutions selected from N374A, K375A, R274A, R274S, R274K, R274D, R315A, R315K, R315S, R315E, R315Q, R315G, R315L, R315H, R315F, R315Y, L324A, D346A, N347A, N347D, R372A, R372K, R372H, R372S, R372Q, S373A, S373K, S373H, S373E, S373D, S373Q, S373G S373F, S373Y, S373L, S373R, N374S, N374K, N374H, N374E, N374Q, N374G, N374F, N374Y, N374L, N374W, K375S, K375Q, K375H, K375L, K375W, K375G, K375E, K375F, K375Y, R376A, R376K, R376E, R376S, R376Q, R376G, R376A, R376L, R376H, E377A, K409A, K409R, K409S, A411D, A411K, A411R, A411S, K412R, R459A, R459S, R459K, R459D, K460A, K460S, K460K, K460D, N462A, N462S, N462K, N462D, or substitutions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the piggyBac transposase further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten, or eleven, or twelve substitutions at positions 374, 375, 30, 82, 103, 109, 165, 189, 191, 198, 201, 274, 282, 312, 313, 314, 315, 316, 321, 324, 346, 347, 362, 369, 370, 371, 372, 373, 376, 377, 378, 379, 380, 387, 388, 390, 400, 409, 411, 412, 425, 428, 450, 459, 460, 462, 500, 504, 509, 538, 571, and / or 591 or substitutions at positions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the piggyBac transposase further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten substitutions selected from I30V, I82N, S103P, V109A, G165S, M282V, Y312A, D450N, S509G, N538K, N571S, and Q591R or substitutions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the piggyBac transposase comprises a substitution selected from Table 3, 4, and / or 13 or a substitution corresponding thereto relative to SEQ ID NO: 1. In embodiments, the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus. In embodiments, the targeting element comprises one or more of a Cas enzyme, which is optionally catalytically inactive and which is optionally associated with a guide RNA (gRNA), transcription activator-like effector (TALE) DNA binding domain (DBD), Zinc finger, catalytically inactive transcription factor, catalytically inactive nickase, a transcriptional activator, a transcriptional repressor, a recombinase, a DNA methyltransferase, a histone methyltransferase, and a paternally expressed gene 10 (PEG10). In embodiments, the piggyBac comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from the N-terminus and / or C-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion at positions about 1- 35, or about 1-45, or about 1-55, or about 1-65, or about 1-75, or about 1-85, or about 1-95, or about 1-105 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1, wherein the deletion comprises an N or C terminal deletion. In embodiments, the N or C terminal deletion yields reduced or ablated off-target effects of the enzyme compared to the enzyme without the N- or C-terminal deletion. In embodiments, the enzyme comprises one or more N- or C-terminal deletions of TABLE 11. In embodiments, the enzyme and the targeting element are fused to one another or linked via a linker or linker domain to one another. In embodiments, the targeting element and / or the linker or linker domain are fused to the N- or C- terminus of the enzyme or inserted into the enzyme at one or more internal loops of the enzyme. In embodiments, the enzyme comprises an insertion in a loop domain of selected from one or more the domains of TABLE 12, with reference to SEQ ID NO: 1. In embodiments, the enzyme comprises an insertion at positions V371-I378, Y312-V322, K407-M413, S385-T392, A424-K432, K383-S393, T319-V322, G321-L324 and / or R275-K290 or positions V390, R315, G321, R376, S387, K409, and / or E428 or positions corresponding thereto, with reference to SEQ ID NO: 1. In embodiments, the enzyme comprises an insertion at position V390or position corresponding thereto, with reference to SEQ ID NO: 1 In aspects, there is provided a composition comprising an enzyme and a targeting element which directs the enzyme to a target site, optionally a genomic safe harbor site (GSHS) and optionally a linker or linking domain which connects the enzyme and targeting element, wherein the enzyme is a piggyBac transposase and the targeting element and / or linker or linking domain are fused to the N- or C-terminus of the piggyBac transposase or inserted into the piggyBac transposase at one or more internal loops of the enzyme. In embodiments, the enzyme comprises an insertion in a loop domain of selected from one or more the domains of TABLE 12, with reference to SEQ ID NO: 1. In embodiments, the enzyme comprises an insertion at positions V371- I378, Y312-V322, K407-M413, S385-T392, A424-K432, K383-S393, T319-V322, G321-L324 and / or R275-K290 or positions V390, R315, G321, R376, S387, K409, and / or E428 or positions corresponding thereto, with reference to SEQ ID NO: 1. In embodiments, the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus. In embodiments, the targeting element comprises one or more of a Cas enzyme, which is optionally catalytically inactive and which is optionally associated with a guide RNA (gRNA), transcription activator-like effector (TALE) DNA binding domain (DBD), Zinc finger, catalytically inactive transcription factor, catalytically inactive nickase, a transcriptional activator, a transcriptional repressor, a recombinase, a DNA methyltransferase, a histone methyltransferase, and a paternally expressed gene 10 (PEG10). In embodiments, the piggyBac comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from the N-terminus and / or C-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion at positions about 1- 35, or about 1-45, or about 1-55, or about 1-65, or about 1-75, or about 1-85, or about 1-95, or about 1-105 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1, wherein the deletion comprises an N or C terminal deletion. In embodiments, the N or C terminal deletion yields reduced or ablated off-target effects of the enzyme compared to the enzyme without the N- or C-terminal deletion. In embodiments, the enzyme comprises one or more N- or C-terminal deletions of TABLE 11. In embodiments, the composition is a nucleic acid, optionally an RNA. In embodiments, the composition further comprises a donor nucleic acid and / or is suitable for inserting a donor nucleic acid into a genome. In embodiments, the donor nucleic acid is or comprises DNA. In embodiments, the composition is in the form of a lipid nanoparticle (LNP). In embodiments, the nucleic acid encoding the enzyme and the donor nucleic acid are in the same LNP. In embodiments, the present disclosure provides a host cell comprising the LNP of the present disclosure. In aspects, there is provided a method for inserting a gene into the genome of a cell, comprising contacting a cell with the composition described herein. In aspects, there is provided a method for treating a disease or disorder ex vivo, comprising contacting a cell with the composition described herein and administering the cell to a subject in need thereof. In aspects, there is provided a method for treating a disease or disorder in vivo, comprising administering the composition described herein to a subject in need thereof. In embodiments, the present disclosure is based, in part, on the discovery that a novel combination of mutations on the piggyBac transposase enzyme unexpectedly result in a significant increase in transposition activity by the transposase enzyme. In aspects, there is provided the novel piggyBac transposase enzyme, hereinafter “hyperactive transposase”, that is engineered further to be excision positive. In aspects, there is provided a hyperactive transposase that is integration deficient. In yet other aspects, there is provided a hyperactive transposase that is excision positive and integration deficient. In aspects, there is provided a system and method of making a hyperactive transposase that is both excision positive and integration deficient. In aspects of the present disclosure, the hyperactive transposase, system, or method serves as a novel tool in gene therapy. The transposon system (e.g., without limitation, the hyperactive transposase) utilizes the specificity of a targeting element (e.g., without limitation, a DNA-binding domain) to particular sites within a host genome, which allows using the targeting element to target any desired location in the genome. Without wishing to be bound by theory, the excision positive and integration deficient characteristics of the transposase are due to mutations that disrupt target DNA binding. Insertion at non-targeted sites is prevented due to excision positive and integration deficient characteristics of the transposase. Without wishing to be bound by theory, the insertion is rescued at the target sequence due to the re-location of the transposase to the target DNA by the DNA binding domain. In this way, the hyperactive transposase, system, or method in accordance with the present disclosure allows achieving targeted integration of a transgene. The piggyBac transposon became a useful tool for genetic manipulation of mammalian cells beginning in 2005. Woodard, L. E., & Wilson, M. H. (2015). piggyBac-ing models and new therapeutic strategies. Trends in Biotechnology, 33(9), 525-533. Like other transposons, piggyBac transposon has two components, a transposon and a transposase. The piggyBac transposase facilitates the integration of the transposon specifically at TTAA sites randomly dispersed in the genome. The predicted frequency of TTAA in the genome is 1 in every 256 base-pairs of DNA sequence, making piggyBac transposon very useful for genetic engineering approaches. The piggyBac transposase unique feature of enabling the excision of the transposon in a completely seamless manner, such that it leaves no sequences or mutations behind, make PiggyBac transposon a very valuable tool. Furthermore, piggyBac offers a large cargo-carrying capacity (over 200 kb has been demonstrated) with no known upper limit. Woodard, L. E., & Wilson, M. H. (2015). piggyBac-ing models and new therapeutic strategies. Trends in Biotechnology, 33(9), 525-533. The piggyBac technology can be used for numerous applications, including transgenesis, gene-trap screens, and gene editing. Transposase Enzyme In embodiments, there is provided a transposase enzyme or a nucleic acid encoding the enzyme, wherein the enzyme comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions R315X, L324X, N347X, R372X, S373X, N374X, K375X, R376X, E377X, K409X, and K412X of SEQ ID NO: 1, or a substitution at a position corresponding thereto. SEQ ID NO: 1: amino acid sequence of piggyBac transposase (594 aa) (GENBANK ACC. No. AAA87375.2) 1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE 51 VHEVQPTSSG SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST 101 SKSTRRSRVS ALNIVRSQRG PTRMCRNIYD PLLCFKLFFT DEIISEIVKW 151 TNAEISLKRR ESMTGATFRD TNEDEIYAFF GILVMTAVRK DNHMSTDDLF 201 DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV FTPVRKIWDL 251 FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD 301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT 351 SIPLAKNLLQ EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP 401 LTLVSYKPKP AKMVYLLSSC DEDASINEST GKPQMVMYYN QTKGGVDTLD 451 QMCSVMTCSR KTNRWPMALL YGMINIACIN SFIIYSHNVS SKGEKVQSRK 501 KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV PGTSDDSTEE 551 PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 1. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 1. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 1. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 1. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 1. SEQ ID NO: 2: nucleotide sequence encoding the wild-type piggyBac transposase (2472 nt) (GENBANK ACC. No. J04364.2) 1 ccctagaaag atagtctgcg taaaattgac gcatgcattc ttgaaatatt gctctctctt 61 tctaaatagc gcgaatccgt cgctgtgcat ttaggacatc tcagtcgccg cttggagctc 121 ccgtgaggcg tgcttgtcaa tgcggtaagt gtcactgatt ttgaactata acgaccgcgt 181 gagtcaaaat gacgcatgat tatcttttac gtgactttta agatttaact catacgataa 241 ttatattgtt atttcatgtt ctacttacgt gataacttat tatatatata ttttcttgtt 301 atagatatcg tgactaatat ataataaaat gggtagttct ttagacgatg agcatatcct 361 ctctgctctt ctgcaaagcg atgacgagct tgttggtgag gattctgaca gtgaaatatc 421 agatcacgta agtgaagatg acgtccagag cgatacagaa gaagcgttta tagatgaggt 481 acatgaagtg cagccaacgt caagcggtag tgaaatatta gacgaacaaa atgttattga 541 acaaccaggt tcttcattgg cttctaacag aatcttgacc ttgccacaga ggactattag 601 aggtaagaat aaacattgtt ggtcaacttc aaagtccacg aggcgtagcc gagtctctgc 661 actgaacatt gtcagatctc aaagaggtcc gacgcgtatg tgccgcaata tatatgaccc 721 acttttatgc ttcaaactat tttttactga tgagataatt tcggaaattg taaaatggac 781 aaatgctgag atatcattga aacgtcggga atctatgaca ggtgctacat ttcgtgacac 841 gaatgaagat gaaatctatg ctttctttgg tattctggta atgacagcag tgagaaaaga 901 taaccacatg tccacagatg acctctttga tcgatctttg tcaatggtgt acgtctctgt 961 aatgagtcgt gatcgttttg attttttgat acgatgtctt agaatggatg acaaaagtat 1021 acggcccaca cttcgagaaa acgatgtatt tactcctgtt agaaaaatat gggatctctt 1081 tatccatcag tgcatacaaa attacactcc aggggctcat ttgaccatag atgaacagtt 1141 acttggtttt agaggacggt gtccgtttag gatgtatatc ccaaacaagc caagtaagta 1201 tggaataaaa atcctcatga tgtgtgacag tggtacgaag tatatgataa atggaatgcc 1261 ttatttggga agaggaacac agaccaacgg agtaccactc ggtgaatact acgtgaagga 1321 gttatcaaag cctgtgcacg gtagttgtcg taatattacg tgtgacaatt ggttcacctc 1381 aatccctttg gcaaaaaact tactacaaga accgtataag ttaaccattg tgggaaccgt 1441 gcgatcaaac aaacgcgaga taccggaagt actgaaaaac agtcgctcca ggccagtggg 1501 aacatcgatg ttttgttttg acggacccct tactctcgtc tcatataaac cgaagccagc 1561 taagatggta tacttattat catcttgtga tgaggatgct tctatcaacg aaagtaccgg 1621 taaaccgcaa atggttatgt attataatca aactaaaggc ggagtggaca cgctagacca 1681 aatgtgttct gtgatgacct gcagtaggaa gacgaatagg tggcctatgg cattattgta 1741 cggaatgata aacattgcct gcataaattc ttttattata tacagccata atgtcagtag 1801 caagggagaa aaggttcaaa gtcgcaaaaa atttatgaga aacctttaca tgagcctgac 1861 gtcatcgttt atgcgtaagc gtttagaagc tcctactttg aagagatatt tgcgcgataa 1921 tatctctaat attttgccaa atgaagtgcc tggtacatca gatgacagta ctgaagagcc 1981 agtaatgaaa aaacgtactt actgtactta ctgcccctct aaaataaggc gaaaggcaaa 2041 tgcatcgtgc aaaaaatgca aaaaagttat ttgtcgagag cataatattg atatgtgcca 2101 aagttgtttc tgactgacta ataagtataa tttgtttcta ttatgtataa gttaagctaa 2161 ttacttattt tataatacaa catgactgtt tttaaagtac aaaataagtt tatttttgta 2221 aaagagagaa tgtttaaaag ttttgttact ttatagaaga aattttgagt ttttgttttt 2281 ttttaataaa taaataaaca taaataaatt gtttgttgaa tttattatta gtatgtaagt 2341 gtaaatataa taaaacttaa tatctattca aattaataaa taaacctcga tatacagacc 2401 gataaaacac atgcgtcaat tttacgcatg attatcttta acgtacgtca caatatgatt 2461 atctttctag gg In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 1 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. In embodiments, X is selected from a non-polar amino acid, optionally selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P), methionine (M), tryptophan (W), and phenylalanine (F), or a polar amino acid, optionally selected from serine (S), cysteine (C), asparagine (N), glutamine (Q), threonine (T), and tyrosine (Y), or a basic amino acid, optionally selected from arginiI(R), and histidine (H), or an acidic amino acid, optionally selected from aspartic acid (D), and glutamic acI(E), or a positively charged hydrophilic amino acid, optionally selected from lysine (K), arginiI(R), and histidine (H). In embodiments, the enzyme comprises one, or two, or three, or four, or five substitutions selected from N374A, K375A, R274A, R274S, R274K, R274D, R315A, R315K, R315S, R315E, R315Q, R315G, R315L, R315H, R315F, R315Y, L324A, D346A, N347A, N347D, R372A, R372K, R372H, R372S, R372Q, S373A, S373K, S373H, S373E, S373D, S373Q, S373G S373F, S373Y, S373L, S373R, N374S, N374K, N374H, N374E, N374Q, N374G, N374F, N374Y, N374L, N374W, K375S, K375Q, K375H, K375L, K375W, K375G, K375E, K375F, K375Y, R376A, R376K, R376E, R376S, R376Q, R376G, R376A, R376L, R376H, E377A, K409A, K409R, K409S, A411D, A411K, A411R, A411S, K412R, R459A, R459S, R459K, R459D, K460A, K460S, K460K, K460D, N462A, N462S, N462K, N462D, or substitutions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten substitutions at positions 374, 375, 30, 82, 103, 109, 165, 189, 191, 198, 201, 274, 282, 312, 313, 314, 315, 316, 321, 324, 346, 347, 362, 369, 370, 371, 372, 373, 376, 377, 378, 379, 380, 387, 388, 390, 400, 409, 411, 412, 425, 428, 450, 459, 460, 462, 500, 504, 509, 538, 571, and / or 591 or substitutions at positions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten substitutions selected from I30V, I82N, S103P, V109A, G165S, M282V, Y312A, D450N, S509G, N538K, N571S, and Q591R or substitutions corresponding thereto relative to SEQ ID NO: 1. In embodiments, the enzyme comprises a substitution selected from Table 3, 4, and / or 13 or a substitution corresponding thereto relative to SEQ ID NO: 1. TABLE 3. Non-limiting examples of hyperactive transposase mutants with excision activity TABLE 4. Non-limiting examples of hyperactive transposase integration deficient mutants Table 13: Non-limiting examples of piggyBac DNA binding mutants that exhibit excision activity and decreased integration activity.
[0002] In embodiments, the enzyme is able to cause excision of a nucleic acid. In embodiments, the enzyme has increased excision activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof. In embodiments, the enzyme has reduced or ablated integration activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof. In embodiments, the enzyme comprises a targeting element. In embodiments, the enzyme is capable of inserting a transposon, transgene and / or cargo nucleic acid comprising a transgene in a genomic safe harbor site (GSHS). In embodiments, the targeting element is able to direct a transposition machinery to the GSHS of a nucleic acid molecule in a mammalian cell. In embodiments, the GSHS is in an open chromatin location in a chromosome. In embodiments, the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus. In embodiments, the GSHS is an adeno-associated virus site 1 (AAVS1). In embodiments, the GSHS is a human Rosa26 locus. In embodiments, the GSHS is located on human chromosome 2, 4, 6, 10, 11, 17, or 22. In embodiments, the GSHS is selected from TALC1, TALC2, TALC3, TALC4, TALC5, TALC7, TALC8, AVS1, AVS2, AVS3, ROSA1, ROSA2, TALER1, TALER2, TALER3, TALER4, TALER5, SHCHR2-1, SHCHR2-2, SHCHR2-3, SHCHR2-4, SHCHR4-1, SHCHR4-2, SHCHR4-3, SHCHR6-1, SHCHR6-2, SHCHR6-3, SHCHR6-4, SHCHR10-1, SHCHR10-2, SHCHR10-3, SHCHR10-4, SHCHR10-5, SHCHR11-1, SHCHR11-2, SHCHR11-3, SHCHR17-1, SHCHR17-2, SHCHR17-3, and SHCHR17-4. In embodiments, the targeting element comprises one or more of a Cas enzyme, which is optionally catalytically inactive and which is optionally associated with a guide RNA (gRNA), transcription activator-like effector (TALE) DNA binding domain (DBD), Zinc finger, catalytically inactive transcription factor, catalytically inactive nickase, CRISPR / Cas enzymes (class I, class II), or their six subtypes (type I–VI), transcriptional activator, a transcriptional repressor, a recombinase, a DNA methyltransferase, a histone methyltransferase, or a paternally expressed gene 10 (PEG10). In embodiments, the targeting element comprises a TALE DBD. In embodiments, the TALE DBD comprises one or more repeat sequences. In embodiments, the TALE DBD comprises about 14, or about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences. In embodiments, the repeat sequences each independently comprises about 33 or 34 amino acids. In embodiments, the repeat sequences each independently comprises a repeat variable di-residue (RVD) at residue 12 or 13 of the 33 or 34 amino acids, respectively. In embodiments, the RVD recognizes one base pair in a target nucleic acid sequence. In embodiments, the RVD recognizes a C residue in the target nucleic acid sequence and is selected from HD, N(gap), HA, ND, and HI. In embodiments, the RVD recognizes a G residue in the target nucleic acid sequence and is selected from NN, NH, NK, HN, and NA. In embodiments, the RVD recognizes an A residue in the target nucleic acid sequence and is selected from NI and NS. In embodiments, the RVD recognizes a T residue in the target nucleic acid sequence and is selected from NG, HG, H(gap), and IG. In embodiments, the targeting element comprises a Cas9 enzyme associated with a gRNA. In embodiments, the Cas9 enzyme associated with a gRNA comprises a catalytically inactive dCas9 associated with a gRNA. In embodiments, the targeting element comprises a CasX enzyme associated with a gRNA. In embodiments, the CasX enzyme associated with a gRNA comprises a catalytically inactive dCasX associated with a gRNA. In embodiments, the targeting element comprises a CasX enzyme associated with a gRNA, optionally wherein the catalytic inactive dCasX. In embodiments, the catalytically inactive dCas9 comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 9 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 10 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon-optimized form thereof. In embodiments, the targeting element comprises CRISPR / Cas enzymes (class I, class II), or their six subtypes (type I–VI) (e.g., (type I–VI) (e.g., Cas12a, Cas12j, Cas12k) associated with gRNA (s). In embodiments, the targeting element comprises a Cas12 enzyme associated with a gRNA. In embodiments, the targeting element comprises a catalytically inactive Cas12 associated with a gRNA, optionally wherein the catalytically inactive Cas12 is dCas12j or dCas12a. In embodiments, the targeting element comprises a nucleic acid binding component of a gene-editing system. SEQ ID NO: 9: amino acid sequence of dead Cas9 protein (GENBANK ACC. No. MT882253.1) 1 MDKKYSIGLA IGTNSVGWAV ITDEYKVPSK KFKVLGNTDR HSIKKNLIGA 51 LLFDSGETAE ATRLKRTARR RYTRRKNRIC YLQEIFSNEM AKVDDSFFHR 101 LEESFLVEED KKHERHPIFG NIVDEVAYHE KYPTIYHLRK KLVDSTDKAD 151 LRLIYLALAH MIKFRGHFLI EGDLNPDNSD VDKLFIQLVQ TYNQLFEENP 201 INASGVDAKA ILSARLSKSR RLENLIAQLP GEKKNGLFGN LIALSLGLTP 251 NFKSNFDLAE DAKLQLSKDT YDDDLDNLLA QIGDQYADLF LAAKNLSDAI 301 LLSDILRVNT EITKAPLSAS MIKRYDEHHQ DLTLLKALVR QQLPEKYKEI 351 FFDQSKNGYA GYIDGGASQE EFYKFIKPIL EKMDGTEELL VKLNREDLLR 401 KQRTFDNGSI PHQIHLGELH AILRRQEDFY PFLKDNREKI EKILTFRIPY 451 YVGPLARGNS RFAWMTRKSE ETITPWNFEE VVDKGASAQS FIERMTNFDK 501 NLPNEKVLPK HSLLYEYFTV YNELTKVKYV TEGMRKPAFL SGEQKKAIVD 551 LLFKTNRKVT VKQLKEDYFK KIECFDSVEI SGVEDRFNAS LGTYHDLLKI 601 IKDKDFLDNE ENEDILEDIV LTLTLFEDRE MIEERLKTYA HLFDDKVMKQ 651 LKRRRYTGWG RLSRKLINGI RDKQSGKTIL DFLKSDGFAN RNFMQLIHDD 701 SLTFKEDIQK AQVSGQGDSL HEHIANLAGS PAIKKGILQT VKVVDELVKV 751 MGRHKPENIV IEMARENQTT QKGQKNSRER MKRIEEGIKE LGSQILKEHP 801 VENTQLQNEK LYLYYLQNGR DMYVDQELDI NRLSDYDVAA IVPQSFLKDD 851 SIDNKVLTRS DKARGKSDNV PSEEVVKKMK NYWRQLLNAK LITQRKFDNL 901 TKAERGGLSE LDKAGFIKRQ LVETRQITKH VAQILDSRMN TKYDENDKLI 951 REVKVITLKS KLVSDFRKDF QFYKVREINN YHHAHDAYLN AVVGTALIKK 1001 YPKLESEFVY GDYKVYDVRK MIAKSEQEIG KATAKYFFYS NIMNFFKTEI 1051 TLANGEIRKR PLIETNGETG EIVWDKGRDF ATVRKVLSMP QVNIVKKTEV 1101 QTGGFSKESI LPKRNSDKLI ARKKDWDPKK YGGFDSPTVA YSVLVVAKVE 1151 KGKSKKLKSV KELLGITIME RSSFEKNPID FLEAKGYKEV KKDLIIKLPK 1201 YSLFELENGR KRMLASAGEL QKGNELALPS KYVNFLYLAS HYEKLKGSPE 1251 DNEQKQLFVE QHKHYLDEII EQISEFSKRV ILADANLDKV LSAYNKHRDK 1301 PIREQAENII HLFTLTNLGA PAAFKYFDTT IDRKRYTSTK EVLDATLIHQ 1351 SITGLYETRI DLSQLGGDSR ADPKKKRKV SEQ ID NO: 10: nucleotide sequence of dead Cas9 protein (GENBANK ACC. NO. MT882253.1) 1 ATGGACAAGA AGTACTCCAT TGGGCTCGCT ATCGGCACAA ACAGCGTCGG CTGGGCCGTC 61 ATTACGGACG AGTACAAGGT GCCGAGCAAA AAATTCAAAG TTCTGGGCAA TACCGATCGC 121 CACAGCATAA AGAAGAACCT CATTGGCGCC CTCCTGTTCG ACTCCGGGGA GACGGCCGAA 181 GCCACGCGGC TCAAAAGAAC AGCACGGCGC AGATATACCC GCAGAAAGAA TCGGATCTGC 241 TACCTGCAGG AGATCTTTAG TAATGAGATG GCTAAGGTGG ATGACTCTTT CTTCCATAGG 301 CTGGAGGAGT CCTTTTTGGT GGAGGAGGAT AAAAAGCACG AGCGCCACCC AATCTTTGGC 361 AATATCGTGG ACGAGGTGGC GTACCATGAA AAGTACCCAA CCATATATCA TCTGAGGAAG 421 AAGCTTGTAG ACAGTACTGA TAAGGCTGAC TTGCGGTTGA TCTATCTCGC GCTGGCGCAT 481 ATGATCAAAT TTCGGGGACA CTTCCTCATC GAGGGGGACC TGAACCCAGA CAACAGCGAT 541 GTCGACAAAC TCTTTATCCA ACTGGTTCAG ACTTACAATC AGCTTTTCGA AGAGAACCCG 601 ATCAACGCAT CCGGAGTTGA CGCCAAAGCA ATCCTGAGCG CTAGGCTGTC CAAATCCCGG 661 CGGCTCGAAA ACCTCATCGC ACAGCTCCCT GGGGAGAAGA AGAACGGCCT GTTTGGTAAT 721 CTTATCGCCC TGTCACTCGG GCTGACCCCC AACTTTAAAT CTAACTTCGA CCTGGCCGAA 781 GATGCCAAGC TTCAACTGAG CAAAGACACC TACGATGATG ATCTCGACAA TCTGCTGGCC 841 CAGATCGGCG ACCAGTACGC AGACCTTTTT TTGGCGGCAA AGAACCTGTC AGACGCCATT 901 CTGCTGAGTG ATATTCTGCG AGTGAACACG GAGATCACCA AAGCTCCGCT GAGCGCTAGT 961 ATGATCAAGC GCTATGATGA GCACCACCAA GACTTGACTT TGCTGAAGGC CCTTGTCAGA 1021 CAGCAACTGC CTGAGAAGTA CAAGGAAATT TTCTTCGATC AGTCTAAAAA TGGCTACGCC 1081 GGATACATTG ACGGCGGAGC AAGCCAGGAG GAATTTTACA AATTTATTAA GCCCATCTTG 1141 GAAAAAATGG ACGGCACCGA GGAGCTGCTG GTAAAGCTTA ACAGAGAAGA TCTGTTGCGC 1201 AAACAGCGCA CTTTCGACAA TGGAAGCATC CCCCACCAGA TTCACCTGGG CGAACTGCAC 1261 GCTATCCTCA GGCGGCAAGA GGATTTCTAC CCCTTTTTGA AAGATAACAG GGAAAAGATT 1321 GAGAAAATCC TCACATTTCG GATACCCTAC TATGTAGGCC CCCTCGCCCG GGGAAATTCC 1381 AGATTCGCGT GGATGACTCG CAAATCAGAA GAGACCATCA CTCCCTGGAA CTTCGAGGAA 1441 GTCGTGGATA AGGGGGCCTC TGCCCAGTCC TTCATCGAAA GGATGACTAA CTTTGATAAA 1501 AATCTGCCTA ACGAAAAGGT GCTTCCTAAA CACTCTCTGC TGTACGAGTA CTTCACAGTT 1561 TATAACGAGC TCACCAAGGT CAAATACGTC ACAGAAGGGA TGAGAAAGCC AGCATTCCTG 1621 TCTGGAGAGC AGAAGAAAGC TATCGTGGAC CTCCTCTTCA AGACGAACCG GAAAGTTACC 1681 GTGAAACAGC TCAAAGAAGA CTATTTCAAA AAGATTGAAT GTTTCGACTC TGTTGAAATC 1741 AGCGGAGTGG AGGATCGCTT CAACGCATCC CTGGGAACGT ATCACGATCT CCTGAAAATC 1801 ATTAAAGACA AGGACTTCCT GGACAATGAG GAGAACGAGG ACATTCTTGA GGACATTGTC 1861 CTCACCCTTA CGTTGTTTGA AGATAGGGAG ATGATTGAAG AACGCTTGAA AACTTACGCT 1921 CATCTCTTCG ACGACAAAGT CATGAAACAG CTCAAGAGGC GCCGATATAC AGGATGGGGG 1981 CGGCTGTCAA GAAAACTGAT CAATGGGATC CGAGACAAGC AGAGTGGAAA GACAATCCTG 2041 GATTTTCTTA AGTCCGATGG ATTTGCCAAC CGGAACTTCA TGCAGTTGAT CCATGATGAC 2101 TCTCTCACCT TTAAGGAGGA CATCCAGAAA GCACAAGTTT CTGGCCAGGG GGACAGTCTT 2161 CACGAGCACA TCGCTAATCT TGCAGGTAGC CCAGCTATCA AAAAGGGAAT ACTGCAGACC 2221 GTTAAGGTCG TGGATGAACT CGTCAAAGTA ATGGGAAGGC ATAAGCCCGA GAATATCGTT 2281 ATCGAGATGG CCCGAGAGAA CCAAACTACC CAGAAGGGAC AGAAGAACAG TAGGGAAAGG 2341 ATGAAGAGGA TTGAAGAGGG TATAAAAGAA CTGGGGTCCC AAATCCTTAA GGAACACCCA 2401 GTTGAAAACA CCCAGCTTCA GAATGAGAAG CTCTACCTGT ACTACCTGCA GAACGGCAGG 2461 GACATGTACG TGGATCAGGA ACTGGACATC AATCGGCTCT CCGACTACGA CGTGGCTGCT 2521 ATCGTGCCCC AGTCTTTTCT CAAAGATGAT TCTATTGATA ATAAAGTGTT GACAAGATCC 2581 GATAAAGCTA GAGGGAAGAG TGATAACGTC CCCTCAGAAG AAGTTGTCAA GAAAATGAAA 2641 AATTATTGGC GGCAGCTGCT GAACGCCAAA CTGATCACAC AACGGAAGTT CGATAATCTG 2701 ACTAAGGCTG AACGAGGTGG CCTGTCTGAG TTGGATAAAG CCGGCTTCAT CAAAAGGCAG 2761 CTTGTTGAGA CACGCCAGAT CACCAAGCAC GTGGCCCAAA TTCTCGATTC ACGCATGAAC 2821 ACCAAGTACG ATGAAAATGA CAAACTGATT CGAGAGGTGA AAGTTATTAC TCTGAAGTCT 2881 AAGCTGGTCT CAGATTTCAG AAAGGACTTT CAGTTTTATA AGGTGAGAGA GATCAACAAT 2941 TACCACCATG CGCATGATGC CTACCTGAAT GCAGTGGTAG GCACTGCACT TATCAAAAAA 3001 TATCCCAAGC TTGAATCTGA ATTTGTTTAC GGAGACTATA AAGTGTACGA TGTTAGGAAA 3061 ATGATCGCAA AGTCTGAGCA GGAAATAGGC AAGGCCACCG CTAAGTACTT CTTTTACAGC 3121 AATATTATGA ATTTTTTCAA GACCGAGATT ACACTGGCCA ATGGAGAGAT TCGGAAGCGA 3181 CCACTTATCG AAACAAACGG AGAAACAGGA GAAATCGTGT GGGACAAGGG TAGGGATTTC 3241 GCGACAGTCC GGAAGGTCCT GTCCATGCCG CAGGTGAACA TCGTTAAAAA GACCGAAGTA 3301 CAGACCGGAG GCTTCTCCAA GGAAAGTATC CTCCCGAAAA GGAACAGCGA CAAGCTGATC 3361 GCACGCAAAA AAGATTGGGA CCCCAAGAAA TACGGCGGAT TCGATTCTCC TACAGTCGCT 3421 TACAGTGTAC TGGTTGTGGC CAAAGTGGAG AAAGGGAAGT CTAAAAAACT CAAAAGCGTC 3481 AAGGAACTGC TGGGCATCAC AATCATGGAG CGATCAAGCT TCGAAAAAAA CCCCATCGAC 3541 TTTCTGGAGG CGAAAGGATA TAAAGAGGTC AAAAAAGACC TCATCATTAA GCTTCCCAAG 3601 TACTCTCTCT TTGAGCTTGA AAACGGCCGG AAACGAATGC TCGCTAGTGC GGGCGAGCTG 3661 CAGAAAGGTA ACGAGCTGGC ACTGCCCTCT AAATACGTTA ATTTCTTGTA TCTGGCCAGC 3721 CACTATGAAA AGCTCAAAGG GTCTCCCGAA GATAATGAGC AGAAGCAGCT GTTCGTGGAA 3781 CAACACAAAC ACTACCTTGA TGAGATCATC GAGCAAATAA GCGAATTCTC CAAAAGAGTG 3841 ATCCTCGCCG ACGCTAACCT CGATAAGGTG CTTTCTGCTT ACAATAAGCA CAGGGATAAG 3901 CCCATCAGGG AGCAGGCAGA AAACATTATC CACTTGTTTA CTCTGACCAA CTTGGGCGCG 3961 CCTGCAGCCT TCAAGTACTT CGACACCACC ATAGACAGAA AGCGGTACAC CTCTACAAAG 4021 GAGGTCCTGG ACGCCACACT GATTCATCAG TCAATTACGG GGCTCTATGA AACAAGAATC 4081 GACCTCTCTC AGCTCGGTGG AGACAGCAGG GCTGACCCCA AGAAGAAGAG GAAGGTG In embodiments, the enzyme or variant thereof and the targeting element are connected. In embodiments, the enzyme and the targeting element are fused to one another or linked via a linker to one another. In embodiments, the composition comprises a linker connecting the enzyme and the targeting element. In embodiments, the linker is a flexible linker. In embodiments, the flexible linker is substantially comprised of glycine and serine residues, optionally wherein the flexible linker comprises (Gly4Ser)n, where n is an integer from 1-12. In embodiments, the flexible linker is of about 20, or about 30, or about 40, or about 50, or about 60 amino acid residues. In embodiments, the linker comprises an amino acid sequence of AKLAGGAPAVGGGPKAADKFAATGGS (SEQ ID NO: 3) or a variant thereof having a substitution or deletion. In embodiments, the enzyme is directly fused to the N-terminus of the dCas9 enzyme. In embodiments, the enzyme or variant thereof is able to directly or indirectly cause transposition of a target gene. In embodiments, the enzyme or variant thereof is able to directly or indirectly interact and / or form a complex with one or more proteins or nucleic acids. In embodiments, the present compositions and methods relate to or comprise one or more mutants or mutations of FIG.3, FIG.4, FIG.5, FIG.6, FIG.7, FIG.8, FIG.9, FIG.10, FIG.11, FIG.12, FIG.13, FIG.14, FIG.15, FIG.16, FIG. 17, FIG.18, FIG.19A, FIG.20, FIG.21, TABLE 3, TABLE 4, or TABLE 13 of SEQ ID NO: 1, or a substitution at a position corresponding thereto. In embodiments, the composition of the present disclosure comprises a transposase enzyme or a nucleic acid encoding the enzyme, wherein the enzyme comprises an amino acid sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 85% or a sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions shown in any one of FIG.3, FIG.4, FIG.5, FIG.6, FIG.7, FIG.8, FIG.9, FIG.10, FIG.11, FIG.12, FIG.13, FIG.14, FIG.15, FIG.16, FIG.17, FIG.18, FIG.19A, FIG.20, FIG.21, TABLE 3, TABLE 4, or TABLE 13 of SEQ ID NO: 1, or a substitution at a position corresponding thereto. Binding Domain Insertion In embodiments, binding domains are fused within the piggyBac (PB) transposase open reading frame. In embodiments, binding domains are fused within the piggyBac (PB) transposase open reading frame covalently. In embodiments, binding domains are fused within the piggyBac (PB) transposase open reading frame at the loop domains. In embodiments, binding domains are covalently fused within the piggyBac (PB) transposase open reading frame at the loop domains. In embodiments, the loop domains tolerate insertions without inactivating the excision activity of piggyBac (PB) transposase. In embodiments, insertions in the PB loop domains at amino acid positions V371-I378, Y312-V322, K407-M413, S385- T392, A424-K432, K383-S393, T319-V322, G321-L324 and / or R275-K290 relative to SEQ ID NO: 1. In embodiments, specific loop insertion sites are at positions: V390, R315, G321, R376, S387, K409, and / or E428 relative to SEQ ID NO: 1. In embodiments, specific loop insertion sites is at position V390. In embodiments, the hyperactive mutant comprises an insertion at one or more of positions V371-I378, Y312-V322, K407-M413, S385-T392, A424-K432, K383- S393, T319-V322, G321-L324, R275-K290, or R315, G321, R376, S387, K409, and E428 relative to SEQ ID NO: 1. In embodiments, the enzyme of the present disclosure comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises an insertion at one or more of positions V371- I378, Y312-V322, K407-M413, S385-T392, A424-K432, K383-S393, T319-V322, G321-L324, R275-K290, or R315, G321, R376, S387, K409, and E428 relative to SEQ ID NO: 1. In embodiments, the enzyme comprising insertion(s) at said positions may be combined with other embodiments of the present disclosure. In embodiments, the insertion is a DNA binding domain in whole, or a functional fragment that is capable of binding. In embodiments, the insertion is or comprises a DNA binding domain in whole, or a functional fragment that is capable of binding. In embodiments, the DNA binding domain is selected from: zinc finger, TAL effector (TALE), leucine zipper, CRISPR-based DNA targeting nuclease, and / or combinations thereof. In embodiments, the CRISPR-based DNA targeting nuclease is selected from CasX, dCasX, Cas9 and / or dCas9. In embodiments, the enzyme of the present disclosure comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises an insertion in a loop domain of piggyBac. In embodiments, the enzyme of the present disclosure comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises an insertion in a loop domain of piggyBac selected from one or more the domains of TABLE 12 (with reference to SEQ ID NO: 1): TABLE 12:
[0003] In embodiments, the enzyme of the present disclosure comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises an insertion at one or more of positions listed in TABLE 12 relative to SEQ ID NO: 1. In embodiments, the enzyme comprising insertion(s) at said positions may be combined with other embodiments of the present disclosure. In embodiments, the insertion is a DNA binding domain in whole, or a functional fragment that is capable of binding. In embodiments, the insertion is or comprises a DNA binding domain in whole, or a functional fragment that is capable of binding. In embodiments, the DNA binding domain is selected from: zinc finger, TAL effector (TALE), leucine zipper, CRISPR-based DNA targeting nuclease, and / or combinations thereof. In embodiments, the CRISPR-based DNA targeting nuclease is selected from CasX, dCasX, Cas9 and / or dCas9. In embodiments, the fusion molecules include domains capable of binding alternate domains from a second bridging protein. Without wishing to be bound by theory, these fusions are believed to provide a docking site for a second protein to bridge the two proteins that is also fused to a DNA binding domain. In embodiments, the configuration entails the second protein binding a target sequence, either on a plasmid or in the genome, and relocating PB to this sequence through the interaction of the domain on the bridging protein with the domain that is fused to the PB loop. In embodiments, because the PB enzyme is located near the target DNA via this bridging protein, integration occurs within close proximity to this sequence. In embodiments, the bridging protein comprises two molecules. In embodiments, the first molecule is the domain that binds to the domain located within PB. Without limitation, some examples of the domain include a camelid VHH and an antigen. Without limitation, some examples of the domain include a monobody and an antigen. Without limitation, some examples of the domain include VNAR, Fab, and scFv. Without limitation, some examples of the domain include a heterodimer. In embodiments, the heterodimer is a E / K leucine zipper. In embodiments, the second molecule of the bridging protein is a DNA binding domain. Without limitation, some examples of the DNA binding domain include zinc fingers, TALEs, CasX, dCasX, Cas9, dCas9, or other CRISPR-based DNA targeting nucleases. In embodiments, E2C NbAlfa has a nucleotide sequence of SEQ ID NO: 515 and an amino acid sequence of SEQ ID NO: 516. In embodiments, Alfa Nterm R315 R372 has a nucleotide sequence of SEQ ID NO: 517 and an amino acid sequence of SEQ ID NO: 518. In embodiments, Alfa E428 loop R315 R372 has a nucleotide sequence of SEQ ID NO: 519 and an amino acid sequence of SEQ ID NO: 520. In embodiments, E2C GCN4 has a nucleotide sequence of SEQ ID NO: 521 and an amino acid sequence of SEQ ID NO: 522. In embodiments, E2C GCN4 (GCN4 underlined) has a nucleotide sequence of SEQ ID NO: 523 and an amino acid sequence of SEQ ID NO: 524. In embodiments, Monobody Nterm R315 R372 has a nucleotide sequence of SEQ ID NO: 525 and an amino acid sequence of SEQ ID NO: 526. In embodiments, Monobody Nterm R315 R372 (monobody underlined) has a nucleotide sequence of SEQ ID NO: 527 and an amino acid sequence of SEQ ID NO: 528. In embodiments, E2C zinc finger has a nucleotide sequence of SEQ ID NO: 567 and an amino acid sequence of SEQ ID NO: 568. SEQ ID NO: 515: nucleotide sequence of E2C NbAlfa ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAA ATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAAT GCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGC CCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGC TAGCGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGAAGTCCAGCTCCAAGAAAGCGGCGGGGGCC TCGTGCAGCCAGGCGGGTCCCTGAGGCTGAGCTGTACCGCATCTGGAGTCACCATCTCTGCCCTTAACGCAATGGCT ATGGGGTGGTATCGGCAGGCGCCCGGCGAGAGGAGAGTCATGGTAGCAGCCGTTAGCGAAAGGGGGAATGCGATGTA CCGAGAGAGTGTTCAGGGACGATTTACTGTCACTCGGGATTTTACGAACAAAATGGTTTCATTGCAAATGGACAATT TGAAACCAGAGGACACCGCTGTTTACTACTGTCACGTCCTGGAAGATCGAGTAGATAGCTTCCATGACTATTGGGGC CAAGGAACACAAGTGACTGTCAGCTCC SEQ ID NO: 516: amino acid sequence of E2C NbAlfa MAPKKKRKVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTASGGSGGSGGSGGSLEEVQLQESGGGLVQPGGSLRLSCTASGVTISALNAMA MGWYRQAPGERRVMVAAVSERGNAMYRESVQGRFTVTRDFTNKMVSLQMDNLKPEDTAVYYCHVLEDRVDSFHDYWG QGTQVTVSS SEQ ID NO: 517: nucleotide sequence of Alfa Nterm R315 R372 ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCTCCAGACTGGAAGAGGAACTGAGAAGAAGGCTCACAGAAGCTAG CGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGGGTCTTCACTGGACGATGAGCATATTCTGAGCG CCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACGTGTCAGAGGACGAT GTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCCGGAAGCGAGATCCT GGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACTGCCACAGCGAACTA TTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCGCCCTGAACATCGTG AGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAGCTGTTCTTTACAGA TGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATCTATGACTAGTGCCA CCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAGTGAGGAAGGACAAC CATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGCAGAGACAGGTTCGA TTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGACGTGTTCACCCCAG TGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATCTGACTATCGACGAA CAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAATATGGCATCAAGAT TCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGGCACCCAGACAAATG GAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACCTGTGAC AATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAACCGTGGC CAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTCTATGTTCTGCTTTG ACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGAT GCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCT GAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCA ACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAG AAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAG GTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAG TGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGT AAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 518: amino acid sequence of Alfa Nterm R315 R372 MAPKKKRKVGGSRLEEELRRRLTEASGGSGGSGGSGGSLEGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDD VQSDTEEAFIDEVHEVQPTSSGSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIV RSQRGPTRMCRNIYDPLLCFKLFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDN HMSTDDLFDRSLSMVYVSVMSRDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDE QLLGFRGRCPFRVYIPNKPSKYGIKILMMCDSGTKYMINGMPYLGAGTQTNGVPLGEYYVKELSKPVHGSCRNITCD NWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDED ASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRK KFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKC KKVICREHNIDMCRSCF SEQ ID NO: 519: nucleotide sequence of Alfa E428 loop R315 R372 ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAATCCAGACTGGAAGAGGAACTGAGAAGAA GGCTCACAGAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGC AAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGAC CTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCA TCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATG GGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAA TATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCA CTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCAT AACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 520: amino acid sequence of Alfa E428 loop R315 R372 MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGAGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKSRLEEELRRRLTEPAKMVYLLSSCDEDASINESTG KPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYM GLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREH NIDMCRSCF* SEQ ID NO: 521: nucleotide sequence of E2C GCN4 ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAATCCAGACTGGAAGAGGAACTGAGAAGAA GGCTCACAGAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGC AAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGAC CTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCA TCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATG GGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAA TATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCA CTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCAT AACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 522: amino acid sequence of E2C GCN4 MAPKKKRKVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTASGGSGGSGGSGGSLEEELLSKNYHLENEVARLKK SEQ ID NO: 523: nucleotide sequence of E2C GCN4 (GCN4 underlined) ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAA ATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAAT GCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGC CCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGC TAGCGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGAAGAACTTTTGAGCAAGAATTATCATCTTG AGAACGAAGTGGCTCGTCTTAAGAAA SEQ ID NO: 524: amino acid sequence of E2C GCN4 (GCN4 underlined) MAPKKKRKVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTASGGSGGSGGSGGSLEEELLSKNYHLENEVARLKK SEQ ID NO: 525: nucleotide sequence of Monobody Nterm R315 R372 ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCGGACCTGATATTGTCATGACACAAAGCCCTAGCTCCCTGAGCGC TAGCGTGGGCGATAGAGTCACAATAACATGCAGATCCAGCACAGGCGCTGTGACTACGTCCAATTACGCTTCTTGGG TCCAGGAGAAACCTGGAAAGCTGTTCAAAGGGCTCATAGGAGGCACTAATAATCGGGCCCCTGGCGTCCCGTCTAGA TTTTCCGGCAGCCTCATTGGGGACAAGGCTACCCTGACCATTAGCTCCCTCCAACCAGAGGACTTCGCTACGTATTT TTGTGCTCTGTGGTATTCCAACCATTGGGTGTTTGGCCAAGGTACTAAGGTCGAACTCAAACGGGGTGGTGGCGGGT CCGGAGGAGGAGGGTCTGGAGGAGGGGGGTCCTCTGGAGGGGGCAGCGAGGTTAAGCTCCTGGAGTCTGGAGGTGGG CTTGTCCAACCCGGCGGATCACTGAAACTGAGCTGCGCTGTCTCCGGTTTTTCCCTCACCGACTACGGGGTGAACTG GGTTCGCCAGGCGCCAGGCCGGGGATTGGAGTGGATTGGTGTAATATGGGGTGATGGGATCACAGACTACAACAGCG CTCTTAAAGATCGGTTTATCATCTCTAAAGATAATGGCAAGAATACGGTCTATCTGCAAATGTCTAAAGTGAGATCC GACGACACCGCCCTCTATTACTGTGTCACCGGACTCTTCGACTACTGGGGCCAAGGCACACTGGTCACAGTCAGCAG CGCTAGCGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGGGTCTTCACTGGACGATGAGCATATTC TGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACGTGTCAGAG GACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCCGGAAGCGA GATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACTGCCACAGC GAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCGCCCTGAAC ATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAGCTGTTCTT TACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATCTATGACTA GTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAGTGAGGAAG GACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGCAGAGACAG GTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGACGTGTTCA CCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATCTGACTATC GACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAATATGGCAT CAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGGCACCCAGA CAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACC TGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAAC CGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTCTATGTTCT GCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGAC GAGGATGCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGA TACCCTGAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGA TGATCAACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCC CGCAAGAAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACT GAAAAGGTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGG AACCAGTGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAG AAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 526: amino acid sequence of Monobody Nterm R315 R372 MAPKKKRKVGGGPDIVMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYASWVQEKPGKLFKGLIGGTNNRAPGVPSR FSGSLIGDKATLTISSLQPEDFATYFCALWYSNHWVFGQGTKVELKRGGGGSGGGGSGGGGSSGGGSEVKLLESGGG LVQPGGSLKLSCAVSGFSLTDYGVNWVRQAPGRGLEWIGVIWGDGITDYNSALKDRFIISKDNGKNTVYLQMSKVRS DDTALYYCVTGLFDYWGQGTLVTVSSASGGSGGSGGSGGSLEGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSE DDVQSDTEEAFIDEVHEVQPTSSGSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALN IVRSQRGPTRMCRNIYDPLLCFKLFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRK DNHMSTDDLFDRSLSMVYVSVMSRDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTI DEQLLGFRGRCPFRVYIPNKPSKYGIKILMMCDSGTKYMINGMPYLGAGTQTNGVPLGEYYVKELSKPVHGSCRNIT CDNWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCD EDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQS RKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCK KCKKVICREHNIDMCRSCF SEQ ID NO: 527: nucleotide sequence of Monobody Nterm R315 R372 (monobody underlined) ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCGGACCTGATATTGTCATGACACAAAGCCCTAGCTCCCTGAGCGC TAGCGTGGGCGATAGAGTCACAATAACATGCAGATCCAGCACAGGCGCTGTGACTACGTCCAATTACGCTTCTTGGG TCCAGGAGAAACCTGGAAAGCTGTTCAAAGGGCTCATAGGAGGCACTAATAATCGGGCCCCTGGCGTCCCGTCTAGA TTTTCCGGCAGCCTCATTGGGGACAAGGCTACCCTGACCATTAGCTCCCTCCAACCAGAGGACTTCGCTACGTATTT TTGTGCTCTGTGGTATTCCAACCATTGGGTGTTTGGCCAAGGTACTAAGGTCGAACTCAAACGGGGTGGTGGCGGGT CCGGAGGAGGAGGGTCTGGAGGAGGGGGGTCCTCTGGAGGGGGCAGCGAGGTTAAGCTCCTGGAGTCTGGAGGTGGG CTTGTCCAACCCGGCGGATCACTGAAACTGAGCTGCGCTGTCTCCGGTTTTTCCCTCACCGACTACGGGGTGAACTG GGTTCGCCAGGCGCCAGGCCGGGGATTGGAGTGGATTGGTGTAATATGGGGTGATGGGATCACAGACTACAACAGCG CTCTTAAAGATCGGTTTATCATCTCTAAAGATAATGGCAAGAATACGGTCTATCTGCAAATGTCTAAAGTGAGATCC GACGACACCGCCCTCTATTACTGTGTCACCGGACTCTTCGACTACTGGGGCCAAGGCACACTGGTCACAGTCAGCAG CGCTAGCGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGGGTCTTCACTGGACGATGAGCATATTC TGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACGTGTCAGAG GACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCCGGAAGCGA GATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACTGCCACAGC GAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCGCCCTGAAC ATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAGCTGTTCTT TACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATCTATGACTA GTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAGTGAGGAAG GACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGCAGAGACAG GTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGACGTGTTCA CCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATCTGACTATC GACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAATATGGCAT CAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGGCACCCAGA CAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACC TGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAAC CGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTCTATGTTCT GCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGAC GAGGATGCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGA TACCCTGAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGA TGATCAACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCC CGCAAGAAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACT GAAAAGGTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGG AACCAGTGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAG AAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 528: amino acid sequence of Monobody Nterm R315 R372 (monobody underlined) MAPKKKRKVGGGPDIVMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYASWVQEKPGKLFKGLIGGTNNRAPGVPSR FSGSLIGDKATLTISSLQPEDFATYFCALWYSNHWVFGQGTKVELKRGGGGSGGGGSGGGGSSGGGSEVKLLESGGG LVQPGGSLKLSCAVSGFSLTDYGVNWVRQAPGRGLEWIGVIWGDGITDYNSALKDRFIISKDNGKNTVYLQMSKVRS DDTALYYCVTGLFDYWGQGTLVTVSSASGGSGGSGGSGGSLEGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSE DDVQSDTEEAFIDEVHEVQPTSSGSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALN IVRSQRGPTRMCRNIYDPLLCFKLFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRK DNHMSTDDLFDRSLSMVYVSVMSRDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTI DEQLLGFRGRCPFRVYIPNKPSKYGIKILMMCDSGTKYMINGMPYLGAGTQTNGVPLGEYYVKELSKPVHGSCRNIT CDNWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCD EDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQS RKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCK KCKKVICREHNIDMCRSCF SEQ ID NO: 567: E2C zinc finger (alone) – nucleotide sequence GGAGGTCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGT TAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCG ATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGAT TGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGAGGT SEQ ID NO: 568: E2C zinc finger (alone) – amino acid sequence GGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSD CRDLARHQRTHTGKKTGG In embodiments, the targeting element comprises a Zinc finger. In embodiments, the Zinc finger comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 568 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 567 or a codon-optimized form thereof. In embodiments, a helper plasmid encodes a PB transposase containing either a loop fusion of a bridging domain or a loop fusion of a zinc finger. In embodiments, a reporter plasmid containing a promotorless-zsGreen fluorescent protein or a promotorless-green fluorescent protein contains the target sequence for the zinc finger. In embodiments, a donor plasmid contains the PB transposon with a CMV promoter oriented pointing outward. In the event of successful targeting, the transposon inserts near the target sequence on the reporter plasmid and aligns the promotor with the zsGreen or GFP, which results in zsGreen or GFP expression. In embodiments, the expression can be detected by flow cytometry or a comparable fluorescence detection method. In embodiments, upon co-expression of a helper plasmid encoding PB with one of several loop insertions, the donor plasmid containing the transposon and CMV promoter, and the reporter plasmid containing the promotorless-zsGreen or promoterless GPF, an increase in zsGreen fluorescence or GFP fluorescence is measured which indicates that the loop infusion strategy is successful at targeting PB to the plasmid target sequence. In embodiments, the reporter plasmid is used to deliver the target sequence into the human genome. In embodiments, the reporter plasmid is used to deliver the target sequence into the human genome by co-transfecting it into HEK293 cells along with a plasmid expressing the Sleeping Beauty transposase. In embodiments, the Sleeping Beauty transposase is used to enzymatically insert the reporter plasmid components, including target sequence and promotorless-zsGreen into random locations within the genome. In embodiments, cell lines are generated containing the reporter components in the genome. Upon co-expression into these cell lines by a helper plasmid encoding PB with one of several loop insertions, the donor plasmid containing the transposon and CMV promoter, an increase in zsGreen fluorescence is measured which indicates that the loop infusion strategy is successful at targeting PB insertion to the genomic target sequence. In embodiments, DNA binding domains are fused to the N-terminus or loop domains of piggyBac. In embodiments, such fusions result in the PB transposase becoming localized to the target DNA where integration occurs within close proximity to the sequence. In embodiments, the zinc fingers are inserted within the PB transposase open reading frame at loop domains. In embodiments, successful targeting of PB is achieved by bridging domain insertions into the loops of PB. In embodiments, successful targeting of PB is achieved by direct covalent DNA binding domain insertions into the loops of PB. Construct In embodiments, the composition (e.g., without limitation, hyperactive transposase of the present disclosure), system, or method further comprising a nucleic acid encoding a transposon comprising a transgene to be integrated. In embodiments, the enzyme or variant thereof is able to directly or indirectly cause transposition of a target gene or nucleic acid cargo. In embodiments, the enzyme or variant thereof is able to directly or indirectly interact and / or form a complex with one or more proteins or nucleic acids. In embodiments, the composition further comprises a nucleic acid encoding a transposon or transgene to be integrated or inserted into a nucleic acid. In embodiments, the transposon, transgene and / or cargo nucleic acid comprises a cargo nucleic acid sequence and a first and a second transposon end sequences. In embodiments, the transposon, transgene and / or cargo nucleic acid is flanked by the first and the second transposon end sequences. In embodiments, the transposon end sequences are selected from nucleotide sequences of SEQ ID NO: 5 and / or SEQ ID NO: 6, or a nucleotide sequence having at least about 90% identity thereto. SEQ ID NO: 5: nucleotide sequence of left hyperactive transposase donor end sequence (310 bp) 1 ATCTATAACA AGAAAATATA TATATAATAA GTTATCACGT AAGTAGAACA 51 TGAAATAACA ATATAATTAT CGTATGAGTT AAATCTTAAA AGTCACGTAA 101 AAGATAATCA TGCGTCATTT TGACTCACGC GGTCGTTATA GTTCAAAATC 151 AGTGACACTT ACCGCATTGA CAAGCACGCC TCACGGGAGC TCCAAGCGGC 201 GACTGAGATG TCCTAAATGC ACAGCGACGG ATTCGCGCTA TTTAGAAAGA 251 GAGAGCAATA TTTCAAGAAT GCATGCGTCA ATTTTACGCA GACTATCTTT 301 CTAGGGTTAA SEQ ID NO: 6: nucleotide sequence of right hyperactive transposase donor end sequence (205 bp) 1 TTAACCCTAG AAAGATAATC ATATTGTGAC GTACGTTAAA GATAATCATG 51 CGTAAAATTG ACGCATGTGT TTTATCGGTC TGTATATCGA GGTTTATTTA 101 TTAATTTGAA TAGATATTAA GTTTTATTAT ATTTACACTT ACATACTAAT 151 AATAAATTCA ACAAACAATT TATTTATGTT TATTTATTTA TTAAAAAAAA 201 ACAAA In embodiments, the end sequences include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 5. In embodiments, the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 5 is positioned at the 5’ end of the transposon, transgene and / or nucleic acid. In embodiments, the end sequences can further include at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 6. In embodiments, the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 6 is positioned at the 3’ end of the transposon, transgene and / or nucleic acid. In embodiments, the enzyme or variant thereof is incorporated into a vector or a vector-like particle. In embodiments, the vector or a vector-like particle comprises one or more expression cassettes. In embodiments, the vector or a vector- like particle comprises one expression cassette. In embodiments, the expression cassette further comprises the enzyme or variant thereof, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into one or more vectors or vector-like particles. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into a same vector or vector-like particle. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof is incorporated into different vectors vector-like particles. In embodiments, the vector or vector-like particle is nonviral. In embodiments, the composition comprises DNA, RNA, or both. In embodiments, the enzyme or variant thereof is in the form of RNA. In embodiments, the composition is a nucleic acid, optionally an RNA. In embodiments, the RNA is or comprises messenger RNA (mRNA). In embodiments, the mRNA is or comprises modified mRNA (mmRNA). In embodiments, the mmRNA comprises one or more of a 5’-m7G cap (cap0, cap1, or cap2), a pseudouridine or n-methyl-pseudouridine substitution, and a poly-A tail of about 30, or of about 50, or of about 100, or of about 150 nucleotides in length. In embodiments, the transposon, transgene and / or nucleic acid is in the form of DNA. Engineered PiggyBac Constructs In aspects, the present disclosure further provides a piggyBac with a deletion in either N or C terminus. In embodiments, the piggyBac comprises a deletion in the N-terminus. In embodiments, the piggyBac comprises a deletion in the C- terminus. In embodiments, the piggyBac comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from an N-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 1, or a sequence having at least about 90% identity thereto. In embodiments, the piggyBac comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from an C-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion of about 74 amino acids from an N-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 1, or a sequence having at least about 90% identity thereto. In embodiments, the helper enzyme comprises a duplication of the C-terminal domain relative to SEQ ID NO: 1. In embodiments, the C-terminal domain comprises residues 542-594 relative to SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion of about 74 amino acids from an N-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 1, or a sequence having at least about 90% identity thereto, and further comprises a duplication of the C-terminal domain relative to SEQ ID NO: 1. In embodiments, the C-terminal domain comprises residues 542-594 relative to SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion at positions about 1-5, or about 1-15, or about 1-25, or about 1- 35, or about 1-45, or about 1-55, or about 1-65, or about 1-75, or about 1-85, or about 1-95, or about 1-105, or about 1-115, or about 1-125, or about 1-135, or about 1-145, or about 1-155 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion at positions about 520-594, or about 530-594, or about 540-594, or about 550-594, or about 560-594, or about 570-594 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1. In embodiments, the piggyBac comprises a deletion at positions about 542-594 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1. In embodiments, the helper enzyme of the present disclosure comprises a deletion at positions about 2-24 (SEQ ID NO: 504), or about 2-39 (SEQ ID NO: 506), or about 2-86 (SEQ ID NO: 508), or about 2-116 (SEQ ID NO: 510) or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1 inlcuding the mutations in TABLE 3, 4 and / or 13. In embodiments, the helper enzyme of the present disclosure comprises a deletion at positions about 570-594 (SEQ ID NO: 512), or about 554-594 (SEQ ID NO: 514) or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 1 inlcuding the mutations in TABLE 3, 4 and / or 13. In embodiments, the piggyBac comprises a deletion from an N- or C-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 502, or a sequence having at least about 90% identity thereto. SEQ ID NO: 501: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence(N0) 1782 bp 1 ATGGGCTCTT CCTTGGACGA CGAGCACATC CTGAGCGCCC TGCTGCAGTC CGATGACGAG 61 CTGGTGGGTG AGGACTCCGA CAGTGAGGTG AGCGATCATG TGTCCGAGGA CGATGTGCAG 121 AGCGACACCG AGGAGGCCTT CATCGATGAG GTGCATGAAG TGCAGCCCAC ATCCTCCGGA 181 TCCGAGATCC TGGATGAGCA GAACGTGATC GAGCAGCCCG GGAGCTCTCT GGCTTCCAAC 241 AGAATCCTGA CCCTGCCTCA GAGGACTATC AGAGGGAAAA ATAAGCACTG CTGGTCCACT 301 TCAAAGCCAA CCAGGCGGTC TAGGGTGTCC GCCCTGAACA TCGTGAGAAG CCAGAGAGGT 361 CCAACCCGGA TGTGCAGAAA CATCTACGAT CCCCTGCTGT GTTTCAAGCT GTTTTTTACT 421 GACGAGATTA TCAGCGAGAT CGTGAAGTGG ACCAACGCCG AGATCTCTCT GAAGCGGAGA 481 GAAAGCATGA CCTCCGCCAC ATTCCGCGAT ACCAACGAAG ACGAGATCTA CGCCTTTTTC 541 GGCATCTTGG TGATGACTGC CGTGAGGAAG GACAATCACA TGAGCACCGA TGACCTGTTC 601 GATCGCAGCC TGAGCATGGT GTACGTGTCC GTGATGTCCA GGGACAGGTT CGACTTCCTG 661 ATCAGGTGCC TGAGAATGGA TGACAAGAGC ATTAGACCTA CCCTGCGCGA GAATGACGTG 721 TTCACCCCCG TCAGGAAGAT CTGGGACCTG TTTATTCACC AGTGCATTCA GAACTATACC 781 CCTGGCGCCC ACCTGACCAT TGATGAGCAG CTCCTGGGAT TCAGGGGCCG GTGTCCCTTC 841 AGAGTGTATA TACCTAACAA GCCCTCTAAG TACGGCATCA AAATCCTGAT GATGTGCGAC 901 TCCGGAACCA AGTACATGAT TAACGGAATG CCCTATCTGG GACGCGGGAC CCAGACCAAT 961 GGAGTGCCTC TGGGCGAGTA TTACGTGAAA GAGCTGTCCA AACCCGTGCA CGGGTCCTGT 1021 CGGAATATCA CCTGCGACAA CTGGTTCACT TCAATCCCCC TGGCCAAAAA CCTGCTGCAG 1081 GAGCCTTACA AATTGACCAT TGTGGGCACT GTGCGCTCCA ATAAGAGAGA AATTCCTGAG 1141 GTGCTGAAGA ACTCCAGGTC CAGACCCGTG GGCACTAGCA TGTTCTGCTT CGACGGGCCT 1201 CTGACCCTGG TGAGCTATAA GCCCAAGCCA GCCAAGATGG TGTACCTGCT GAGCAGCTGC 1261 GACGAGGATG CCTCAATCAA CGAGAGCACC GGCAAGCCCC AGATGGTGAT GTACTACAAT 1321 CAGACCAAAG GCGGCGTGGA TACCCTGGAC CAGATGTGTT CCGTGATGAC CTGTAGCAGG 1381 AAGACCAACC GGTGGCCAAT GGCCCTGCTG TATGGAATGA TCAACATTGC CTGCATCAAC 1441 AGCTTCATTA TTTACTCCCA CAATGTGTCC TCTAAGGGGG AGAAGGTGCA GTCTAGAAAA 1501 AAGTTTATGA GGAATCTGTA TATGGGCCTG ACCTCTTCCT TCATGCGGAA GCGCCTGGAG 1561 GCACCCACAC TGAAGAGGTA CCTTCGCGAC AATATCTCCA ATATTCTGCC GAAAGAGGTG 1621 CCCGGCACCT CCGACGACAG CACAGAAGAG CCCGTGATGA AAAAGAGGAC CTACTGCACC 1681 TACTGCCCCT CAAAGATCCG CAGGAAGGCC TCCGCATCCT GTAAGAAGTG CAAGAAGGTC 1741 ATCTGCAGGG AACACAATAT CGACATGTGC CAGTCATGCT TC SEQ ID NO: 502: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (N0) 594 aa 1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG 61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKPTRRSRVS ALNIVRSQRG 121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF 181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV 241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD 301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ 361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC 421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN 481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMGL TSSFMRKRLE APTLKRYLRD NISNILPKEV 541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA SASCKKCKKV ICREHNIDMC QSCF In embodiments, the piggyBac comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from an N-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 502, or a sequence having at least about 90% identity thereto. In embodiments, the piggyBac with deletion from the N-terminus comprises SEQ ID NO: 504, SEQ ID NO: 506, SEQ ID NO: 508, or SEQ ID NO: 510, or a sequence having at least about 90% identity thereto. SEQ ID NO: 503: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence (N1; nucleotide 4-72 deletion).1710 bp 1 ATGGACTCCG ACAGTGAGGT GAGCGATCAT GTGTCCGAGG ACGATGTGCA GAGCGACACC 61 GAGGAGGCCT TCATCGATGA GGTGCATGAA GTGCAGCCCA CATCCTCCGG ATCCGAGATC 121 CTGGATGAGC AGAACGTGAT CGAGCAGCCC GGGAGCTCTC TGGCTTCCAA CAGAATCCTG 181 ACCCTGCCTC AGAGGACTAT CAGAGGGAAA AATAAGCACT GCTGGTCCAC TTCAAAGCCA 241 ACCAGGCGGT CTAGGGTGTC CGCCCTGAAC ATCGTGAGAA GCCAGAGAGG TCCAACCCGG 301 ATGTGCAGAA ACATCTACGA TCCCCTGCTG TGTTTCAAGC TGTTTTTTAC TGACGAGATT 361 ATCAGCGAGA TCGTGAAGTG GACCAACGCC GAGATCTCTC TGAAGCGGAG AGAAAGCATG 421 ACCTCCGCCA CATTCCGCGA TACCAACGAA GACGAGATCT ACGCCTTTTT CGGCATCTTG 481 GTGATGACTG CCGTGAGGAA GGACAATCAC ATGAGCACCG ATGACCTGTT CGATCGCAGC 541 CTGAGCATGG TGTACGTGTC CGTGATGTCC AGGGACAGGT TCGACTTCCT GATCAGGTGC 601 CTGAGAATGG ATGACAAGAG CATTAGACCT ACCCTGCGCG AGAATGACGT GTTCACCCCC 661 GTCAGGAAGA TCTGGGACCT GTTTATTCAC CAGTGCATTC AGAACTATAC CCCTGGCGCC 721 CACCTGACCA TTGATGAGCA GCTCCTGGGA TTCAGGGGCC GGTGTCCCTT CAGAGTGTAT 781 ATACCTAACA AGCCCTCTAA GTACGGCATC AAAATCCTGA TGATGTGCGA CTCCGGAACC 841 AAGTACATGA TTAACGGAAT GCCCTATCTG GGACGCGGGA CCCAGACCAA TGGAGTGCCT 901 CTGGGCGAGT ATTACGTGAA AGAGCTGTCC AAACCCGTGC ACGGGTCCTG TCGGAATATC 961 ACCTGCGACA ACTGGTTCAC TTCAATCCCC CTGGCCAAAA ACCTGCTGCA GGAGCCTTAC 1021 AAATTGACCA TTGTGGGCAC TGTGCGCTCC AATAAGAGAG AAATTCCTGA GGTGCTGAAG 1081 AACTCCAGGT CCAGACCCGT GGGCACTAGC ATGTTCTGCT TCGACGGGCC TCTGACCCTG 1141 GTGAGCTATA AGCCCAAGCC AGCCAAGATG GTGTACCTGC TGAGCAGCTG CGACGAGGAT 1201 GCCTCAATCA ACGAGAGCAC CGGCAAGCCC CAGATGGTGA TGTACTACAA TCAGACCAAA 1261 GGCGGCGTGG ATACCCTGGA CCAGATGTGT TCCGTGATGA CCTGTAGCAG GAAGACCAAC 1321 CGGTGGCCAA TGGCCCTGCT GTATGGAATG ATCAACATTG CCTGCATCAA CAGCTTCATT 1381 ATTTACTCCC ACAATGTGTC CTCTAAGGGG GAGAAGGTGC AGTCTAGAAA AAAGTTTATG 1441 AGGAATCTGT ATATGGGCCT GACCTCTTCC TTCATGCGGA AGCGCCTGGA GGCACCCACA 1501 CTGAAGAGGT ACCTTCGCGA CAATATCTCC AATATTCTGC CGAAAGAGGT GCCCGGCACC 1561 TCCGACGACA GCACAGAAGA GCCCGTGATG AAAAAGAGGA CCTACTGCAC CTACTGCCCC 1621 TCAAAGATCC GCAGGAAGGC CTCCGCATCC TGTAAGAAGT GCAAGAAGGT CATCTGCAGG 1681 GAACACAATA TCGACATGTG CCAGTCATGC TTC SEQ ID NO: 504: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (N1; amino acid 2-24 deletion).571 aa 1 MDSDSEVSDH VSEDDVQSDT EEAFIDEVHE VQPTSSGSEI LDEQNVIEQP GSSLASNRIL 61 TLPQRTIRGK NKHCWSTSKP TRRSRVSALN IVRSQRGPTR MCRNIYDPLL CFKLFFTDEI 121 ISEIVKWTNA EISLKRRESM TSATFRDTNE DEIYAFFGIL VMTAVRKDNH MSTDDLFDRS 181 LSMVYVSVMS RDRFDFLIRC LRMDDKSIRP TLRENDVFTP VRKIWDLFIH QCIQNYTPGA 241 HLTIDEQLLG FRGRCPFRVY IPNKPSKYGI KILMMCDSGT KYMINGMPYL GRGTQTNGVP 301 LGEYYVKELS KPVHGSCRNI TCDNWFTSIP LAKNLLQEPY KLTIVGTVRS NKREIPEVLK 361 NSRSRPVGTS MFCFDGPLTL VSYKPKPAKM VYLLSSCDED ASINESTGKP QMVMYYNQTK 421 GGVDTLDQMC SVMTCSRKTN RWPMALLYGM INIACINSFI IYSHNVSSKG EKVQSRKKFM 481 RNLYMGLTSS FMRKRLEAPT LKRYLRDNIS NILPKEVPGT SDDSTEEPVM KKRTYCTYCP 541 SKIRRKASAS CKKCKKVICR EHNIDMCQSC F SEQ ID NO: 505: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence (N2; nucleotide 4-117 deletion) 1668 bp 1 ATGCAGAGCG ACACCGAGGA GGCCTTCATC GATGAGGTGC ATGAAGTGCA GCCCACATCC 61 TCCGGATCCG AGATCCTGGA TGAGCAGAAC GTGATCGAGC AGCCCGGGAG CTCTCTGGCT 121 TCCAACAGAA TCCTGACCCT GCCTCAGAGG ACTATCAGAG GGAAAAATAA GCACTGCTGG 181 TCCACTTCAA AGCCAACCAG GCGGTCTAGG GTGTCCGCCC TGAACATCGT GAGAAGCCAG 241 AGAGGTCCAA CCCGGATGTG CAGAAACATC TACGATCCCC TGCTGTGTTT CAAGCTGTTT 301 TTTACTGACG AGATTATCAG CGAGATCGTG AAGTGGACCA ACGCCGAGAT CTCTCTGAAG 361 CGGAGAGAAA GCATGACCTC CGCCACATTC CGCGATACCA ACGAAGACGA GATCTACGCC 421 TTTTTCGGCA TCTTGGTGAT GACTGCCGTG AGGAAGGACA ATCACATGAG CACCGATGAC 481 CTGTTCGATC GCAGCCTGAG CATGGTGTAC GTGTCCGTGA TGTCCAGGGA CAGGTTCGAC 541 TTCCTGATCA GGTGCCTGAG AATGGATGAC AAGAGCATTA GACCTACCCT GCGCGAGAAT 601 GACGTGTTCA CCCCCGTCAG GAAGATCTGG GACCTGTTTA TTCACCAGTG CATTCAGAAC 661 TATACCCCTG GCGCCCACCT GACCATTGAT GAGCAGCTCC TGGGATTCAG GGGCCGGTGT 721 CCCTTCAGAG TGTATATACC TAACAAGCCC TCTAAGTACG GCATCAAAAT CCTGATGATG 781 TGCGACTCCG GAACCAAGTA CATGATTAAC GGAATGCCCT ATCTGGGACG CGGGACCCAG 841 ACCAATGGAG TGCCTCTGGG CGAGTATTAC GTGAAAGAGC TGTCCAAACC CGTGCACGGG 901 TCCTGTCGGA ATATCACCTG CGACAACTGG TTCACTTCAA TCCCCCTGGC CAAAAACCTG 961 CTGCAGGAGC CTTACAAATT GACCATTGTG GGCACTGTGC GCTCCAATAA GAGAGAAATT 1021 CCTGAGGTGC TGAAGAACTC CAGGTCCAGA CCCGTGGGCA CTAGCATGTT CTGCTTCGAC 1081 GGGCCTCTGA CCCTGGTGAG CTATAAGCCC AAGCCAGCCA AGATGGTGTA CCTGCTGAGC 1141 AGCTGCGACG AGGATGCCTC AATCAACGAG AGCACCGGCA AGCCCCAGAT GGTGATGTAC 1201 TACAATCAGA CCAAAGGCGG CGTGGATACC CTGGACCAGA TGTGTTCCGT GATGACCTGT 1261 AGCAGGAAGA CCAACCGGTG GCCAATGGCC CTGCTGTATG GAATGATCAA CATTGCCTGC 1321 ATCAACAGCT TCATTATTTA CTCCCACAAT GTGTCCTCTA AGGGGGAGAA GGTGCAGTCT 1381 AGAAAAAAGT TTATGAGGAA TCTGTATATG GGCCTGACCT CTTCCTTCAT GCGGAAGCGC 1441 CTGGAGGCAC CCACACTGAA GAGGTACCTT CGCGACAATA TCTCCAATAT TCTGCCGAAA 1501 GAGGTGCCCG GCACCTCCGA CGACAGCACA GAAGAGCCCG TGATGAAAAA GAGGACCTAC 1561 TGCACCTACT GCCCCTCAAA GATCCGCAGG AAGGCCTCCG CATCCTGTAA GAAGTGCAAG 1621 AAGGTCATCT GCAGGGAACA CAATATCGAC ATGTGCCAGT CATGCTTC SEQ ID NO: 506: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (N2; amino acid 2-39 deletion) 556 aa 1 MQSDTEEAFI DEVHEVQPTS SGSEILDEQN VIEQPGSSLA SNRILTLPQR TIRGKNKHCW 61 STSKPTRRSR VSALNIVRSQ RGPTRMCRNI YDPLLCFKLF FTDEIISEIV KWTNAEISLK 121 RRESMTSATF RDTNEDEIYA FFGILVMTAV RKDNHMSTDD LFDRSLSMVY VSVMSRDRFD 181 FLIRCLRMDD KSIRPTLREN DVFTPVRKIW DLFIHQCIQN YTPGAHLTID EQLLGFRGRC 241 PFRVYIPNKP SKYGIKILMM CDSGTKYMIN GMPYLGRGTQ TNGVPLGEYY VKELSKPVHG 301 SCRNITCDNW FTSIPLAKNL LQEPYKLTIV GTVRSNKREI PEVLKNSRSR PVGTSMFCFD 361 GPLTLVSYKP KPAKMVYLLS SCDEDASINE STGKPQMVMY YNQTKGGVDT LDQMCSVMTC 421 SRKTNRWPMA LLYGMINIAC INSFIIYSHN VSSKGEKVQS RKKFMRNLYM GLTSSFMRKR 481 LEAPTLKRYL RDNISNILPK EVPGTSDDST EEPVMKKRTY CTYCPSKIRR KASASCKKCK 541 KVICREHNID MCQSCF SEQ ID NO: 507: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence (N3; nucleotide 4-258 deletion). 1524 bp 1 ATGAGGACTA TCAGAGGGAA AAATAAGCAC TGCTGGTCCA CTTCAAAGCC AACCAGGCGG 61 TCTAGGGTGT CCGCCCTGAA CATCGTGAGA AGCCAGAGAG GTCCAACCCG GATGTGCAGA 121 AACATCTACG ATCCCCTGCT GTGTTTCAAG CTGTTTTTTA CTGACGAGAT TATCAGCGAG 181 ATCGTGAAGT GGACCAACGC CGAGATCTCT CTGAAGCGGA GAGAAAGCAT GACCTCCGCC 241 ACATTCCGCG ATACCAACGA AGACGAGATC TACGCCTTTT TCGGCATCTT GGTGATGACT 301 GCCGTGAGGA AGGACAATCA CATGAGCACC GATGACCTGT TCGATCGCAG CCTGAGCATG 361 GTGTACGTGT CCGTGATGTC CAGGGACAGG TTCGACTTCC TGATCAGGTG CCTGAGAATG 421 GATGACAAGA GCATTAGACC TACCCTGCGC GAGAATGACG TGTTCACCCC CGTCAGGAAG 481 ATCTGGGACC TGTTTATTCA CCAGTGCATT CAGAACTATA CCCCTGGCGC CCACCTGACC 541 ATTGATGAGC AGCTCCTGGG ATTCAGGGGC CGGTGTCCCT TCAGAGTGTA TATACCTAAC 601 AAGCCCTCTA AGTACGGCAT CAAAATCCTG ATGATGTGCG ACTCCGGAAC CAAGTACATG 661 ATTAACGGAA TGCCCTATCT GGGACGCGGG ACCCAGACCA ATGGAGTGCC TCTGGGCGAG 721 TATTACGTGA AAGAGCTGTC CAAACCCGTG CACGGGTCCT GTCGGAATAT CACCTGCGAC 781 AACTGGTTCA CTTCAATCCC CCTGGCCAAA AACCTGCTGC AGGAGCCTTA CAAATTGACC 841 ATTGTGGGCA CTGTGCGCTC CAATAAGAGA GAAATTCCTG AGGTGCTGAA GAACTCCAGG 901 TCCAGACCCG TGGGCACTAG CATGTTCTGC TTCGACGGGC CTCTGACCCT GGTGAGCTAT 961 AAGCCCAAGC CAGCCAAGAT GGTGTACCTG CTGAGCAGCT GCGACGAGGA TGCCTCAATC 1021 AACGAGAGCA CCGGCAAGCC CCAGATGGTG ATGTACTACA ATCAGACCAA AGGCGGCGTG 1081 GATACCCTGG ACCAGATGTG TTCCGTGATG ACCTGTAGCA GGAAGACCAA CCGGTGGCCA 1141 ATGGCCCTGC TGTATGGAAT GATCAACATT GCCTGCATCA ACAGCTTCAT TATTTACTCC 1201 CACAATGTGT CCTCTAAGGG GGAGAAGGTG CAGTCTAGAA AAAAGTTTAT GAGGAATCTG 1261 TATATGGGCC TGACCTCTTC CTTCATGCGG AAGCGCCTGG AGGCACCCAC ACTGAAGAGG 1321 TACCTTCGCG ACAATATCTC CAATATTCTG CCGAAAGAGG TGCCCGGCAC CTCCGACGAC 1381 AGCACAGAAG AGCCCGTGAT GAAAAAGAGG ACCTACTGCA CCTACTGCCC CTCAAAGATC 1441 CGCAGGAAGG CCTCCGCATC CTGTAAGAAG TGCAAGAAGG TCATCTGCAG GGAACACAAT 1501 ATCGACATGT GCCAGTCATG CTTC SEQ ID NO: 508: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (N3; amino acid 2-86 deletion) 508 aa 1 MRTIRGKNKH CWSTSKPTRR SRVSALNIVR SQRGPTRMCR NIYDPLLCFK LFFTDEIISE 61 IVKWTNAEIS LKRRESMTSA TFRDTNEDEI YAFFGILVMT AVRKDNHMST DDLFDRSLSM 121 VYVSVMSRDR FDFLIRCLRM DDKSIRPTLR ENDVFTPVRK IWDLFIHQCI QNYTPGAHLT 181 IDEQLLGFRG RCPFRVYIPN KPSKYGIKIL MMCDSGTKYM INGMPYLGRG TQTNGVPLGE 241 YYVKELSKPV HGSCRNITCD NWFTSIPLAK NLLQEPYKLT IVGTVRSNKR EIPEVLKNSR 301 SRPVGTSMFC FDGPLTLVSY KPKPAKMVYL LSSCDEDASI NESTGKPQMV MYYNQTKGGV 361 DTLDQMCSVM TCSRKTNRWP MALLYGMINI ACINSFIIYS HNVSSKGEKV QSRKKFMRNL 421 YMGLTSSFMR KRLEAPTLKR YLRDNISNIL PKEVPGTSDD STEEPVMKKR TYCTYCPSKI 481 RRKASASCKK CKKVICREHN IDMCQSCF SEQ ID NO: 509: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence (N4; nucleotide 4-348 deletion).1437 bp 1 ATGAGCCAGA GAGGTCCAAC CCGGATGTGC AGAAACATCT ACGATCCCCT GCTGTGTTTC 61 AAGCTGTTTT TTACTGACGA GATTATCAGC GAGATCGTGA AGTGGACCAA CGCCGAGATC 121 TCTCTGAAGC GGAGAGAAAG CATGACCTCC GCCACATTCC GCGATACCAA CGAAGACGAG 181 ATCTACGCCT TTTTCGGCAT CTTGGTGATG ACTGCCGTGA GGAAGGACAA TCACATGAGC 241 ACCGATGACC TGTTCGATCG CAGCCTGAGC ATGGTGTACG TGTCCGTGAT GTCCAGGGAC 301 AGGTTCGACT TCCTGATCAG GTGCCTGAGA ATGGATGACA AGAGCATTAG ACCTACCCTG 361 CGCGAGAATG ACGTGTTCAC CCCCGTCAGG AAGATCTGGG ACCTGTTTAT TCACCAGTGC 421 ATTCAGAACT ATACCCCTGG CGCCCACCTG ACCATTGATG AGCAGCTCCT GGGATTCAGG 481 GGCCGGTGTC CCTTCAGAGT GTATATACCT AACAAGCCCT CTAAGTACGG CATCAAAATC 541 CTGATGATGT GCGACTCCGG AACCAAGTAC ATGATTAACG GAATGCCCTA TCTGGGACGC 601 GGGACCCAGA CCAATGGAGT GCCTCTGGGC GAGTATTACG TGAAAGAGCT GTCCAAACCC 661 GTGCACGGGT CCTGTCGGAA TATCACCTGC GACAACTGGT TCACTTCAAT CCCCCTGGCC 721 AAAAACCTGC TGCAGGAGCC TTACAAATTG ACCATTGTGG GCACTGTGCG CTCCAATAAG 781 AGAGAAATTC CTGAGGTGCT GAAGAACTCC AGGTCCAGAC CCGTGGGCAC TAGCATGTTC 841 TGCTTCGACG GGCCTCTGAC CCTGGTGAGC TATAAGCCCA AGCCAGCCAA GATGGTGTAC 901 CTGCTGAGCA GCTGCGACGA GGATGCCTCA ATCAACGAGA GCACCGGCAA GCCCCAGATG 961 GTGATGTACT ACAATCAGAC CAAAGGCGGC GTGGATACCC TGGACCAGAT GTGTTCCGTG 1021 ATGACCTGTA GCAGGAAGAC CAACCGGTGG CCAATGGCCC TGCTGTATGG AATGATCAAC 1081 ATTGCCTGCA TCAACAGCTT CATTATTTAC TCCCACAATG TGTCCTCTAA GGGGGAGAAG 1141 GTGCAGTCTA GAAAAAAGTT TATGAGGAAT CTGTATATGG GCCTGACCTC TTCCTTCATG 1201 CGGAAGCGCC TGGAGGCACC CACACTGAAG AGGTACCTTC GCGACAATAT CTCCAATATT 1261 CTGCCGAAAG AGGTGCCCGG CACCTCCGAC GACAGCACAG AAGAGCCCGT GATGAAAAAG 1321 AGGACCTACT GCACCTACTG CCCCTCAAAG ATCCGCAGGA AGGCCTCCGC ATCCTGTAAG 1381 AAGTGCAAGA AGGTCATCTG CAGGGAACAC AATATCGACA TGTGCCAGTC ATGCTTC SEQ ID NO: 510: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (N4; amino acid 2-116 deletion).479 aa 1 MSQRGPTRMC RNIYDPLLCF KLFFTDEIIS EIVKWTNAEI SLKRRESMTS ATFRDTNEDE 61 IYAFFGILVM TAVRKDNHMS TDDLFDRSLS MVYVSVMSRD RFDFLIRCLR MDDKSIRPTL 121 RENDVFTPVR KIWDLFIHQC IQNYTPGAHL TIDEQLLGFR GRCPFRVYIP NKPSKYGIKI 181 LMMCDSGTKY MINGMPYLGR GTQTNGVPLG EYYVKELSKP VHGSCRNITC DNWFTSIPLA 241 KNLLQEPYKL TIVGTVRSNK REIPEVLKNS RSRPVGTSMF CFDGPLTLVS YKPKPAKMVY 301 LLSSCDEDAS INESTGKPQM VMYYNQTKGG VDTLDQMCSV MTCSRKTNRW PMALLYGMIN 361 IACINSFIIY SHNVSSKGEK VQSRKKFMRN LYMGLTSSFM RKRLEAPTLK RYLRDNISNI 421 LPKEVPGTSD DSTEEPVMKK RTYCTYCPSK IRRKASASCK KCKKVICREH NIDMCQSCF In embodiments, the piggyBac comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from an C-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 502. In embodiments, the piggyBac with deletion from the C-terminus comprises SEQ ID NO: 512 or SEQ ID NO: 514, or a sequence having at least about 90% identity thereto. SEQ ID NO: 511: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence (C1; nucleotide 1708-1782 deletion). 1707 bp 1 ATGGGCTCTT CCTTGGACGA CGAGCACATC CTGAGCGCCC TGCTGCAGTC CGATGACGAG 61 CTGGTGGGTG AGGACTCCGA CAGTGAGGTG AGCGATCATG TGTCCGAGGA CGATGTGCAG 121 AGCGACACCG AGGAGGCCTT CATCGATGAG GTGCATGAAG TGCAGCCCAC ATCCTCCGGA 181 TCCGAGATCC TGGATGAGCA GAACGTGATC GAGCAGCCCG GGAGCTCTCT GGCTTCCAAC 241 AGAATCCTGA CCCTGCCTCA GAGGACTATC AGAGGGAAAA ATAAGCACTG CTGGTCCACT 301 TCAAAGCCAA CCAGGCGGTC TAGGGTGTCC GCCCTGAACA TCGTGAGAAG CCAGAGAGGT 361 CCAACCCGGA TGTGCAGAAA CATCTACGAT CCCCTGCTGT GTTTCAAGCT GTTTTTTACT 421 GACGAGATTA TCAGCGAGAT CGTGAAGTGG ACCAACGCCG AGATCTCTCT GAAGCGGAGA 481 GAAAGCATGA CCTCCGCCAC ATTCCGCGAT ACCAACGAAG ACGAGATCTA CGCCTTTTTC 541 GGCATCTTGG TGATGACTGC CGTGAGGAAG GACAATCACA TGAGCACCGA TGACCTGTTC 601 GATCGCAGCC TGAGCATGGT GTACGTGTCC GTGATGTCCA GGGACAGGTT CGACTTCCTG 661 ATCAGGTGCC TGAGAATGGA TGACAAGAGC ATTAGACCTA CCCTGCGCGA GAATGACGTG 721 TTCACCCCCG TCAGGAAGAT CTGGGACCTG TTTATTCACC AGTGCATTCA GAACTATACC 781 CCTGGCGCCC ACCTGACCAT TGATGAGCAG CTCCTGGGAT TCAGGGGCCG GTGTCCCTTC 841 AGAGTGTATA TACCTAACAA GCCCTCTAAG TACGGCATCA AAATCCTGAT GATGTGCGAC 901 TCCGGAACCA AGTACATGAT TAACGGAATG CCCTATCTGG GACGCGGGAC CCAGACCAAT 961 GGAGTGCCTC TGGGCGAGTA TTACGTGAAA GAGCTGTCCA AACCCGTGCA CGGGTCCTGT 1021 CGGAATATCA CCTGCGACAA CTGGTTCACT TCAATCCCCC TGGCCAAAAA CCTGCTGCAG 1081 GAGCCTTACA AATTGACCAT TGTGGGCACT GTGCGCTCCA ATAAGAGAGA AATTCCTGAG 1141 GTGCTGAAGA ACTCCAGGTC CAGACCCGTG GGCACTAGCA TGTTCTGCTT CGACGGGCCT 1201 CTGACCCTGG TGAGCTATAA GCCCAAGCCA GCCAAGATGG TGTACCTGCT GAGCAGCTGC 1261 GACGAGGATG CCTCAATCAA CGAGAGCACC GGCAAGCCCC AGATGGTGAT GTACTACAAT 1321 CAGACCAAAG GCGGCGTGGA TACCCTGGAC CAGATGTGTT CCGTGATGAC CTGTAGCAGG 1381 AAGACCAACC GGTGGCCAAT GGCCCTGCTG TATGGAATGA TCAACATTGC CTGCATCAAC 1441 AGCTTCATTA TTTACTCCCA CAATGTGTCC TCTAAGGGGG AGAAGGTGCA GTCTAGAAAA 1501 AAGTTTATGA GGAATCTGTA TATGGGCCTG ACCTCTTCCT TCATGCGGAA GCGCCTGGAG 1561 GCACCCACAC TGAAGAGGTA CCTTCGCGAC AATATCTCCA ATATTCTGCC GAAAGAGGTG 1621 CCCGGCACCT CCGACGACAG CACAGAAGAG CCCGTGATGA AAAAGAGGAC CTACTGCACC 1681 TACTGCCCCT CAAAGATCCG CAGGAAG SEQ ID NO: 512: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (C1; amino acid 570-594 deletion). 569 aa 1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG 61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKPTRRSRVS ALNIVRSQRG 121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF 181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV 241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD 301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ 361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC 421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN 481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMGL TSSFMRKRLE APTLKRYLRD NISNILPKEV 541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRK SEQ ID NO: 513: Trichnoplusia ni (hyperactive piggyBac) nucleotide sequence (C2; nucleotide 1660-1782 deletion). 1659 bp 1 ATGGGCTCTT CCTTGGACGA CGAGCACATC CTGAGCGCCC TGCTGCAGTC CGATGACGAG 61 CTGGTGGGTG AGGACTCCGA CAGTGAGGTG AGCGATCATG TGTCCGAGGA CGATGTGCAG 121 AGCGACACCG AGGAGGCCTT CATCGATGAG GTGCATGAAG TGCAGCCCAC ATCCTCCGGA 181 TCCGAGATCC TGGATGAGCA GAACGTGATC GAGCAGCCCG GGAGCTCTCT GGCTTCCAAC 241 AGAATCCTGA CCCTGCCTCA GAGGACTATC AGAGGGAAAA ATAAGCACTG CTGGTCCACT 301 TCAAAGCCAA CCAGGCGGTC TAGGGTGTCC GCCCTGAACA TCGTGAGAAG CCAGAGAGGT 361 CCAACCCGGA TGTGCAGAAA CATCTACGAT CCCCTGCTGT GTTTCAAGCT GTTTTTTACT 421 GACGAGATTA TCAGCGAGAT CGTGAAGTGG ACCAACGCCG AGATCTCTCT GAAGCGGAGA 481 GAAAGCATGA CCTCCGCCAC ATTCCGCGAT ACCAACGAAG ACGAGATCTA CGCCTTTTTC 541 GGCATCTTGG TGATGACTGC CGTGAGGAAG GACAATCACA TGAGCACCGA TGACCTGTTC 601 GATCGCAGCC TGAGCATGGT GTACGTGTCC GTGATGTCCA GGGACAGGTT CGACTTCCTG 661 ATCAGGTGCC TGAGAATGGA TGACAAGAGC ATTAGACCTA CCCTGCGCGA GAATGACGTG 721 TTCACCCCCG TCAGGAAGAT CTGGGACCTG TTTATTCACC AGTGCATTCA GAACTATACC 781 CCTGGCGCCC ACCTGACCAT TGATGAGCAG CTCCTGGGAT TCAGGGGCCG GTGTCCCTTC 841 AGAGTGTATA TACCTAACAA GCCCTCTAAG TACGGCATCA AAATCCTGAT GATGTGCGAC 901 TCCGGAACCA AGTACATGAT TAACGGAATG CCCTATCTGG GACGCGGGAC CCAGACCAAT 961 GGAGTGCCTC TGGGCGAGTA TTACGTGAAA GAGCTGTCCA AACCCGTGCA CGGGTCCTGT 1021 CGGAATATCA CCTGCGACAA CTGGTTCACT TCAATCCCCC TGGCCAAAAA CCTGCTGCAG 1081 GAGCCTTACA AATTGACCAT TGTGGGCACT GTGCGCTCCA ATAAGAGAGA AATTCCTGAG 1141 GTGCTGAAGA ACTCCAGGTC CAGACCCGTG GGCACTAGCA TGTTCTGCTT CGACGGGCCT 1201 CTGACCCTGG TGAGCTATAA GCCCAAGCCA GCCAAGATGG TGTACCTGCT GAGCAGCTGC 1261 GACGAGGATG CCTCAATCAA CGAGAGCACC GGCAAGCCCC AGATGGTGAT GTACTACAAT 1321 CAGACCAAAG GCGGCGTGGA TACCCTGGAC CAGATGTGTT CCGTGATGAC CTGTAGCAGG 1381 AAGACCAACC GGTGGCCAAT GGCCCTGCTG TATGGAATGA TCAACATTGC CTGCATCAAC 1441 AGCTTCATTA TTTACTCCCA CAATGTGTCC TCTAAGGGGG AGAAGGTGCA GTCTAGAAAA 1501 AAGTTTATGA GGAATCTGTA TATGGGCCTG ACCTCTTCCT TCATGCGGAA GCGCCTGGAG 1561 GCACCCACAC TGAAGAGGTA CCTTCGCGAC AATATCTCCA ATATTCTGCC GAAAGAGGTG 1621 CCCGGCACCT CCGACGACAG CACAGAAGAG CCCGTGATG SEQ ID NO: 514: Trichnoplusia ni (hyperactive piggyBac) amino acid sequence (C2; amino acid 554-594 deletion). 553 aa 1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG 61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKPTRRSRVS ALNIVRSQRG 121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF 181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV 241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD 301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ 361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC 421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN 481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMGL TSSFMRKRLE APTLKRYLRD NISNILPKEV 541 PGTSDDSTEE PVM In embodiments, the piggyBac comprises a deletion at positions about 1-5, or about 1-15, or about 1-25, or about 1- 35, or about 1-45, or about 1-55, or about 1-65, or about 1-75, or about 1-85, or about 1-95, or about 1-105, or about 1-115, or about 1-125, or about 1-135, or about 1-145, or about 1-155 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO: 502. Illustrative structural rationale, without wishing to be bound by theory, for deleting the N- and C-termini amino acid residues in the piggyBac are shown in TABLE 11. TABLE 11. Non-limiting structural rationale for deleting the N- and C-termini amino acid residues. * Numbering of amino acids is relative to SEQ ID NO: 502 In aspects, the N terminal deletion variant is further fused one or more DNA binding domains. In embodiments, the DNA binding domain comprises, without limitation, dCasX, dCas9, dCas12j, TALEs, and ZnF. In embodiments, the DNA binding domain guides donor insertion to specific genomic sites. In embodiments, the C terminal deletion variant is further fused one or more DNA binding domains. In embodiments, the N terminal deletion variant is further fused one or more DNA binding domains at the N-terminus. In embodiments, the N terminal deletion variant is further fused one or more DNA binding domains at the C-terminus. In embodiments, the C terminal deletion variant is further fused one or more DNA binding domains at the N-terminus. In embodiments, the C terminal deletion variant is further fused one or more DNA binding domains at the C-terminus. In embodiments, the piggyBac mutant exhibits improved excision frequencies compared to those without the terminal deletions and / or DNA binding domains. In embodiments, the piggyBac mutant exhibits improved integration frequencies compared to those without the terminal deletions and / or DNA binding domains. In embodiments, the piggyBac mutant exhibits improved excision and integration frequencies compared to those without the terminal deletions and / or DNA binding domains. In embodiments, the N or C terminal mutant exhibit different Exc+ / Int- frequencies compared to those without the terminal deletions and / or DNA binding domains. In embodiments, deletion of either N or C termini can result in piggyBac with increased excision activity compared to those without the terminal deletions and / or DNA binding domains. In embodiments, N-terminal deletion yields a mutant with decreased integration compared to those without the terminal deletions and / or DNA binding domains. In embodiments, C-terminal deletion yields a mutant with reduced excision and no integration compared to those without the terminal deletions and / or DNA binding domains. In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 566. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 566. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 566. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 566. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 566. SEQ ID NO: 566: hyper piggyBac – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVRSNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKG GVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEA PTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNIDMCRSCF In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 566 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 565 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 565: hyper piggyBac – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGAGAAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAA GCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGC GGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCT GTACGGGATGATCAACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAG TCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCA CCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTC TACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTT CTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTTTGA In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 570. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 570. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 570. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 570. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 570. In embodiments, the piggyBac mutant of the present disclosure comprises E2C zinc fingers inserted at the V390 piggybac loop domain. SEQ ID NO: 570: E2C V390 R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLR RHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASI NESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFM RNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKV ICREHNIDMCRSCF* In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 570 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 569 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 569: E2C V390 R372A – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGAGGTCT CGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACC AGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGG AGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGA CCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGAGGTGGCACTTCTATGTTCTGCTTTGACGGGCCAC TGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATC AATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGAT GTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTT GCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATG CGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCG CGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGA AACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTG ATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTTTGA In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 572. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 572. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 572. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 572. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 572. In embodiments, the piggyBac mutant of the present disclosure comprises E2C zinc fingers inserted at the V390 piggybac loop domain. In embodiments, the piggyBac mutant further comprises a short linker (e.g., GG) that connects the ZnF to the transposase. SEQ ID NO: 572: E2C GG V390 R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQR THTGEKPYKCPECGKSFSDCRDLARHQRTHTGGGGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASINESTGKP QMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYMGL TSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNI DMCRSCF* In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 572 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 571 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 571: E2C GG V390 R372A – nucleotide sequence (has a shorter linker between the zinc finger and the transposase) ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGAGGTGA GAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATA CAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGA ACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACA TCAAAGGACACATACAGGCGGAGGTGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGC CCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAAGCCC CAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCTGTAG TAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATCATCT ACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGGACTG ACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATATTCT GCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACTTATT GTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATT GATATGTGCCGGTCCTGTTTTTGA In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 574. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 574. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 574. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 574. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 574. In embodiments, the piggyBac mutant of the present disclosure comprises E2C zinc fingers inserted at the V390 piggybac loop domain. In embodiments, the piggyBac mutant further comprises a linker (e.g., GGSn, wherein n = 1-4) that connects the ZnF to the transposase. In embodiments, the ZnF is flanked by linkers on both the left and / or the right. SEQ ID NO: 574: E2C LR V390 R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGGSGGSGGSGGSLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECG KSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGSGGSGGSGGSGTSMFCFDGPLTLVSY KPKPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFI IYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCT YCPSKIRRKASASCKKCKKVICREHNIDMCRSCF* In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 574 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 573 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 573: E2C LR V390 R372A – nucleotide sequence (has a 4x glycine-glycine-serine linker on the left and right (LR) side of the zinc finger) ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGTGGATC CGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCT TCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGA AAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGA GTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGTGGTT CAGGTGGCAGCGGAGGGTCAGGAGGCTCTGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTAC AAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAA GCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCT GTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATC ATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGG ACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATA TTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACT TATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAA CATTGATATGTGCCGGTCCTGTTTTTGA In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 576. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 576. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 576. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 576. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 576. In embodiments, the piggyBac mutant of the present disclosure comprises E2C zinc fingers inserted at the V390 piggybac loop domain. In embodiments, the piggyBac mutant comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from an N-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 576, or a sequence having at least about 90% identity thereto. In embodiments, the piggyBac mutant comprises a deletion of about 5, or about 10, or about 20, or about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100, or about 110, or about 120, or about 130, or about 140, or about 150, or about 160 amino acids from an C-terminus of the polypeptide having an amino acid sequence of SEQ ID NO: 576. SEQ ID NO: 576: del74 V390 E2C R372A – amino acid sequence MSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFKLFFTDEIISEIVKW TNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMSRDRFDFLIRCLRMD DKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSKYGIKILMMCDSGTK YMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEV LKNSRSRPVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTGGGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASINESTGKPQMVMYYN QTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRK RLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNIDMCQSCF TSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNIDMCQSCF* In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 576 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 575 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 575: del74 V390 E2C R372A – nucleotide sequence ATGTCTAGTCTGGCTTCCAATAGGAACCTGACACTGCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAG CACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCGCCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGT GCCGAAATATCTACGACCCCCTGCTGTGCTTTAAGCTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGG ACTAACGCAGAGATTTCACTGAAAAGGCGCGAATCTATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAAT CTACGCTTTCTTTGGCATTCTGGTCATGACCGCAGTGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATC GCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGCAGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGAC GATAAGAGCATTCGACCTACACTGCGGGAGAATGACGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCA CCAGTGTATTCAGAACTACACACCCGGAGCCCATCTGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCC CTTTTCGCGTATACATTCCAAATAAGCCCAGCAAATATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAA TACATGATCAACGGAATGCCATATCTGGGACGGGGCACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAA GGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCA AGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTG CTGAAGAACAGCCGGAGCAGACCTGTCGGAGGTCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAA ATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAAT GCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGC CCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGG AGGTGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGT ATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAAC CAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCC TATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTA AGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAG CGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCAC TTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGA AAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCAGTCCTGTTTT ACTAGCGATGATTCCACTGAAGAGCCTGTAATGAAGAAAAGAACTTACTGCACATACTGCCCTTCCAAGATAAGGCG AAAGGCGAGCGCATCCTGTAAGAAATGCAAGAAGGTTATTTGTAGAGAGCATAATATAGATATGTGCCAGAGCTGCT TCTGA In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 578. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 578. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 578. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 578. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 578. In embodiments, the piggyBac mutant of the present disclosure comprises E2C zinc fingers inserted at the G321 piggybac loop domain. In embodiments, the piggyBac mutant further comprises a linker (e.g., GGSn, wherein n = 1-4) that connects the ZnF to the transposase. In embodiments, the ZnF is flanked by linkers on both the left and / or the right. SEQ ID NO: 578: G321 E2C LR R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGGGSGGSGGSGGSLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEK PYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGSGGSGGSGGSVPLGEYYV KELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSY KPKPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFI IYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCT YCPSKIRRKASASCKKCKKVICREHNIDMCRSCF* In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 578 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 577 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 577: G321 E2C LR R372A – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAACCAGGCGAGAAGCCTTATG CCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAA CCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGG CGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACAC ATACAGGCAAGAAGACCGGTGGTTCAGGTGGCAGCGGAGGGTCAGGAGGCTCTGTCCCCCTGGGCGAGTACTATGTG AAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGC CAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAG TGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTAC AAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAA GCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCT GTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATC ATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGG ACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATA TTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACT TATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAA CATTGATATGTGCCGGTCCTGTTTTTGA In embodiments, the enzyme comprises an amino acid sequence of at least about 90% identity to SEQ ID NO: 580. In embodiments, the enzyme comprises an amino acid sequence of at least about 93% identity to SEQ ID NO: 580. In embodiments, the enzyme comprises an amino acid sequence of at least about 95% identity to SEQ ID NO: 580. In embodiments, the enzyme comprises an amino acid sequence of at least about 98% identity to SEQ ID NO: 580. In embodiments, the enzyme comprises an amino acid sequence of at least about 99% identity to SEQ ID NO: 580. In embodiments, the piggyBac mutant of the present disclosure comprises E2C zinc fingers inserted at the K409 piggybac loop domain. In embodiments, the piggyBac mutant further comprises a linker (e.g., GGSn, wherein n = 1-4) that connects the ZnF to the transposase. In embodiments, the ZnF is flanked by linkers on both the left and / or the right. SEQ ID NO: 580: K409 E2C LR pB – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVRSNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKGGSGGSGGSGGSLEPGEKPYACPECGKSFSRKDSL VRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGSGGSGGS GGSPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFI IYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCT YCPSKIRRKASASCKKCKKVICREHNIDMCRSCF* In embodiments, the enzyme comprises an amino acid sequence of SEQ ID NO: 580 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 579 or a nucleotide sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto or a codon- optimized form thereof. SEQ ID NO: 579: K409 E2C LR pB – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGAGAAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAAGGTGGATCCGGAGGGTCCGGAGGTAGTG GCGGCAGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTG GTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGG CGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCG ATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGTGGTTCAGGTGGCAGCGGAGGGTCA GGAGGCTCTCCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAA GCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCT GTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATC ATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGG ACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATA TTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACT TATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAA CATTGATATGTGCCGGTCCTGTTTTTGA Host Cell In aspects, the present disclosure further provides a host cell comprising the composition in accordance with embodiments of the present disclosure. Methods In certain embodiments, the present disclosure provides a method for inserting a gene into the genome of a cell, comprising contacting a cell with the composition of the present disclosure or host cell of the present disclosure. In embodiments, the method further comprises contacting the cell with a polynucleotide encoding a transposon, transgene, and / or nucleic acid. In embodiments, the transposon, transgene, and / or nucleic acid comprises a gene encoding a complete polypeptide. In embodiments, the transposon, transgene, and / or nucleic acid comprises a gene which is defective or substantially absent in a disease state. In embodiments, the present disclosure provides a method for treating a disease or disorder ex vivo, comprising contacting a cell with the composition of the present disclosure or host cell of the present disclosure and administering the cell to a subject in need thereof. In embodiments, the present disclosure provides a method for treating a disease or disorder in vivo, comprising administering the composition of the present disclosure or host cell of the present disclosure to a subject in need thereof. Transgene In embodiments, the transgene is an exogenous wild-type gene that, e.g., corrects a defective function of one or more mutations in a recipient. For instance, in embodiments, the recipient may have a mutation that provides a disease phenotype (e.g., a defective or absent gene product). In embodiments, the transposon system or method of the present disclosure provides a correction that restores the gene product and diminishes the disease phenotype. In embodiments, the transgene is a gene that replaces, inactivates, or provides suicide or helper functions. In embodiments, the transgene and / or disease to be treated is one or more of: • beta-thalassemia: BCL11a or β-globin or βA-T87Q-globin, • LCA: RPE65, • LHON: ND4, • Achromatopsia: CNGA3 or CNGA3 / CNGB3, • Choroideremia: REP1, • PKD: RPK (Red cell PK), • Hemophilia: F8, • ADA-SCID: ADA, • Fabry disease: GLA, • MPS type I: IDUA, and • MPS type II: IDS. In embodiments, the disease or disorder to be treated comprises all inherited monogenic disorders. In embodiments, the disease or disorder to be treated comprises all inherited polygenic disorders. In embodiments, the transposon comprises a gene encoding a complete polypeptide. In embodiments, the transposon comprises a gene which is defective or substantially absent in a disease state. In embodiments, the transfecting of the cell is carried out using electroporation or calcium phosphate precipitation. In embodiments, the composition is encapsulated in a lipid nanoparticle (LNP). In embodiments, the polynucleotide encoding the enzyme or variant thereof and the polynucleotide encoding the donor are in the form of the same LNP, optionally in a co-formulation. In embodiments, the LNP comprises one or more lipids selected from 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), a cationic cholesterol derivative mixed with dimethylaminoethane-carbamoyl (DC-Chol), phosphatidylcholine (PC), triolein (glyceryl trioleate), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol – 2000 (DMG-PEG 2K), and 1,2 distearol -sn-glycerol-3phosphocholine (DSPC) and / or comprising of one or more molecules selected from polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), and N-Acetylgalactosamine (GalNAc). In embodiments, the transfecting of the cell is carried out using a lipid vehicle, optionally N-[1-(2,3-dioleoyloxy)propyl]- N,N,N-trimethylammonium chloride (DOTMA), 1,2-bis(oleoyloxy)-3-3-(trimethylammonia) propane (DOTAP), or 1,2- dioleoyl-3-dimethylammonium-propane (DODAP), dioleoylphosphatidylethanolamine (DOPE), cholesterol, LIPOFECTIN (cationic liposome formulation), LIPOFECTAMINE (cationic liposome formulation), LIPOFECTAMINE 2000 (cationic liposome formulation), LIPOFECTAMINE 3000 (cationic liposome formulation), TRANSFECTAM (cationic liposome formulation), a lipid nanoparticle, or a liposome and combinations thereof. In embodiments, the transfecting of the cell is carried out using a lipid selected from one or more of the following categories: cationic lipids; anionic lipids; neutral lipids; multi-valent charged lipids; and zwitterionic lipids. In embodiments, a cationic lipid may be used to facilitate a charge-charge interaction with nucleic acids. In embodiments, the lipid is a neutral lipid. In embodiments, the neutral lipid is dioleoylphosphatidylethanolamine (DOPE), 1,2-Dioleoyl- sn-glycero-3-phosphocholine (DOPC), or cholesterol. In embodiments, cholesterol is derived from plant sources. In other embodiments, cholesterol is derived from animal, fungal, bacterial, or archaeal sources. In embodiments, the lipid is a cationic lipid. In embodiments, the cationic lipid is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1,2-bis(oleoyloxy)-3-3-(trimethylammonia) propane (DOTAP), or 1,2-dioleoyl-3- dimethylammonium-propane (DODAP). In embodiments, one or more of the phospholipids 18:0 PC, 18:1 PC, 18:2 PC, DMPC, DSPE, DOPE, 18:2 PE, DMPE, or a combination thereof are used as lipids. In embodiments, the lipid is DOTMA and DOPE, optionally in a ratio of about 1:1. In embodiments, the lipid is DHDOS and DOPE, optionally in a ratio of about 1:1. In embodiments, the lipid is a commercially available product (e.g., LIPOFECTIN (cationic liposome formulation), LIPOFECTAMINE (cationic liposome formulation), LIPOFECTAMINE 2000 (cationic liposome formulation), LIPOFECTAMINE 3000 (cationic liposome formulation) (Life Technologies)). In embodiments, the transfecting of the cell is carried out using a cationic vehicle, optionally LIPOFECTIN or TRANSFECTAM. In embodiments, the transfecting of the cell is carried out using a lipid nanoparticle or a liposome. In embodiments, the method is helper virus-free. Epigenetic regulatory elements can be used to protect a transgene from unwanted epigenetic effects when placed near the transgene on a vector, including the transgene. See Ley et al., PloS One vol. 8,4 e62784. 30 Apr. 2013, doi:10.1371 / journal.pone.0062784. For example, MARs were shown to increase genomic integration and integration of a transgene while preventing heterochromatin silencing, as exemplified by the human MAR 1–68. See id.; see also Grandjean et al., Nucleic Acids Res.2011 Aug; 39(15): e104. MARs can also act as insulators and thereby prevent the activation of neighboring cellular genes. Gaussin et al., Gene Ther.2012 Jan; 19(1):15-24. It has been shown that a piggyBac transposon containing human MARs in CHO cells mediated efficient and sustained expression from a few transgene copies, using cell populations generated without an antibiotic selection procedure. See Ley et al. (2013). In embodiments, the cell is further transfected with a third nucleic acid having at least one chromatin element, wherein the at least one chromatin element is optionally a Matrix Attachment Region (MAR) element. MARs are expression- enhancing, epigenetic regulator elements which are used to enhance and / or facilitate transgene expression, as described, for example, in PCT / IB2010 / 002337 (WO2011033375), which is incorporated by reference herein in its entirety. A MAR element can be located in cis or trans to the transgene. In embodiments, the transgene has a size of 100,000 bases or less, e.g., about 100,000 bases, or about 50,000 bases, or about 30,000 bases, or about 10,000 bases, or about 5,000 bases, or about 10,000 to about 100,000 bases, or about 30,000 to about 100,000 bases, or about 50,000 to about 100,000 bases, or about 10,000 to about 50,000 bases, or about 10,000 to about 30,000 bases, or about 30,000 to about 50,000 bases. In embodiments, the transgene has a size of about 200,000 bases or less, e.g., about 200,000 bases, or about 10,000 to about 200,000 bases, or about 30,000 to about 200,000 bases, or about 50,000 to about 200,000 bases, or about 100,000 to about 200,000 bases, or about 150,000 to about 200,000 bases. Targeting Chimeric Constructs In aspects, the present disclosure provides for a transposon system, e.g., in embodiments, a transposase enzyme comprises a targeting element. In embodiments, the transposase enzyme associated with the targeting element, is capable of inserting the transposon comprising a transgene, optionally at a TA dinucleotide site or a TTAA (SEQ ID NO: 440) tetranucleotide site in a target site, optionally a genomic safe harbor site (GSHS). In embodiments, the GSHS comprises one or more TTAA integration sites. In embodiments, the targeting element directs the helper enzyme to either one or more nucleic acid binding sites that are upstream and / or downstream of the TTAA integration sites or to the TTAA integration sites. In embodiments, the targeting element directs the helper enzyme to one or more nucleic acid binding sites that are upstream and / or downstream of the TTAA integration sites and within about 5 to about 30 base pairs of the TTAA integration sites or within about 11 to about 15 base pairs of the TTAA integration sites. In embodiments, the targeting element directs the helper enzyme to two nucleic acid binding sites of the TTAA integration sites, wherein a first site is upstream of TTAA and within about 5 to about 30 base pairs or about 11 to about 15 base pairs of the TTAA and a second site is downstream of TTAA and within about 5 to about 30 base pairs or about 11 to about 15 base pairs of the TTAA. In embodiments, the transposase enzyme associated with the targeting element has one or more mutations which confer hyperactivity. In embodiments, the transposase enzyme associated with the targeting element has gene cleavage (Exc) and / or gene integration (Int+) activity. In embodiments, the transposase enzyme associated with the targeting element has gene cleavage (Exc) and / or a lack of gene integration (Int-) activity. In embodiments, the targeting element comprises one or more proteins or nucleic acids that are capable of binding to a nucleic acid. In embodiments, the targeting element comprises one or more of a of a gRNA, optionally associated with a CRISPR / Cas enzyme (class I, class II), or their six subtypes (type I–VI) (e.g., Cas12a, Cas12j, Cas12k), which is optionally catalytically inactive, transcription activator-like effector (TALE), Zinc finger, catalytically inactive transcription factor, nickase, a transcriptional activator, a transcriptional repressor, a recombinase, a DNA methyltransferase, a histone methyltransferase, and paternally expressed gene 10 (PEG10). In embodiments, the targeting element comprises a transcription activator-like effector (TALE) DNA binding domain (DBD). In embodiments, the TALE DBD comprises one or more repeat sequences. In embodiments, the TALE DBD comprises about 14, or about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences. In embodiments, the TALE DBD repeat sequences comprise 33 or 34 amino acids. In embodiments, the TALE DBD repeat sequences comprise a repeat variable di-residue (RVD) at residue 12 or 13 of the 33 or 34 amino acids. In embodiments, the RVD recognizes one base pair in the nucleic acid molecule. In embodiments, the RVD recognizes a C residue in the nucleic acid molecule and is selected from HD, N(gap), HA, ND, and HI. In embodiments, the RVD recognizes a G residue in the nucleic acid molecule and is selected from NN, NH, NK, HN, and NA. In embodiments, the RVD recognizes an A residue in the nucleic acid molecule and is selected from NI and NS. In embodiments, the RVD recognizes a T residue in the nucleic acid molecule and is selected from NG, HG, H(gap), and IG. In embodiments, the GSHS is in an open chromatin location in a chromosome. In embodiments, the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus. In embodiments, the GSHS is located on human chromosome 2, 4, 6, 10, 11, or 17. In embodiments, the GSHS is selected from TALC1, TALC2, TALC3, TALC4, TALC5, TALC7, TALC8, AVS1, AVS2, AVS3, ROSA1, ROSA2, TALER1, TALER2, TALER3, TALER4, TALER5, SHCHR2-1, SHCHR2-2, SHCHR2-3, SHCHR2-4, SHCHR4-1, SHCHR4-2, SHCHR4-3, SHCHR6-1, SHCHR6-2, SHCHR6-3, SHCHR6-4, SHCHR10-1, SHCHR10-2, SHCHR10-3, SHCHR10-4, SHCHR10-5, SHCHR11-1, SHCHR11-2, SHCHR11-3, SHCHR17-1, SHCHR17-2, SHCHR17-3, and SHCHR17-4. In embodiments, the targeting element comprises a Cas9 enzyme guide RNA complex. In embodiments, the Cas9 enzyme guide RNA complex comprises a nuclease-deficient dCas9 guide RNA complex. In embodiments, the targeting element comprises a CRISPR / Cas enzyme (class I, class II), or their six subtypes (type I–VI) (e.g., Cas12a, Cas12j, Cas12k) guide RNA complex. In embodiments, the targeting element comprises a CasX enzyme associated with a gRNA. In embodiments, the CasX enzyme associated with a gRNA comprises a catalytically inactive dCasX associated with a gRNA. In embodiments, the targeting element comprises a CasX enzyme associated with a gRNA, optionally wherein the catalytic inactive dCasX. In embodiments, a targeting chimeric system or construct, having a DBD fused to the transposase enzyme directs binding of the transposase to a specific sequence (e.g., transcription activator-like effector proteins (TALE) repeat variable di-residues (RVD) or gRNA) near an enzyme recognition site. The enzyme is thus prevented from binding to random recognition sites. In embodiments, the targeting chimeric construct binds to human GSHS. In embodiments, dCas9 (i.e., deficient for nuclease activity) is programmed with gRNAs directed to bind at a desired sequence of DNA in GSHS. In embodiments, TALEs described herein can physically sequester the enzyme to GSHS and promote transposition to nearby TTAA (SEQ ID NO: 440) sequences in close proximity to the RVD TALE nucleotide sequences. GSHS in open chromatin sites are specifically targeted based on the predilection for transposases to insert into open chromatin. In embodiments, the transposase enzyme is capable of targeted genomic integration by transposition is linked to or fused with a TALE DNA binding domain (DBD) or a Cas-based gene-editing system, such as, e.g., Cas9, CasX or a variant thereof. In embodiments, the targeting element targets the transposase enzyme to a locus of interest. In embodiments, the targeting element comprises CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) associated protein 9 (Cas9), or a variant thereof. A CRISPR / Cas9 tool only requires Cas9 nuclease for DNA cleavage and a single-guide RNA (sgRNA) for target specificity. See Jinek et al. (2012) Science 337, 816–821; Chylinski et al. (2014) Nucleic Acids Res 42, 6091–6105. The inactivated form of Cas9, which is a nuclease-deficient (or inactive, or “catalytically dead” Cas9, is typically denoted as “dCas9,” has no substantial nuclease activity. Qi, L. S. et al. (2013). Cell 152, 1173–1183. CRISPR / dCas9 binds precisely to specific genomic sequences through targeting of guide RNA (gRNA) sequences. See Dominguez et al., Nat Rev Mol Cell Biol.2016;17:5–15; Wang et al., Annu Rev Biochem.2016; 85:227–64. dCas9 is utilized to edit gene expression when applied to the transcription binding site of a desired site and / or locus in a genome. When the dCas9 protein is coupled to guide RNA (gRNA) to create dCas9 guide RNA complex, dCas9 prevents the proliferation of repeating codons and DNA sequences that might be harmful to an organism's genome. Essentially, when multiple repeat codons are produced, it elicits a response, or recruits an abundance of dCas9 to combat the overproduction of those codons and results in the shut-down of transcription. Thus, dCas9 works synergistically with gRNA and directly affects the DNA polymerase II from continuing transcription. In embodiments, the targeting element comprises a nuclease-deficient Cas enzyme guide RNA complex. In embodiments, the targeting element comprises a nuclease-deficient (or inactive, or “catalytically dead” Cas, e.g., Cas9, or CasX, typically denoted as “dCas” or “dCas9” or “dCasX”) guide RNA complex. In embodiments, the dCas9 / gRNA or dCasX / gRNA complex comprises a guide RNA selected from: GTTTAGCTCACCCGTGAGCC (SEQ ID NO: 91), CCCAATATTATTGTTCTCTG (SEQ ID NO: 92), GGGGTGGGATAGGGGATACG (SEQ ID NO: 93), GGATCCCCCTCTACATTTAA (SEQ ID NO: 94), GTGATCTTGTACAAATCATT (SEQ ID NO: 95), CTACACAGAATCTGTTAGAA (SEQ ID NO: 96), TAAGCTAGAGAATAGATCTC (SEQ ID NO: 97), and TCAATACACTTAATGATTTA (SEQ ID NO: 98), wherein the guide RNA directs the enzyme to a chemokine (C-C motif) receptor 5 (CCR5) gene. In embodiments, the dCas9 / gRNA or dCasX / gRNA complex comprises a guide RNA selected from: CACCGGGAGCCACGAAAACAGATCC (SEQ ID NO: 99);CACCGCGAAAACAGATCCAGGGACA (SEQ ID NO: 100); CACCGAGATCCAGGGACACGGTGCT (SEQ ID NO: 101); CACCGGACACGGTGCTAGGACAGTG (SEQ ID NO: 102); CACCGGAAAATGACCCAACAGCCTC (SEQ ID NO: 103); CACCGGCCTGGCCGGCCTGACCACT (SEQ ID NO: 104); CACCGCTGAGCACTGAAGGCCTGGC (SEQ ID NO: 105); CACCGTGGTTTCCACTGAGCACTGA (SEQ ID NO: 106); CACCGGATAGCCAGGAGTCCTTTCG (SEQ ID NO: 107); CACCGGCGCTTCCAGTGCTCAGACT (SEQ ID NO: 108); CACCGCAGTGCTCAGACTAGGGAAG (SEQ ID NO: 109); CACCGGCCCCTCCTCCTTCAGAGCC (SEQ ID NO: 110); CACCGTCCTTCAGAGCCAGGAGTCC (SEQ ID NO: 111); CACCGTGGTTTCCGAGCTTGACCCT (SEQ ID NO: 112); CACCGCTGCAGAGTATCTGCTGGGG (SEQ ID NO: 113); CACCGCGTTCCTGCAGAGTATCTGC (SEQ ID NO: 114); AAACGGATCTGTTTTCGTGGCTCCC (SEQ ID NO: 115); AAACTGTCCCTGGATCTGTTTTCGC (SEQ ID NO: 116); AAACAGCACCGTGTCCCTGGATCTC (SEQ ID NO: 117); AAACCACTGTCCTAGCACCGTGTCC (SEQ ID NO: 118); AAACGAGGCTGTTGGGTCATTTTCC (SEQ ID NO: 119); AAACAGTGGTCAGGCCGGCCAGGCC (SEQ ID NO: 120); AAACGCCAGGCCTTCAGTGCTCAGC (SEQ ID NO: 121); AAACTCAGTGCTCAGTGGAAACCAC (SEQ ID NO: 122); AAACCGAAAGGACTCCTGGCTATCC (SEQ ID NO: 123); AAACAGTCTGAGCACTGGAAGCGCC (SEQ ID NO: 124); AAACCTTCCCTAGTCTGAGCACTGC (SEQ ID NO: 125); AAACGGCTCTGAAGGAGGAGGGGCC (SEQ ID NO: 126); AAACGGACTCCTGGCTCTGAAGGAC (SEQ ID NO: 127); AAACAGGGTCAAGCTCGGAAACCAC (SEQ ID NO: 128); AAACCCCCAGCAGATACTCTGCAGC (SEQ ID NO: 129); AAACGCAGATACTCTGCAGGAACGC (SEQ ID NO: 130); TCCCCTCCCAGAAAGACCTG (SEQ ID NO: 131); TGGGCTCCAAGCAATCCTGG (SEQ ID NO: 132); GTGGCTCAGGAGGTACCTGG (SEQ ID NO: 133); GAGCCACGAAAACAGATCCA (SEQ ID NO: 134); AAGTGAACGGGGAAGGGAGG (SEQ ID NO: 135); GACAAAAGCCGAAGTCCAGG (SEQ ID NO: 136); GTGGTTGATAAACCCACGTG (SEQ ID NO: 137); TGGGAACAGCCACAGCAGGG (SEQ ID NO: 138); GCAGGGGAACGGGGATGCAG (SEQ ID NO: 139); GAGATGGTGGACGAGGAAGG (SEQ ID NO: 140); GAGATGGCTCCAGGAAATGG (SEQ ID NO: 141); TAAGGAATCTGCCTAACAGG (SEQ ID NO: 142); TCAGGAGACTAGGAAGGAGG (SEQ ID NO: 143); TATAAGGTGGTCCCAGCTCG (SEQ ID NO: 144); CTGGAAGATGCCATGACAGG (SEQ ID NO: 145); GCACAGACTAGAGAGGTAAG (SEQ ID NO: 146); ACAGACTAGAGAGGTAAGGG (SEQ ID NO: 147); GAGAGGTGACCCGAATCCAC (SEQ ID NO: 148); GCACAGGCCCCAGAAGGAGA (SEQ ID NO: 149); CCGGAGAGGACCCAGACACG (SEQ ID NO: 150); GAGAGGACCCAGACACGGGG (SEQ ID NO: 151); GCAACACAGCAGAGAGCAAG (SEQ ID NO: 152); GAAGAGGGAGTGGAGGAAGA (SEQ ID NO: 153); AAGACGGAACCTGAAGGAGG (SEQ ID NO: 154); AGAAAGCGGCACAGGCCCAG (SEQ ID NO: 155); GGGAAACAGTGGGCCAGAGG (SEQ ID NO: 156); GTCCGGACTCAGGAGAGAGA (SEQ ID NO: 157); GGCACAGCAAGGGCACTCGG (SEQ ID NO: 158); GAAGAGGGGAAGTCGAGGGA (SEQ ID NO: 159); GGGAATGGTAAGGAGGCCTG (SEQ ID NO: 160); GCAGAGTGGTCAGCACAGAG (SEQ ID NO: 161); GCACAGAGTGGCTAAGCCCA (SEQ ID NO: 162); GACGGGGTGTCAGCATAGGG (SEQ ID NO: 163); GCCCAGGGCCAGGAACGACG (SEQ ID NO: 164); GGTGGAGTCCAGCACGGCGC (SEQ ID NO: 165); ACAGGCCGCCAGGAACTCGG (SEQ ID NO: 166); ACTAGGAAGTGTGTAGCACC (SEQ ID NO: 167); ATGAATAGCAGACTGCCCCG (SEQ ID NO: 168); ACACCCCTAAAAGCACAGTG (SEQ ID NO: 169); CAAGGAGTTCCAGCAGGTGG (SEQ ID NO: 170); AAGGAGTTCCAGCAGGTGGG (SEQ ID NO: 171); TGGAAAGAGGAGGGAAGAGG (SEQ ID NO: 172); TCGAATTCCTAACTGCCCCG (SEQ ID NO: 173); GACCTGCCCAGCACACCCTG (SEQ ID NO: 174); GGAGCAGCTGCGGCAGTGGG (SEQ ID NO: 175); GGGAGGGAGAGCTTGGCAGG (SEQ ID NO: 176); GTTACGTGGCCAAGAAGCAG (SEQ ID NO: 177); GCTGAACAGAGAAGAGCTGG (SEQ ID NO: 178); TCTGAGGGTGGAGGGACTGG (SEQ ID NO: 179); GGAGAGGTGAGGGACTTGGG (SEQ ID NO: 180); GTGAACCAGGCAGACAACGA (SEQ ID NO: 181); CAGGTACCTCCTGAGCCACG (SEQ ID NO: 182); GGGGGAGTAGGGGCATGCAG (SEQ ID NO: 183); GCAAATGGCCAGCAAGGGTG (SEQ ID NO: 184); CAAATGGCCAGCAAGGGTGG (SEQ ID NO: 309); GCAGAACCTGAGGATATGGA (SEQ ID NO: 310); AATACACAGAATGAAAATAG (SEQ ID NO: 311); CTGGTGACTAGAATAGGCAG (SEQ ID NO: 312); TGGTGACTAGAATAGGCAGT (SEQ ID NO: 313); TAAAAGAATGTGAAAAGATG (SEQ ID NO: 314); TCAGGAGTTCAAGACCACCC (SEQ ID NO: 315); TGTAGTCCCAGTTATGCAGG (SEQ ID NO: 316); GGGTTCACACCACAAATGCA (SEQ ID NO: 317); GGCAAATGGCCAGCAAGGGT (SEQ ID NO: 318); AGAAACCAATCCCAAAGCAA (SEQ ID NO: 319); GCCAAGGACACCAAAACCCA (SEQ ID NO: 320); AGTGGTGATAAGGCAACAGT (SEQ ID NO: 321); CCTGAGACAGAAGTATTAAG (SEQ ID NO: 322); AAGGTCACACAATGAATAGG (SEQ ID NO: 323); CACCATACTAGGGAAGAAGA (SEQ ID NO: 324); CAATACCCTGCCCTTAGTGG (SEQ ID NO: 327); AATACCCTGCCCTTAGTGGG (SEQ ID NO: 325); TTAGTGGGGGGTGGAGTGGG (SEQ ID NO: 326); GTGGGGGGTGGAGTGGGGGG (SEQ ID NO: 328); GGGGGGTGGAGTGGGGGGTG (SEQ ID NO: 329); GGGGTGGAGTGGGGGGTGGG (SEQ ID NO: 330); GGGTGGAGTGGGGGGTGGGG (SEQ ID NO: 331); GGGGGTGGGGAAAGACATCG (SEQ ID NO: 332); GCAGCTGTGAATTCTGATAG (SEQ ID NO: 333); GAGATCAGAGAAACCAGATG (SEQ ID NO: 334); TCTATACTGATTGCAGCCAG (SEQ ID NO: 335); CACCGAATCGAGAAGCGACTCGACA (SEQ ID NO: 185); CACCGGTCCCTGGGCGTTGCCCTGC (SEQ ID NO: 186); CACCGCCCTGGGCGTTGCCCTGCAG (SEQ ID NO: 187); CACCGCCGTGGGAAGATAAACTAAT (SEQ ID NO: 188); CACCGTCCCCTGCAGGGCAACGCCC (SEQ ID NO: 189); CACCGGTCGAGTCGCTTCTCGATTA (SEQ ID NO: 190); CACCGCTGCTGCCTCCCGTCTTGTA (SEQ ID NO: 191); CACCGGAGTGCCGCAATACCTTTAT (SEQ ID NO: 192); CACCGACACTTTGGTGGTGCAGCAA (SEQ ID NO: 193); CACCGTCTCAAATGGTATAAAACTC (SEQ ID NO: 194); CACCGAATCCCGCCCATAATCGAGA (SEQ ID NO: 195); CACCGTCCCGCCCATAATCGAGAAG (SEQ ID NO: 196); CACCGCCCATAATCGAGAAGCGACT (SEQ ID NO: 197); CACCGGAGAAGCGACTCGACATGGA (SEQ ID NO: 198); CACCGGAAGCGACTCGACATGGAGG (SEQ ID NO: 199); CACCGGCGACTCGACATGGAGGCGA (SEQ ID NO: 200); AAACTGTCGAGTCGCTTCTCGATTC (SEQ ID NO: 201); AAACGCAGGGCAACGCCCAGGGACC (SEQ ID NO: 202); AAACCTGCAGGGCAACGCCCAGGGC (SEQ ID NO: 203); AAACATTAGTTTATCTTCCCACGGC (SEQ ID NO: 204); AAACGGGCGTTGCCCTGCAGGGGAC (SEQ ID NO: 205); AAACTAATCGAGAAGCGACTCGACC (SEQ ID NO: 206); AAACTACAAGACGGGAGGCAGCAGC (SEQ ID NO: 207); AAACATAAAGGTATTGCGGCACTCC (SEQ ID NO: 208); AAACTTGCTGCACCACCAAAGTGTC (SEQ ID NO: 209); AAACGAGTTTTATACCATTTGAGAC (SEQ ID NO: 210); AAACTCTCGATTATGGGCGGGATTC (SEQ ID NO: 211); AAACCTTCTCGATTATGGGCGGGAC (SEQ ID NO: 212); AAACAGTCGCTTCTCGATTATGGGC (SEQ ID NO: 213); AAACTCCATGTCGAGTCGCTTCTCC (SEQ ID NO: 214); AAACCCTCCATGTCGAGTCGCTTCC (SEQ ID NO: 215); AAACTCGCCTCCATGTCGAGTCGCC (SEQ ID NO: 216); CACCGACAGGGTTAATGTGAAGTCC (SEQ ID NO: 217); CACCGTCCCCCTCTACATTTAAAGT (SEQ ID NO: 218); CACCGCATTTAAAGTTGGTTTAAGT (SEQ ID NO: 219); CACCGTTAGAAAATATAAAGAATAA (SEQ ID NO: 220); CACCGTAAATGCTTACTGGTTTGAA (SEQ ID NO: 221); CACCGTCCTGGGTCCAGAAAAAGAT (SEQ ID NO: 222); CACCGTTGGGTGGTGAGCATCTGTG (SEQ ID NO: 223); CACCGCGGGGAGAGTGGAGAAAAAG (SEQ ID NO: 224); CACCGGTTAAAACTCTTTAGACAAC (SEQ ID NO: 225); CACCGGAAAATCCCCACTAAGATCC (SEQ ID NO: 226); AAACGGACTTCACATTAACCCTGTC (SEQ ID NO: 227); AAACACTTTAAATGTAGAGGGGGAC (SEQ ID NO: 228); AAACACTTAAACCAACTTTAAATGC (SEQ ID NO: 229); AAACTTATTCTTTATATTTTCTAAC (SEQ ID NO: 230); AAACTTCAAACCAGTAAGCATTTAC (SEQ ID NO: 231); AAACATCTTTTTCTGGACCCAGGAC (SEQ ID NO: 232); AAACCACAGATGCTCACCACCCAAC (SEQ ID NO: 233); AAACCTTTTTCTCCACTCTCCCCGC (SEQ ID NO: 234); AAACGTTGTCTAAAGAGTTTTAACC (SEQ ID NO: 235); AAACGGATCTTAGTGGGGATTTTCC (SEQ ID NO: 236); AGTAGCAGTAATGAAGCTGG (SEQ ID NO: 237); ATACCCAGACGAGAAAGCTG (SEQ ID NO: 238); TACCCAGACGAGAAAGCTGA (SEQ ID NO: 239); GGTGGTGAGCATCTGTGTGG (SEQ ID NO: 240); AAATGAGAAGAAGAGGCACA (SEQ ID NO: 241); CTTGTGGCCTGGGAGAGCTG (SEQ ID NO: 242); GCTGTAGAAGGAGACAGAGC (SEQ ID NO: 243); GAGCTGGTTGGGAAGACATG (SEQ ID NO: 244); CTGGTTGGGAAGACATGGGG (SEQ ID NO: 245); CGTGAGGATGGGAAGGAGGG (SEQ ID NO: 246); ATGCAGAGTCAGCAGAACTG (SEQ ID NO: 247); AAGACATCAAGCACAGAAGG (SEQ ID NO: 248); TCAAGCACAGAAGGAGGAGG (SEQ ID NO: 249); AACCGTCAATAGGCAAAGGG (SEQ ID NO: 250); CCGTATTTCAGACTGAATGG (SEQ ID NO: 251); GAGAGGACAGGTGCTACAGG (SEQ ID NO: 252); AACCAAGGAAGGGCAGGAGG (SEQ ID NO: 253); GACCTCTGGGTGGAGACAGA (SEQ ID NO: 254); CAGATGACCATGACAAGCAG (SEQ ID NO: 255); AACACCAGTGAGTAGAGCGG (SEQ ID NO: 256); AGGACCTTGAAGCACAGAGA (SEQ ID NO: 257); TACAGAGGCAGACTAACCCA (SEQ ID NO: 258); ACAGAGGCAGACTAACCCAG (SEQ ID NO: 259); TAAATGACGTGCTAGACCTG (SEQ ID NO: 260); AGTAACCACTCAGGACAGGG (SEQ ID NO: 261); ACCACAAAACAGAAACACCA (SEQ ID NO: 262); GTTTGAAGACAAGCCTGAGG (SEQ ID NO: 263); GCTGAACCCCAAAAGACAGG (SEQ ID NO: 264); GCAGCTGAGACACACACCAG (SEQ ID NO: 265); AGGACACCCCAAAGAAGCTG (SEQ ID NO: 266); GGACACCCCAAAGAAGCTGA (SEQ ID NO: 267); CCAGTGCAATGGACAGAAGA (SEQ ID NO: 268); AGAAGAGGGAGCCTGCAAGT (SEQ ID NO: 269); GTGTTTGGGCCCTAGAGCGA (SEQ ID NO: 270); CATGTGCCTGGTGCAATGCA (SEQ ID NO: 271); TACAAAGAGGAAGATAAGTG (SEQ ID NO: 272); GTCACAGAATACACCACTAG (SEQ ID NO: 273); GGGTTACCCTGGACATGGAA (SEQ ID NO: 274); CATGGAAGGGTATTCACTCG (SEQ ID NO: 275); AGAGTGGCCTAGACAGGCTG (SEQ ID NO: 276); CATGCTGGACAGCTCGGCAG (SEQ ID NO: 277); AGTGAAAGAAGAGAAAATTC (SEQ ID NO: 278); TGGTAAGTCTAAGAAACCTA (SEQ ID NO: 279); CCCACAGCCTAACCACCCTA (SEQ ID NO: 280); AATATTTCAAAGCCCTAGGG (SEQ ID NO: 281); GCACTCGGAACAGGGTCTGG (SEQ ID NO: 282); AGATAGGAGCTCCAACAGTG (SEQ ID NO: 283); AAGTTAGAGCAGCCAGGAAA (SEQ ID NO: 284); TAGAGCAGCCAGGAAAGGGA (SEQ ID NO: 285); TGAATACCCTTCCATGTCCA (SEQ ID NO: 286); CCTGCATTGCACCAGGCACA (SEQ ID NO: 287); TCTAGGGCCCAAACACACCT (SEQ ID NO: 288); TCCCTCCATCTATCAAAAGG (SEQ ID NO: 289); AGCCCTGAGACAGAAGCAGG (SEQ ID NO: 290); GCCCTGAGACAGAAGCAGGT (SEQ ID NO: 291); AGGAGATGCAGTGATACGCA (SEQ ID NO: 292); ACAATACCAAGGGTATCCGG (SEQ ID NO: 293); TGATAAAGAAAACAAAGTGA (SEQ ID NO: 294); AAAGAAAACAAAGTGAGGGA (SEQ ID NO: 295); GTGGCAAGTGGAGAAATTGA (SEQ ID NO: 296); CAAGTGGAGAAATTGAGGGA (SEQ ID NO: 297); GTGGTGATGATTGCAGCTGG (SEQ ID NO: 298); CTATGTGCCTGACACACAGG (SEQ ID NO: 299); GGGTTGGACCAGGAAAGAGG (SEQ ID NO: 300); GATGCCTGGAAAAGGAAAGA (SEQ ID NO: 301); TAGTATGCACCTGCAAGAGG (SEQ ID NO: 302); TATGCACCTGCAAGAGGCGG (SEQ ID NO: 303); AGGGGAAGAAGAGAAGCAGA (SEQ ID NO: 304); GCTGAATCAAGAGACAAGCG (SEQ ID NO: 305); AAGCAAATAAATCTCCTGGG (SEQ ID NO: 306); AGATGAGTGCTAGAGACTGG (SEQ ID NO: 307); and CTGATGGTTGAGCACAGCAG (SEQ ID NO: 308). In embodiments, the guide RNAs are: AATCGAGAAGCGACTCGACA (SEQ ID NO: 425), and tgccctgcaggggagtgagc (SEQ ID NO: 426). In embodiments, the guide RNAs are gaagcgactcgacatggagg (SEQ ID NO: 427) and cctgcaggggagtgagcagc (SEQ ID NO: 428). In embodiments, guide RNAs (gRNAs) for targeting human genomic safe harbor sites are synthesized using any of the oligonucleotide primers elements, e.g., without limitation dCas, in areas of open chromatin are as shown in TABLE 1. TABLE 1
[0004] In embodiments, gRNAs for targeting human genomic safe harbor sites using any of the gRNA-based targeting elements, e.g., without limitation, dCas, in areas of open chromatin are shown in TABLE 5 or TABLE 6. TABLE 5 Guide RNA Sequences Targeting the Genomic Safe Harbor Site hROSA26
[0005] TABLE 6. Guide RNA Sequences Targeting the Genomic Safe Harbor Site, AAVS1. In embodiments, gRNAs for targeting human genomic safe harbor sites using any of the gRNA-based targeting elements, e.g., without limitation, dCas, in areas of open chromatin are shown in TABLE 9. TABLE 9. Guide RNA seqences targeting chromosome 22 TTAA hotspot. [hg38 chr22:35,373,912-35,373,916 (861); chr22:35,377,843-35,377,847 (1153)]. In embodiments, the gRNA comprises one or more of the sequences outlined herein or a variant sequence having at least about 10 mutations, or at least about 9 mutations, or at least about 8 mutations, or at least about 7 mutations, or at least about 6 mutations, or at least about 5 mutations, or at least about 4 mutations, or at least about 3 mutations, or at least about 2 mutations, or at least about 1 mutation. In embodiments, a Cas-based targeting element comprises CRISPR / Cas enzymes (class I, class II), or their six subtypes (type I–VI or a variant thereof, e.g., without limitation, Cas12a (e.g., dCas12a), or Cas12j (e.g., dCas12j), or Cas12k (e.g., dCas12k). In embodiments, the targeting element comprises a Cas enzyme guide RNA complex. In embodiments, comprises a nuclease-deficient dCas12 guide RNA complex, optionally dCas12j guide RNA complex or dCas12a guide RNA complex. In embodiments, the Cas-based targeting element comprises a CasX enzyme associated with a gRNA. In embodiments, the CasX enzyme associated with a gRNA comprises a catalytically inactive dCasX associated with a gRNA. In embodiments, the targeting element comprises a CasX enzyme associated with a gRNA, optionally wherein the catalytic inactive dCasX. In embodiments, the targeting element is selected from a zinc finger (ZnF), transcription activator-like effector (TALE), meganuclease, and clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein, any of which are, in embodiments, catalytically inactive. In embodiments, the CRISPR-associated protein is selected from CRISPR / Cas enzymes (class I, class II), or their six subtypes (type I–VI including but not limited to Cas9, CasX, CasY, Cas12a (Cpf1), and gRNA complexes thereof. In embodiments, the CRISPR-associated protein is selected from Cas9, xCas9, Cas 6, Cas7, Cas8, Cas12a (Cpf1), Cas13a, Cas14, CasX, CasY, a Class 1 Cas protein, a Class 2 Cas protein, MAD7, MG1 nuclease, MG2 nuclease, MG3 nuclease, or catalytically inactive forms thereof, and gRNA complexes thereof. In embodiments, the transposase enzyme of the present disclosure is capable of inserting a transposon at a TA dinucleotide site or a TTAA tetranucleotide site in a target site, optionally a genomic safe harbor site (GSHS) of a nucleic acid molecule. The transposase enzyme of the present disclosure is suitable for causing insertion of the transposon in a GSHS when contacted with a biological cell. In embodiments, the targeting element is suitable for directing the transposase enzyme of the present disclosure to the GSHS sequence. In embodiments, the targeting element comprises transcription activator-like effector (TALE) DNA binding domain (DBD). The TALE DBD comprises one or more repeat sequences. For example, in embodiments, the TALE DBD comprises about 14, or about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences. In embodiments, the TALE DBD repeat sequences comprise 33 or 34 amino acids. In embodiments, the one or more of the TALE DBD repeat sequences comprise a repeat variable di-residue (RVD) at residue 12 or 13 of the 33 or 34 amino acids. In embodiments, the targeting element (e.g., TALE or Cas (e.g., CasX, Cas9 or Cas12, or variants thereof) DBDs cause the transposase enzyme of the present disclosure to bind specifically to human GSHS. In embodiments, the TALEs or Cas DBDs sequester the transposase to GSHS and promote transposition to nearby TA dinucleotide or a TTAA tetranucleotide sites which can be located in proximity to the repeat variable di-residues (RVD) TALE or gRNA nucleotide sequences. The GSHS regions are located in open chromatin sites that are susceptible to transposase activity. Accordingly, the transposase enzyme of the present disclosure does not only operate based on its ability to recognize TA or TTAA sites, but it also directs a transposon (having a transgene) to specific locations in proximity to a TALE or Cas DBD. The transposase enzyme of the present disclosure in accordance with embodiments of the present disclosure has negligible risk of genotoxicity and exhibits superior features as compared to existing gene therapies. In embodiments, the transposase enzyme of the present disclosure is mutated to be characterized by reduced or inhibited binding of off-target sequences and consequently reliant on a DBD fused thereto, such as a TALE or Cas DBD, for transposition. The described cells, compositions, and methods allow reducing vector and transgene insertions that increase a mutagenic risk. The described cells and methods make use of a gene transfer system that reduces genotoxicity compared to viral- and nuclease-mediated gene therapies. In embodiments, TALE or Cas DBDs are customizable, such as a TALE or Cas DBDs is selected for targeting a specific genomic location. In embodiments, the genomic location is in proximity to a TA dinucleotide site or a TTAA (SEQ ID NO: 440) tetranucleotide site. Embodiments of the present disclosure make use of the ability of TALE or Cas or dCas9 / gRNA DBDs to target specific sites in a host genome. The DNA targeting ability of a TALE or Cas DBD or dCas9 / gRNA DBD is provided by TALE repeat sequences (e.g., modular arrays) or gRNA which are linked together to recognize flanking DNA sequences. Each TALE or gRNA can recognize certain base pair(s) or residue(s). TALE nucleases (TALENs) are a known tool for genome editing and introducing targeted double-stranded breaks. TALENs comprise endonucleases, such as FokI nuclease domain, fused to a customizable DBD. This DBD is composed of highly conserved repeats from TALEs, which are proteins secreted by Xanthomonas bacteria to alter transcription of genes in host plant cells. The DBD includes a repeated highly conserved 33–34 amino acid sequence with divergent 12th and 13th amino acids. These two positions, referred to as the RVD, are highly variable and show a strong correlation with specific base pair or nucleotide recognition. This straightforward relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DBDs by selecting a combination of repeat segments containing the appropriate RVDs. Boch et al. Nature Biotechnology.2011; 29 (2): 135–6. Accordingly, TALENs can be readily designed using a “protein-DNA code” that relates modular DNA-binding TALE repeat domains to individual bases in a target-binding site. See Joung et al. Nat Rev Mol Cell Biol.2013;14(1):49-55. doi:10.1038 / nrm3486. The following table, for example, shows such code: It has been demonstrated that TALENs can be used to target essentially any DNA sequence of interest in human cell. Miller et al. Nat Biotechnol.2011; 29:143–148. Guidelines for selection of potential target sites and for use of particular TALE repeat domains (harboring NH residues at the hypervariable positions) for recognition of G bases have been proposed. See Streubel et al. Nat Biotechnol.2012; 30:593–595. Accordingly, in embodiments, the TALE DBD comprises one or more repeat sequences. In embodiments, the TALE DBD comprises about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences. In embodiments, the TALE DBD repeat sequences comprise 33 or 34 amino acids. In embodiments, the one or more of the TALE DBD repeat sequences comprise an RVD at residue 12 or 13 of the 33 or 34 amino acids. The RVD can recognize certain base pair(s) or residue(s). In embodiments, the RVD recognizes one base pair in the nucleic acid molecule. In embodiments, the RVD recognizes a C residue in the nucleic acid molecule and is selected from HD, N(gap), HA, ND, and HI. In embodiments, the RVD recognizes a G residue in the nucleic acid molecule and is selected from NN, NH, NK, HN, and NA. In embodiments, the RVD recognizes an A residue in the nucleic acid molecule and is selected from NI and NS. In embodiments, the RVD recognizes a T residue in the nucleic acid molecule and is selected from NG, HG, H(gap), and IG. In embodiments, the GSHS is in an open chromatin location in a chromosome. In embodiments, the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor; and human Rosa26 locus. In embodiments, the GSHS is located on human chromosome 2, 4, 6, 10, 11, or 17. In embodiments, the GSHS is selected from TALC1, TALC2, TALC3, TALC4, TALC5, TALC7, TALC8, AVS1, AVS2, AVS3, ROSA1, ROSA2, TALER1, TALER2, TALER3, TALER4, TALER5, SHCHR2-1, SHCHR2-2, SHCHR2-3, SHCHR2-4, SHCHR4-1, SHCHR4-2, SHCHR4-3, SHCHR6-1, SHCHR6-2, SHCHR6-3, SHCHR6-4, SHCHR10-1, SHCHR10-2, SHCHR10-3, SHCHR10-4, SHCHR10-5, SHCHR11-1, SHCHR11-2, SHCHR11-3, SHCHR17-1, SHCHR17-2, SHCHR17-3, and SHCHR17-4. In embodiments, the GSHS comprises one or more of TGGCCGGCCTGACCACTGG (SEQ ID NO: 23), TGAAGGCCTGGCCGGCCTG (SEQ ID NO: 24), TGAGCACTGAAGGCCTGGC (SEQ ID NO: 25), TCCACTGAGCACTGAAGGC (SEQ ID NO: 26), TGGTTTCCACTGAGCACTG (SEQ ID NO: 27), TGGGGAAAATGACCCAACA (SEQ ID NO: 28), TAGGACAGTGGGGAAAATG (SEQ ID NO: 29), TCCAGGGACACGGTGCTAG (SEQ ID NO: 30), TCAGAGCCAGGAGTCCTGG (SEQ ID NO: 31), TCCTTCAGAGCCAGGAGTC (SEQ ID NO: 32), TCCTCCTTCAGAGCCAGGA (SEQ ID NO: 33), TCCAGCCCCTCCTCCTTCA (SEQ ID NO: 34), TCCGAGCTTGACCCTTGGA (SEQ ID NO: 35), TGGTTTCCGAGCTTGACCC (SEQ ID NO: 36), TGGGGTGGTTTCCGAGCTT (SEQ ID NO: 37), TCTGCTGGGGTGGTTTCCG (SEQ ID NO: 38), TGCAGAGTATCTGCTGGGG (SEQ ID NO: 39), CCAATCCCCTCAGT (SEQ ID NO: 40), CAGTGCTCAGTGGAA (SEQ ID NO: 41), GAAACATCCGGCGACTCA (SEQ ID NO: 42), TCGCCCCTCAAATCTTACA (SEQ ID NO: 43), TCAAATCTTACAGCTGCTC (SEQ ID NO: 44), TCTTACAGCTGCTCACTCC (SEQ ID NO: 45), TACAGCTGCTCACTCCCCT (SEQ ID NO: 46), TGCTCACTCCCCTGCAGGG (SEQ ID NO: 47), TCCCCTGCAGGGCAACGCC (SEQ ID NO: 48), TGCAGGGCAACGCCCAGGG (SEQ ID NO: 49), TCTCGATTATGGGCGGGAT (SEQ ID NO: 50), TCGCTTCTCGATTATGGGC (SEQ ID NO: 51), TGTCGAGTCGCTTCTCGAT (SEQ ID NO: 52), TCCATGTCGAGTCGCTTCT (SEQ ID NO: 53), TCGCCTCCATGTCGAGTCG (SEQ ID NO: 54), TCGTCATCGCCTCCATGTC (SEQ ID NO: 55), TGATCTCGTCATCGCCTCC (SEQ ID NO: 56), GCTTCAGCTTCCTA (SEQ ID NO: 57), CTGTGATCATGCCA (SEQ ID NO: 58), ACAGTGGTACACACCT (SEQ ID NO: 59), CCACCCCCCACTAAG (SEQ ID NO: 60), CATTGGCCGGGCAC (SEQ ID NO: 61), GCTTGAACCCAGGAGA (SEQ ID NO: 62), ACACCCGATCCACTGGG (SEQ ID NO: 63), GCTGCATCAACCCC (SEQ ID NO: 64), GCCACAAACAGAAATA (SEQ ID NO: 65), GGTGGCTCATGCCTG (SEQ ID NO: 66), GATTTGCACAGCTCAT (SEQ ID NO: 67), AAGCTCTGAGGAGCA (SEQ ID NO: 68), CCCTAGCTGTCCC (SEQ ID NO: 69), GCCTAGCATGCTAG (SEQ ID NO: 70), ATGGGCTTCACGGAT (SEQ ID NO: 71), GAAACTATGCCTGC (SEQ ID NO: 72), GCACCATTGCTCCC (SEQ ID NO: 73), GACATGCAACTCAG (SEQ ID NO: 74), ACACCACTAGGGGT (SEQ ID NO: 75), GTCTGCTAGACAGG (SEQ ID NO: 76), GGCCTAGACAGGCTG (SEQ ID NO: 77), GAGGCATTCTTATCG (SEQ ID NO: 78), GCCTGGAAACGTTCC (SEQ ID NO: 79), GTGCTCTGACAATA (SEQ ID NO: 80), GTTTTGCAGCCTCC (SEQ ID NO: 81), ACAGCTGTGGAACGT (SEQ ID NO: 82), GGCTCTCTTCCTCCT (SEQ ID NO: 83), CTATCCCAAAACTCT (SEQ ID NO: 84), GAAAAACTATGTAT (SEQ ID NO: 85), AGGCAGGCTGGTTGA (SEQ ID NO: 86), CAATACAACCACGC (SEQ ID NO: 87), ATGACGGACTCAACT (SEQ ID NO: 88), CACAACATTTGTAA (SEQ ID NO: 89), and ATTTCCAGTGCACA (SEQ ID NO: 90). In embodiments, the TALE DBD binds to one of TGGCCGGCCTGACCACTGG (SEQ ID NO: 23), TGAAGGCCTGGCCGGCCTG (SEQ ID NO: 24), TGAGCACTGAAGGCCTGGC (SEQ ID NO: 25), TCCACTGAGCACTGAAGGC (SEQ ID NO: 26), TGGTTTCCACTGAGCACTG (SEQ ID NO: 27), TGGGGAAAATGACCCAACA (SEQ ID NO: 28), TAGGACAGTGGGGAAAATG (SEQ ID NO: 29), TCCAGGGACACGGTGCTAG (SEQ ID NO: 30), TCAGAGCCAGGAGTCCTGG (SEQ ID NO: 31), TCCTTCAGAGCCAGGAGTC (SEQ ID NO: 32), TCCTCCTTCAGAGCCAGGA (SEQ ID NO: 33), TCCAGCCCCTCCTCCTTCA (SEQ ID NO: 34), TCCGAGCTTGACCCTTGGA (SEQ ID NO: 35), TGGTTTCCGAGCTTGACCC (SEQ ID NO: 36), TGGGGTGGTTTCCGAGCTT (SEQ ID NO: 37), TCTGCTGGGGTGGTTTCCG (SEQ ID NO: 38), TGCAGAGTATCTGCTGGGG (SEQ ID NO: 39), CCAATCCCCTCAGT (SEQ ID NO: 40), CAGTGCTCAGTGGAA (SEQ ID NO: 41), GAAACATCCGGCGACTCA (SEQ ID NO: 42), TCGCCCCTCAAATCTTACA (SEQ ID NO: 43), TCAAATCTTACAGCTGCTC (SEQ ID NO: 44), TCTTACAGCTGCTCACTCC (SEQ ID NO: 45), TACAGCTGCTCACTCCCCT (SEQ ID NO: 46), TGCTCACTCCCCTGCAGGG (SEQ ID NO: 47), TCCCCTGCAGGGCAACGCC (SEQ ID NO: 48), TGCAGGGCAACGCCCAGGG (SEQ ID NO: 49), TCTCGATTATGGGCGGGAT (SEQ ID NO: 50), TCGCTTCTCGATTATGGGC (SEQ ID NO: 51), TGTCGAGTCGCTTCTCGAT (SEQ ID NO: 52), TCCATGTCGAGTCGCTTCT (SEQ ID NO: 53), TCGCCTCCATGTCGAGTCG (SEQ ID NO: 54), TCGTCATCGCCTCCATGTC (SEQ ID NO: 55), TGATCTCGTCATCGCCTCC (SEQ ID NO: 56), GCTTCAGCTTCCTA (SEQ ID NO: 57), CTGTGATCATGCCA (SEQ ID NO: 58), ACAGTGGTACACACCT (SEQ ID NO: 59), CCACCCCCCACTAAG (SEQ ID NO: 60), CATTGGCCGGGCAC (SEQ ID NO: 61), GCTTGAACCCAGGAGA (SEQ ID NO: 62), ACACCCGATCCACTGGG (SEQ ID NO: 63), GCTGCATCAACCCC (SEQ ID NO: 64), GCCACAAACAGAAATA (SEQ ID NO: 65), GGTGGCTCATGCCTG (SEQ ID NO: 66), GATTTGCACAGCTCAT (SEQ ID NO: 67), AAGCTCTGAGGAGCA (SEQ ID NO: 68), CCCTAGCTGTCCC (SEQ ID NO: 69), GCCTAGCATGCTAG (SEQ ID NO: 70), ATGGGCTTCACGGAT (SEQ ID NO: 71), GAAACTATGCCTGC (SEQ ID NO: 72), GCACCATTGCTCCC (SEQ ID NO: 73), GACATGCAACTCAG (SEQ ID NO: 74), ACACCACTAGGGGT (SEQ ID NO: 75), GTCTGCTAGACAGG (SEQ ID NO: 76), GGCCTAGACAGGCTG (SEQ ID NO: 77), GAGGCATTCTTATCG (SEQ ID NO: 78), GCCTGGAAACGTTCC (SEQ ID NO: 79), GTGCTCTGACAATA (SEQ ID NO: 80), GTTTTGCAGCCTCC (SEQ ID NO: 81), ACAGCTGTGGAACGT (SEQ ID NO: 82), GGCTCTCTTCCTCCT (SEQ ID NO: 83), CTATCCCAAAACTCT (SEQ ID NO: 84), GAAAAACTATGTAT (SEQ ID NO: 85), AGGCAGGCTGGTTGA (SEQ ID NO: 86), CAATACAACCACGC (SEQ ID NO: 87), ATGACGGACTCAACT (SEQ ID NO: 88), CACAACATTTGTAA (SEQ ID NO: 89), and ATTTCCAGTGCACA (SEQ ID NO: 90). In embodiments, the TALE DBD comprises one or more of NH NH HD HD NH NH HD HD NG NH NI HD HD NI HD NG NH NH, NH NI NI NH NH HD HD NG NH NH HD HD NH NH HD HD NG NH, NH NI NH HD NI HD NG NH NI NI NH NH HD HD NG NH NH HD, HD HD NI HD NG NH NI NH HD NI HD NG NH NI NI NH NH HD, NH NH NG NG NG HD HD NI HD NG NH NI NH HD NI HD NG NH, NH NH NH NH NI NI NI NI NG NH NI HD HD HD NI NI HD NI, NI NH NH NI HD NI NH NG NH NH NH NH NI NI NI NI NG NH, HD HD NI NH NH NH NI HD NI HD NH NH NG NH HD NG NI NH, HD NI NH NI NH HD HD NI NH NH NI NH NG HD HD NG NH NH, HD HD NG NG HD NI NH NI NH HD HD NI NH NH NI NH NG HD, HD HD NG HD HD NG NG HD NI NH NI NH HD HD NI NH NH NI, HD HD NI NH HD HD HD HD NG HD HD NG HD HD NG NG HD NI, HD HD NH NI NH HD NG NG NH NI HD HD HD NG NG NH NH NI, NH NH NG NG NG HD HD NH NI NH HD NG NG NH NI HD HD HD, NH NH NH NH NG NH NH NG NG NG HD HD NH NI NH HD NG NG, HD NG NH HD NG NH NH NH NH NG NH NH NG NG NG HD HD NH, NH HD NI NH NI NH NG NI NG HD NG NH HD NG NH NH NH NH, HD HD NI NI NG HD HD HD HD NG HD NI NH NG, HD NI NH NG NH HD NG HD NI NH NG NH NH NI NI, NH NI NI NI HD NI NG HD HD NH NH HD NH NI HD NG HD NI, HD NH HD HD HD HD NG HD NI NI NI NG HD NG NG NI HD NI, HD NI NI NI NG HD NG NG NI HD NI NH HD NG NH HD NG HD, HD NG NG NI HD NI NH HD NG NH HD NG HD NI HD NG HD HD, NI HD NI NH HD NG NH HD NG HD NI HD NG HD HD HD HD NG, NH HD NG HD NI HD NG HD HD HD HD NG NH HD NI NH NH NH, HD HD HD HD NG NH HD NI NH NH NH HD NI NI HD NH HD HD, NH HD NI NH NH NH HD NI NI HD NH HD HD HD NI NH NH NH, HD NG HD NH NI NG NG NI NG NH NH NH HD NH NH NH NI NG, HD NH HD NG NG HD NG HD NH NI NG NG NI NG NH NH NH HD, NH NG HD NH NI NH NG HD NH HD NG NG HD NG HD NH NI NG, HD HD NI NG NH NG HD NH NI NH NG HD NH HD NG NG HD NG, HD NH HD HD NG HD HD NI NG NH NG HD NH NI NH NG HD NH, HD NH NG HD NI NG HD NH HD HD NG HD HD NI NG NH NG HD, NH NI NG HD NG HD NH NG HD NI NG HD NH HD HD NG HD HD, NH HD NG NG HD NI NH HD NG NG HD HD NG NI, HD NG NK NG NH NI NG HD NI NG NH HD HD NI, NI HD NI NN NG NN NN NG NI HD NI HD NI HD HD NG, HD HD NI HD HD HD HD HD HD NI HD NG NI NI NN, HD NI NG NG NN NN HD HD NN NN NN HD NI HD, NN HD NG NG NN NI NI HD HD HD NI NN NN NI NN NI, NI HD NI HD HD HD NN NI NG HD HD NI HD NG NN NN NN, NN HD NG NN HD NI NG HD NI NI HD HD HD HD, NN NN HD NI HD NN NI NI NI HD NI HD HD HD NG HD HD, NN NN NG NN NN HD NG HD NI NG NN HD HD NG NN, NN NI NG NG NG NN HD NI HD NI NN HD NG HD NI NG, NI NI NH HD NG HD NG NH NI NH NH NI NH HD, HD HD HD NG NI NK HD NG NH NG HD HD HD HD, NH HD HD NG NI NH HD NI NG NH HD NG NI NH, NI NG NH NH NH HD NG NG HD NI HD NH NH NI NG, NH NI NI NI HD NG NI NG NH HD HD NG NH HD, NH HD NI HD HD NI NG NG NH HD NG HD HD HD, NH NI HD NI NG NH HD NI NI HD NG HD NI NH, NI HD NI HD HD NI HD NG NI NH NH NH NH NG, NH NG HD NG NH HD NG NI NH NI HD NI NH NH, NH NH HD HD NG NI NH NI HD NI NH NH HD NG NH, NH NI NH NH HD NI NG NG HD NG NG NI NG HD NH, NN HD HD NG NN NN NI NI NI HD NN NG NG HD HD, NN NG NN HD NG HD NG NN NI HD NI NI NG NI, NN NG NG NG NG NN HD NI NN HD HD NG HD HD, NI HD NI NN HD NG NN NG NN NN NI NI HD NN NG, HD NI NI NN NI HD HD NN NI NN HD NI HD NG NN HD NG NN, HD NG NI NG HD HD HD NI NI NI NI HD NG HD NG, NH NI NI NI NI NI HD NG NI NG NH NG NI NG, NI NH NH HD NI NH NH HD NG NH NH NG NG NH NI, HD NI NI NG NI HD NI NI HD HD NI HD NN HD, NI NG NN NI HD NN NN NI HD NG HD NI NI HD NG, HD NI HD NI NI HD NI NG NG NG NN NG NI NI, and NI NG NG NG HD HD NI NN NG NN HD NI HD NI. In embodiments, the TALE DBD comprises one or more of the sequences outlined herein or a variant sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto, or at least about 10 mutations, or at least about 9 mutations, or at least about 8 mutations, or at least about 7 mutations, or at least about 6 mutations, or at least about 5 mutations, or at least about 4 mutations, or at least about 3 mutations, or at least about 2 mutations, or at least about 1 mutation. In embodiments, the GSHS and the TALE DBD sequences are selected from: TGGCCGGCCTGACCACTGG (SEQ ID NO: 23) and NH NH HD HD NH NH HD HD NG NH NI HD HD NI HD NG NH NH; TGAAGGCCTGGCCGGCCTG (SEQ ID NO: 24) and NH NI NI NH NH HD HD NG NH NH HD HD NH NH HD HD NG NH; TGAGCACTGAAGGCCTGGC (SEQ ID NO: 25) and NH NI NH HD NI HD NG NH NI NI NH NH HD HD NG NH NH HD; TCCACTGAGCACTGAAGGC (SEQ ID NO: 26) and HD HD NI HD NG NH NI NH HD NI HD NG NH NI NI NH NH HD; TGGTTTCCACTGAGCACTG (SEQ ID NO: 27) and NH NH NG NG NG HD HD NI HD NG NH NI NH HD NI HD NG NH; TGGGGAAAATGACCCAACA (SEQ ID NO: 28) and NH NH NH NH NI NI NI NI NG NH NI HD HD HD NI NI HD NI; TAGGACAGTGGGGAAAATG (SEQ ID NO: 29) and NI NH NH NI HD NI NH NG NH NH NH NH NI NI NI NI NG NH; TCCAGGGACACGGTGCTAG (SEQ ID NO: 30) and HD HD NI NH NH NH NI HD NI HD NH NH NG NH HD NG NI NH; TCAGAGCCAGGAGTCCTGG (SEQ ID NO: 31) and HD NI NH NI NH HD HD NI NH NH NI NH NG HD HD NG NH NH; TCCTTCAGAGCCAGGAGTC (SEQ ID NO: 32) and HD HD NG NG HD NI NH NI NH HD HD NI NH NH NI NH NG HD; TCCTCCTTCAGAGCCAGGA (SEQ ID NO: 33) and HD HD NG HD HD NG NG HD NI NH NI NH HD HD NI NH NH NI; TCCAGCCCCTCCTCCTTCA (SEQ ID NO: 34) and HD HD NI NH HD HD HD HD NG HD HD NG HD HD NG NG HD NI; TCCGAGCTTGACCCTTGGA (SEQ ID NO: 35) and HD HD NH NI NH HD NG NG NH NI HD HD HD NG NG NH NH NI; TGGTTTCCGAGCTTGACCC (SEQ ID NO: 36) and NH NH NG NG NG HD HD NH NI NH HD NG NG NH NI HD HD HD; TGGGGTGGTTTCCGAGCTT (SEQ ID NO: 37) and NH NH NH NH NG NH NH NG NG NG HD HD NH NI NH HD NG NG; TCTGCTGGGGTGGTTTCCG (SEQ ID NO: 38) and HD NG NH HD NG NH NH NH NH NG NH NH NG NG NG HD HD NH; TGCAGAGTATCTGCTGGGG (SEQ ID NO: 39) and NH HD NI NH NI NH NG NI NG HD NG NH HD NG NH NH NH NH; CCAATCCCCTCAGT (SEQ ID NO: 40) and HD HD NI NI NG HD HD HD HD NG HD NI NH NG; CAGTGCTCAGTGGAA (SEQ ID NO: 41) and HD NI NH NG NH HD NG HD NI NH NG NH NH NI NI; GAAACATCCGGCGACTCA (SEQ ID NO: 42) and NH NI NI NI HD NI NG HD HD NH NH HD NH NI HD NG HD NI; TCGCCCCTCAAATCTTACA (SEQ ID NO: 43) and HD NH HD HD HD HD NG HD NI NI NI NG HD NG NG NI HD NI; TCAAATCTTACAGCTGCTC (SEQ ID NO: 44) and HD NI NI NI NG HD NG NG NI HD NI NH HD NG NH HD NG HD; TCTTACAGCTGCTCACTCC (SEQ ID NO: 45) and HD NG NG NI HD NI NH HD NG NH HD NG HD NI HD NG HD HD; TACAGCTGCTCACTCCCCT (SEQ ID NO: 46) and NI HD NI NH HD NG NH HD NG HD NI HD NG HD HD HD HD NG; TGCTCACTCCCCTGCAGGG (SEQ ID NO: 47) and NH HD NG HD NI HD NG HD HD HD HD NG NH HD NI NH NH NH; TCCCCTGCAGGGCAACGCC (SEQ ID NO: 48) and HD HD HD HD NG NH HD NI NH NH NH HD NI NI HD NH HD HD; TGCAGGGCAACGCCCAGGG (SEQ ID NO: 49) and NH HD NI NH NH NH HD NI NI HD NH HD HD HD NI NH NH NH; TCTCGATTATGGGCGGGAT (SEQ ID NO: 50) and HD NG HD NH NI NG NG NI NG NH NH NH HD NH NH NH NI NG; TCGCTTCTCGATTATGGGC (SEQ ID NO: 51) and HD NH HD NG NG HD NG HD NH NI NG NG NI NG NH NH NH HD; TGTCGAGTCGCTTCTCGAT (SEQ ID NO: 52) and NH NG HD NH NI NH NG HD NH HD NG NG HD NG HD NH NI NG; TCCATGTCGAGTCGCTTCT (SEQ ID NO: 53) and HD HD NI NG NH NG HD NH NI NH NG HD NH HD NG NG HD NG; TCGCCTCCATGTCGAGTCG (SEQ ID NO: 54) and HD NH HD HD NG HD HD NI NG NH NG HD NH NI NH NG HD NH; TCGTCATCGCCTCCATGTC (SEQ ID NO: 55) and HD NH NG HD NI NG HD NH HD HD NG HD HD NI NG NH NG HD; TGATCTCGTCATCGCCTCC (SEQ ID NO: 56) and NH NI NG HD NG HD NH NG HD NI NG HD NH HD HD NG HD HD; GCTTCAGCTTCCTA (SEQ ID NO: 57) and NH HD NG NG HD NI NH HD NG NG HD HD NG NI; CTGTGATCATGCCA (SEQ ID NO: 58) and HD NG NK NG NH NI NG HD NI NG NH HD HD NI; ACAGTGGTACACACCT (SEQ ID NO: 59) and NI HD NI NN NG NN NN NG NI HD NI HD NI HD HD NG; CCACCCCCCACTAAG (SEQ ID NO: 60) and HD HD NI HD HD HD HD HD HD NI HD NG NI NI NN; CATTGGCCGGGCAC (SEQ ID NO: 61) and HD NI NG NG NN NN HD HD NN NN NN HD NI HD; GCTTGAACCCAGGAGA (SEQ ID NO: 62) and NN HD NG NG NN NI NI HD HD HD NI NN NN NI NN NI; ACACCCGATCCACTGGG (SEQ ID NO: 63) and NI HD NI HD HD HD NN NI NG HD HD NI HD NG NN NN NN; GCTGCATCAACCCC (SEQ ID NO: 64) and NN HD NG NN HD NI NG HD NI NI HD HD HD HD; GCCACAAACAGAAATA (SEQ ID NO: 65) and NN NN HD NI HD NN NI NI NI HD NI HD HD HD NG HD HD; GGTGGCTCATGCCTG (SEQ ID NO: 66) and NN NN NG NN NN HD NG HD NI NG NN HD HD NG NN; GATTTGCACAGCTCAT (SEQ ID NO: 67) and NN NI NG NG NG NN HD NI HD NI NN HD NG HD NI NG; AAGCTCTGAGGAGCA (SEQ ID NO: 68) and NI NI NH HD NG HD NG NH NI NH NH NI NH HD; CCCTAGCTGTCCC (SEQ ID NO: 69) and HD HD HD NG NI NK HD NG NH NG HD HD HD HD; GCCTAGCATGCTAG (SEQ ID NO: 70) and NH HD HD NG NI NH HD NI NG NH HD NG NI NH; ATGGGCTTCACGGAT (SEQ ID NO: 71) and NI NG NH NH NH HD NG NG HD NI HD NH NH NI NG; GAAACTATGCCTGC (SEQ ID NO: 72) and NH NI NI NI HD NG NI NG NH HD HD NG NH HD; GCACCATTGCTCCC (SEQ ID NO: 73) and NH HD NI HD HD NI NG NG NH HD NG HD HD HD; GACATGCAACTCAG (SEQ ID NO: 74) and NH NI HD NI NG NH HD NI NI HD NG HD NI NH; ACACCACTAGGGGT (SEQ ID NO: 75) and NI HD NI HD HD NI HD NG NI NH NH NH NH NG; GTCTGCTAGACAGG (SEQ ID NO: 76) and NH NG HD NG NH HD NG NI NH NI HD NI NH NH; GGCCTAGACAGGCTG (SEQ ID NO: 77) and NH NH HD HD NG NI NH NI HD NI NH NH HD NG NH; GAGGCATTCTTATCG (SEQ ID NO: 78) and NH NI NH NH HD NI NG NG HD NG NG NI NG HD NH; GCCTGGAAACGTTCC (SEQ ID NO: 79) and NN HD HD NG NN NN NI NI NI HD NN NG NG HD HD; GTGCTCTGACAATA (SEQ ID NO: 80) and NN NG NN HD NG HD NG NN NI HD NI NI NG NI; GTTTTGCAGCCTCC (SEQ ID NO: 81) and NN NG NG NG NG NN HD NI NN HD HD NG HD HD; ACAGCTGTGGAACGT (SEQ ID NO: 82) and NI HD NI NN HD NG NN NG NN NN NI NI HD NN NG; GGCTCTCTTCCTCCT (SEQ ID NO: 83) and HD NI NI NN NI HD HD NN NI NN HD NI HD NG NN HD NG NN; CTATCCCAAAACTCT (SEQ ID NO: 84) and HD NG NI NG HD HD HD NI NI NI NI HD NG HD NG; GAAAAACTATGTAT (SEQ ID NO: 85) and NH NI NI NI NI NI HD NG NI NG NH NG NI NG; AGGCAGGCTGGTTGA (SEQ ID NO: 86) and NI NH NH HD NI NH NH HD NG NH NH NG NG NH NI; CAATACAACCACGC (SEQ ID NO: 87) and HD NI NI NG NI HD NI NI HD HD NI HD NN HD; ATGACGGACTCAACT (SEQ ID NO: 88) and NI NG NN NI HD NN NN NI HD NG HD NI NI HD NG; and CACAACATTTGTAA (SEQ ID NO: 89) and HD NI HD NI NI HD NI NG NG NG NN NG NI NI. In embodiments, the GSHS is within about 25, or about 50, or about 100, or about 150, or about 200, or about 300, or about 500 nucleotides of the TA dinucleotide site or TTAA (SEQ ID NO: 440) tetranucleotide site. Illustrative DNA binding codes for targeting human genomic safe harbor in areas of open chromatin via TALES, encompassed by various embodiments are provided in TABLE 2. TABLE 2
[0006] Further illustrative DNA binding codes for targeting human genomic safe harbor in areas of open chromatin via TALES, encompassed by embodiments are provided in TABLE 7 and TABLE 8. In embodiments, the transposase enzyme of the present disclosure is capable of inserting a transposon at a TA dinucleotide site. In embodiments, the transposase enzyme of the present disclosure is capable of inserting a transposon at a TTAA (SEQ ID NO: 440) tetranucleotide site. TABLE 7 TALE Sequences Targeting the Genomic Safe Harbor Site hROSA26 TABLE 8 TALE Sequences Targeting the Genomic Safe Harbor Site AAVS1 Illustrative DNA binding codes for targeting human genomic safe harbor in areas of open chromatin via TALES, encompassed by various embodiments are provided in TABLE 10. TABLE 10. TALE sequences targeting the chromosome 22 hotspot. [hg38 chr22:35,373,912-35,373,916 (861); chr22:35,377,843-35,377,847 (1153)].
[0007] In embodiments, the present disclosure relates to a system having nucleic acids encoding the enzyme (e.g., without limitation, the transposase enzyme) and the transposon, respectively. Linkers In embodiments, the targeting element comprises a nucleic acid binding component of a gene-editing system. In embodiments, the transposase enzyme the targeting element are connected. Without wishing to be bound by a particular theory, the targeting element may refer to a nucleic acid binding component of the gene-editing system. In embodiments, the transposase enzyme and the targeting element are connected. For example, in embodiments, the transposase enzyme and the targeting element are fused to one another or linked via a linker to one another. In embodiments, the linker is a covalent linker or a non-covalent linker. In embodiments, the linker is a flexible linker. In embodiments, the flexible linker is a glycine-glycine linker. In embodiments, the flexible linker is substantially comprised of glycine and serine residues, optionally wherein the flexible linker comprises (Gly4Ser)n, where n is an integer from 1 to 12. In embodiments, the flexible linker is of about 20, or about 30, or about 40, or about 50, or about 60 amino acid residues. In embodiments, the flexible linker is about 50, or about 100, or about 150, or about 200 amino acid residues in length. In embodiments, the flexible linker comprises at least about 150 nucleotides (nt), or at least about 200 nt, or at least about 250 nt, or at least about 300 nt, or at least about 350 nt, or at least about 400 nt, or at least about 450 nt, or at least about 500 nt, or at least about 500 nt, or at least about 600 nt. In embodiments, the flexible linker comprises from about 450 nt to about 500 nt. In embodiments, the linker comprises an amino acid sequence of AKLAGGAPAVGGGPKAADKFAATGGS (SEQ ID NO: 3) or a variant thereof having a substitution or deletion. In embodiment, the linker is a non-covalent linker. In embodiments, the non-covalent linker comprises an epitope tag. In embodiments, the non-covalent linker comprises an ALFA tag. In embodiments, the ALFA tag further comprises recombinant variable domains of heavy-chain-only antibodies (VHH) (NANOBODY). In embodiments, the non-covalent linker comprises recombinant variable domains of heavy-chain-only antibodies (VHH) (NANOBODY). In embodiments, the non-covalent linker comprises recombinant variable domains of heavy-chain-only antibodies (VHH) (NANOBODY) binding to ALFA tagged protein (NbALFA). In embodiments, the linker comprises a monobody. In embodiments, the linker comprises an ALFA tag and monobody. In embodiments, the linker is inserted after a residue selected from V390, R315, T319, N320, G321, V322, P323, L324, R376, K383, N384, S385, R386, S387, R388, P389, G391, T392, S393, K407, P408, K409, P410, A411, K412, M413, or E428 relative to SEQ ID NO: 1. In embodiments, the enzyme further comprises an epitope tag. In embodiments, the epitope tag comprises a human influenza hemagglutinin (HA) tag or ALFA tag. Inteins Inteins (INTervening protEINS) are mobile genetic elements that are protein domains, found in nature, with the capability to carry out the process of protein splicing. See Sarmiento & Camarero (2019) Current Protein & Peptide Science, 20(5), 408–424, which is incorporated by reference herein in its entirety. Protein spicing is a post-translation biochemical modification which results in the cleavage and formation of peptide bonds between precursor polypeptide segments flanking the intein. Id. Inteins apply standard enzymatic strategies to excise themselves post-translationally from a precursor protein via protein splicing. Nanda et al., Microorganisms vol. 8,12 2004. 16 Dec. 2020, doi:10.3390 / microorganisms8122004. An intein can splice its flanking N- and C-terminal domains to become a mature protein and excise itself from a sequence. For example, split inteins have been used to control the delivery of heterologous genes into transgenic organisms. See Wood & Camarero (2014) J. Biol. Chem.289(21):14512-14519. This approach relies on splitting the target protein into two segments, which are then post-translationally reconstituted in vivo by protein trans-splicing (PTS). See Aboye & Camarero (2012) J. Biol. Chem.287, 27026–27032. More recently, an intein-mediated split-Cas9 system has been developed to incorporate Cas9 into cells and reconstitute nuclease activity efficiently. Truong et al., Nucleic Acids Res.2015, 43 (13), 6450–6458. The protein splicing excises the internal region of the precursor protein, which is then followed by the ligation of the N-extein and C-extein fragments, resulting in two polypeptides – the excised intein and the new polypeptide produced by joining the C- and N-exteins. Sarmiento & Camarero (2019). In embodiments, intein-mediated incorporation of DNA binding domains such as, without limitation, dCasX, dCas9, dCas12j, or TALEs, allows creation of a split-enzyme system such as, without limitation, split transposase system, that permits reconstitution of the full-length enzyme, e.g., transposase, from two smaller fragments. This allows avoiding the need to express DNA binding domains at the N- or C-terminus of an enzyme, e.g., transposase. In this approach, the two portions of an enzyme, e.g., transposase, are fused to the intein and, after co-expression, the intein allows producing a full-length enzyme, e.g., transposase, by post-translation modification. Thus, in embodiments, a nucleic acid encoding the enzyme capable of targeted genomic integration by transposition comprises an intein. In embodiments, the nucleic acid encodes the enzyme in the form of first and second portions with the intein encoded between the first and second portions, such that the first and second portions are fused into a functional enzyme upon post-translational excision of the intein from the enzyme. In embodiments, an intein is a suitable ligand-dependent intein, for example, an intein selected from those described in U.S. Patent No.9,200,045; Mootz et al., J. Am. Chem. Soc.2002; 124, 9044-9045; Mootz et al., J. Am. Chem. Soc. 2003; 125, 10561-10569; Buskirk et al., Proc. Natl. Acad. Sci. USA.2004; 101, 10505-10510; Skretas & Wood. Protein Sci.2005; 14, 523-532; Schwartz, et al., Nat. Chem. Biol.2007; 3, 50-54; Peck et al., Chem. Biol.2011; 18 (5), 619- 630; the entire contents of each of which are hereby incorporated by reference herein. In embodiments the intein is NpuN (Intein-N) (SEQ ID NO: 423) and / or NpuC (Intein-C) (SEQ ID NO: 424), or a variant thereof, e.g., a sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto. SEQ ID NO: 423: nucleotide sequence of NpuN (Intein-N) GGCGGATCTGGCGGTAGTGCTGAGTATTGTCTGAGTTACGAAACGGAAATACTCACGGTTGAGTATGGGCTTCTTCC AATTGGCAAAATCGTTGAAAAGCGCATAGAGTGTACGGTGTATTCCGTCGATAACAACGGTAATATCTACACCCAGC CGGTAGCTCAGTGGCACGACCGAGGCGAACAGGAAGTGTTCGAGTATTGCTTGGAAGATGGCTCCCTTATCCGCGCC ACTAAAGACCATAAGTTTATGACGGTTGACGGGCAGATGCTGCCTATAGACGAAATATTTGAGAGAGAGCTGGACTT GATGAGAGTCGATAATCTGCCAAAT SEQ ID NO: 424: nucleotide sequence of NpuC (Intein-C) GGCGGATCTGGCGGTAGTGGGGGTTCCGGATCCATAAAGATAGCTACTAGGAAATATCTTGGCAAACAAAACGTCTA TGACATAGGAGTTGAGCGAGATCACAATTTTGCTTTGAAGAATGGGTTCATCGCGTCTAATTGCTTCAACGCTAGCG GCGGGTCAGGAGGCTCTGGTGGAAGC Nucleic Acids of the Disclosure In embodiments, a nucleic acid encoding the enzyme (e.g., without limitation, the transposase enzyme) is RNA. In embodiments, a nucleic acid encoding the transgene is DNA. In embodiments, thr RNA is or comprises messenger RNA (mRNA). In embodiments, the mRNA is or comprises modified mRNA. In embodiments, the enzyme (e.g., without limitation, the transposase enzyme) is encoded by a recombinant or synthetic nucleic acid. In embodiments, the nucleic acid is RNA, optionally a helper RNA. In embodiments, the nucleic acid is RNA that has a 5’-m7G cap (cap0, or cap1, or cap2), optionally with pseudouridine substitution (e.g., without limitation n-methyl-pseudouridine), and optionally a poly-A tail of about 30, or about 50, or about 100, of about 150 nucleotides in length. In embodiments, the poly-A tail is of about 30 nucleotides in length, optionally 34 nucleotides in length. In embodiments, a nuclear localization signal is placed before the enzyme start codon at the N-terminus, optionally at the C-terminus. In embodiments, the enzyme further comprises a SV40 nuclear localization signal. In embodiments, the SV40 nuclear localization signal comprises a nucleotide sequence of ccgaaaaaaaaacgaaaggtgtacccctacgatgtaccggactatgcaggaagc (SEQ ID NO: 657) or a variant thereof having a substitution or deletion. In embodiments, the SV40 nuclear localization signal is inserted immediately after residue M1 relative to SEQ ID NO: 1. In embodiments, the nucleic acid that is RNA has a 5’-m7G cap (cap 0, or cap 1, or cap 2). In embodiments, the nucleic acid comprises a 5′ cap structure, a 5′-UTR comprising a Kozak consensus sequence, a 5′-UTR comprising a sequence that increases RNA stability in vivo, a 3′-UTR comprising a sequence that increases RNA stability in vivo, and / or a 3′ poly(A) tail. In embodiments, the enzyme (e.g., without limitation, a transposase) is incorporated into a vector or a vector-like particle. In embodiments, the vector is a non-viral vector. In embodiments, a nucleic acid encoding the enzyme in accordance with embodiments of the present disclosure, is DNA. In embodiments, the one or more nucleic acid-based agents is in the form of DNA. In embodiments, the DNA is or comprises plasmid DNA. In embodiments, the plasmid DNA has a size of up to about 10 kb, or up to about 12 kb, up to about 15 kb, or about 7.5 to about 15 kb, or about 10 to about 15 kb. In embodiments, the plasmid is conjugative, non-conjugative or mobilized. In embodiments, the plasmid is selected from fertility F-plasmids, resistance plasmids, Col plasmids, degradative plasmids, or virulence plasmids. In embodiments, the plasmid is an artificially construct plasmid that is used as vectors in genetic engineering. In embodiments, the plasmid is selected from miniplasmid, nanoplasmid, doggyboneDNA or close-ended linear DNA. In embodiments, a construct comprising a transposon is any suitable genetic construct, such as a nucleic acid construct, a plasmid, or a vector. In embodiments, the construct is DNA, which is referred to herein as a donor DNA. In embodiments, sequences of a nucleic acid encoding the transposon is codon optimized to provide improved mRNA stability and protein expression in mammalian systems. In embodiments, the enzyme or variant thereof is incorporated into a vector or a vector-like particle. In embodiments, the vector or a vector-like particle comprises one or more expression cassettes. In embodiments, the vector or a vector- like particle comprises one expression cassette. In embodiments, the expression cassette further comprises the enzyme or variant thereof, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into one or more vectors or vector-like particles. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into a same vector or vector-like particle. In embodiments, the enzyme or variant thereof, the transgene, transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof is incorporated into different vectors vector-like particles. In embodiments, a nucleic acid encoding the enzyme capable of targeted genomic integration by transposition (e.g., without limitation, the transposase enzyme) is RNA (e.g., helper RNA), and a nucleic acid encoding a transposon is DNA. As would be appreciated in the art, a transposon often includes an open reading frame that encodes a transgene at the middle of transposon and terminal repeat sequences at the 5’ and 3’ end of the transposon. The translated transposase (e.g., without limitation, the transposase enzyme) binds to the 5’ and 3’ sequence of the transposon and carries out the transposition function. In embodiments, a transposon is used interchangeably with transposable elements, which are used to refer to polynucleotides capable of inserting copies of themselves into other polynucleotides. The term transposon is well known to those skilled in the art and includes classes of transposons that can be distinguished on the basis of sequence organization, for example inverted terminal sequences at each end, and / or directly repeated long terminal repeats (LTRs) at the ends. In embodiments, the transposon as described herein may be described as a piggyBac like element, e.g., a transposon element that is characterized by its traceless excision, which recognizes TTAA (SEQ ID NO: 440) sequence and restores the sequence at the insert site back to the original TTAA (SEQ ID NO: 440) sequence after removal of the transposon. In embodiments, the transposon is flanked by one or more end sequences or terminal ends. In embodiments, the transposon is or comprises a gene encoding a complete polypeptide. In embodiments, the transposon is or comprises a gene which is defective or substantially absent in a disease state. In embodiments, a transgene is associated with various regulatory elements that are selected to ensure stable expression of a construct with the transgene. Thus, in embodiments, a transgene is encoded by a non-viral vector (e.g., without limitation, a DNA plasmid) that can comprise one or more insulator sequences that prevent or mitigate activation or inactivation of nearby genes. The insulators flank the transposon (transgene cassette) to reduce transcriptional silencing and position effects imparted by chromosomal sequences. As an additional effect, the insulators can eliminate functional interactions of the transgene enhancer and promoter sequences with neighboring chromosomal sequences. In embodiments, the one or more insulator sequences comprise an HS4 insulator (1.2-kb 5’ -HS4 chicken β-globin (cHS4) insulator element) and an D4Z4 insulator (tandem macrosatellite repeats linked to Facio-Scapulo-Humeral Dystrophy (FSHD). In embodiments, the sequences of the HS4 insulator and the D4Z4 insulator are as described in Rival-Gervier et al. Mol Ther.2013 Aug; 21(8):1536-50, which is incorporated herein by reference in its entirety. In embodiments, the transgene is inserted into a GSHS location in a host genome. GSHSs is defined as loci well-suited for gene transfer, as integrations within these sites are not associated with adverse effects such as proto-oncogene activation, tumor suppressor inactivation, or insertional mutagenesis. GSHSs can defined by the following criteria: 1) distance of at least 50 kb from the 5’ end of any gene, (2) distance of at least 300 kb from any cancer-related gene, (3) distance of at least 300 kb from any microRNA (miRNA), (4) location outside a transcription unit, and (5) location outside ultra-conserved regions (UCRs) of the human genome. See Papapetrou et al. Nat Biotechnol 2011; 29:73-8; Bejerano et al. Science 2004;304:1321-5. Furthermore, the use of GSHS locations can allow stable transgene expression across multiple cell types. One such site, chemokine C-C motif receptor 5 (CCR5) has been identified and used for integrative gene transfer. CCR5 is a member of the beta chemokine receptor family and is required for the entry of R5 tropic viral strains involved in primary infections. A homozygous 32 bp deletion in the CCR5 gene confers resistance to HIV-1 virus infections in humans. Disrupted CCR5 expression, naturally occurring in about 1% of the Caucasian population, does not appear to result in any reduction in immunity. Lobritz at al., Viruses 2010;2:1069-105. A clinical trial has demonstrated safety and efficacy of disrupting CCR5 via targetable nucleases. Tebas at al., HIV. N Engl J Med 2014;370 :901-10. In embodiments, the transposon is under control of a tissue-specific promoter. The tissue-specific promoter is, e.g., without limitation, a liver-specific promoter. In embodiments, the liver-specific promoter is an LP1 promoter that, in embodiments, is a human LP1 promoter. The LP1 promoter is described, e.g., in Nathwani et al. Blood vol. 2006;107(7):2653-61, and it is constructed, without limitation, as described in Nathawani et al. It should be appreciated however that a variety of promoters can be used, including other tissue-specific promoters, inducible promoters, constitutive promoters, etc. In embodiments, the present nucleic acids include polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, or analogs or derivatives thereof. In embodiments, there is provided double- and single- stranded DNA, as well as double- and single-stranded RNA, and RNA-DNA hybrids. In embodiments, transcriptionally- activated polynucleotides such as methylated or capped polynucleotides are provided. In embodiments, the present compositions are mRNA or DNA. In embodiments, the RNA is or comprises messenger RNA (mRNA). In embodiments, the mRNA is or comprises modified mRNA (mmRNA). In embodiments, the mmRNA comprises one or more of a 5’- m7G cap (cap0, cap1, or cap2), a pseudouridine or n-methyl-pseudouridine substitution, and a poly-A tail of about 30, or of about 50, or of about 100, or of about 150 nucleotides in length. In embodiments, the present non-viral vectors are linear or circular DNA molecules that comprise a polynucleotide encoding a polypeptide and is operably linked to control sequences, wherein the control sequences provide for expression of the polynucleotide encoding the polypeptide. In embodiments, the non-viral vector comprises a promoter sequence, and transcriptional and translational stop signal sequences. Such vectors may include, among others, chromosomal and episomal vectors, e.g., vectors bacterial plasmids, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, and vectors from combinations thereof. The present constructs may contain control regions that regulate as well as engender expression. In embodiments, the construct comprising the enzyme and / or transgene is codon optimized. Transgene codon optimization is used to optimize therapeutic potential of the transgene and its expression in the host organism. Codon optimization is performed to match the codon usage in the transgene with the abundance of transfer RNA (tRNA) for each codon in a host organism or cell. Codon optimization methods are known in the art and described in, for example, WO 2007 / 142954, which is incorporated by reference herein in its entirety. Optimization strategies can include, for example, the modification of translation initiation regions, alteration of mRNA structural elements, and the use of different codon biases. In embodiments, the construct comprising the enzyme and / or transgene includes several other regulatory elements that are selected to ensure stable expression of the construct. Thus, in embodiments, the non-viral vector is a DNA plasmid that can comprise one or more insulator sequences that prevent or mitigate activation or inactivation of nearby genes. In embodiments, the one or more insulator sequences comprise an HS4 insulator (1.2-kb 5′-HS4 chicken β- globin (cHS4) insulator element) and an D4Z4 insulator (tandem macrosatellite repeats linked to Facio-Scapulo- Humeral Dystrophy (FSHD). In embodiments, the sequences of the HS4 insulator and the D4Z4 insulator are as described in Rival-Gervier et al. Mol Ther.2013 Aug; 21(8):1536-50, which is incorporated herein by reference in its entirety. In embodiments, the gene of the construct comprising the enzyme and / or transgene is capable of transposition in the presence of a transposase. In embodiments, the non-viral vector in accordance with embodiments of the present disclosure comprises a nucleic acid construct encoding a transposase. The transposase (e.g., without limitation, the transposase enzyme of the present disclosure) is an RNA transposase plasmid. In embodiments, the non-viral vector further comprises a nucleic acid construct encoding a DNA transposase plasmid. In embodiments, the transposase is an in vitro-transcribed mRNA transposase. The transposase (e.g., without limitation, the transposase enzyme of the present disclosure) is capable of excising and / or transposing the gene from the construct comprising the enzyme and / or transgene to site- or locus-specific genomic regions. In embodiments, the enzyme (e.g., without limitation, the transposase enzyme) and the transposon are included in the same vector. In embodiments, the enzyme is disposed on the same (cis) or different vector (trans) than a transposon with a transgene. Accordingly, in embodiments, the enzyme and the transposon encompassing a transgene are in cis configuration such that they are included in the same vector. In embodiments, the enzyme and the transposon encompassing a transgene are in trans configuration such that they are included in different vectors. The vector is any non-viral vector in accordance with the present disclosure. In aspects, a nucleic acid encoding the transposon system of the present disclosure capable of targeted genomic integration by transposition (e.g., a transposase) in accordance with embodiments of the present disclosure is provided. The nucleic acid is or comprises DNA or RNA. In embodiments, the nucleic acid encoding the enzyme is DNA. In embodiments, the nucleic acid encoding the enzyme capable of targeted genomic integration by transposition (e.g., a transposase of the present disclosure) is RNA such as, e.g., helper RNA. In embodiments, the transposase is incorporated into a vector. In embodiments, the vector is a non-viral vector. In embodiments, a nucleic acid encoding the transgene in accordance with embodiments of the present disclosure is provided. The nucleic acid is or comprises DNA or RNA. In embodiments, the nucleic acid encoding the transgene is DNA. In embodiments, the nucleic acid encoding the transgene is RNA such as, e.g., helper RNA. In embodiments, the transgene is incorporated into a vector. In embodiments, the vector is a non-viral vector. In embodiments, the present enzyme can be in the form or an RNA or DNA and have one or two N-terminus nuclear localization signal (NLS) to shuttle the protein more efficiently into the nucleus. For example, in embodiments, the present enzyme further comprises one, two, three, four, five, or more NLSs. Examples of NLS are provided in Kosugi et al. (J. Biol. Chem. (2009) 284:478-485; incorporated by reference herein). In a particular embodiment, the NLS comprises the consensus sequence K(K / R)X(K / R) (SEQ ID NO: 348). In an embodiment, the NLS comprises the consensus sequence (K / R)(K / R)X10-12(K / R)3 / 5(SEQ ID NO: 349), where (K / R)3 / 5represents at least three of the five amino acids is either lysine or arginine. In an embodiment, the NLS comprises the c-myc NLS. In a particular embodiment, the c-myc NLS comprises the sequence PAAKRVKLD (SEQ ID NO: 350). In a particular embodiment, the NLS is the nucleoplasmin NLS. In embodiments, the nucleoplasmin NLS comprises the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 351). In embodiments, the NLS comprises the SV40 Large T-antigen NLS. In embodiments, the SV40 Large T-antigen NLS comprises the sequence PKKKRKV (SEQ ID NO: 352). In a particular embodiment, the NLS comprises three SV40 Large T-antigen NLSs (e.g., DPKKKRKVDPKKKRKVDPKKKRKV (SEQ ID NO: 353). In embodiments, the enzyme further comprises a SV40 nuclear localization signal. In embodiments, the SV40 nuclear localization signal comprises an amino acid sequence of PKKKRKVYPYDVPDYAGS (SEQ ID NO: 656) or a variant thereof having a substitution or deletion. the SV40 nuclear localization signal is inserted immediately after residue M1 relative to SEQ ID NO: 1. In embodiments, the NLS may comprise mutations / variations in the above sequences such that they contain 1 or more substitutions, additions, or deletions (e.g., about 1, or about 2, or about 3, or about 4, or about 5, or about 10 substitutions, additions, or deletions). In aspects, a host cell comprising the nucleic acid in accordance with embodiments of the present disclosure is provided. Lipids and LNP Delivery In embodiments, a composition or a nucleic acid in accordance with embodiments of the present disclosure is provided wherein the composition is in the form of a lipid nanoparticle (LNP). In embodiments, the composition is encapsulated in an LNP. In embodiments, a nucleic acid encoding the enzyme and a nucleic acid encoding the transgene are contained within the same lipid nanoparticle (LNP). In embodiments, the nucleic acid encoding the enzyme and the nucleic acid encoding the transposon are a mixture incorporated into or associated with the same LNP. In embodiments, the polynucleotide encoding the transposase enzyme and the polynucleotide encoding the transposon are in the form of the same LNP, optionally in a co-formulation. In embodiments, the LNP is selected from 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), a cationic cholesterol derivative mixed with dimethylaminoethane-carbamoyl (DC-Chol), phosphatidylcholine (PC), triolein (glyceryl trioleate), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG), 1,2- dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol – 2000 (DMG-PEG 2K), and 1,2 distearol -sn-glycerol- 3phosphocholine (DSPC) and / or comprising of one or more molecules selected from polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), and N-Acetylgalactosamine (GalNAc). In embodiments, an LNP is as described, e.g., in Patel et al., J Control Release 2019; 303:91-100. The LNP can comprise one or more of a structural lipid (e.g., DSPC), a PEG-conjugated lipid (CDM-PEG), a cationic lipid (MC3), cholesterol, and a targeting ligand (e.g., GalNAc). In embodiments, a nanoparticle is a particle having a diameter of less than about 1000 nm. In embodiments, nanoparticles of the present disclosure have a greatest dimension (e.g., diameter) of about 500 nm or less, or about 400 nm or less, or about 300 nm or less, or about 200 nm or less, or about 100 nm or less. In embodiments, nanoparticles of the present disclosure have a greatest dimension ranging between about 50 nm and about 150 nm, or between about 70 nm and about 130 nm, or between about 80 nm and about 120 nm, or between about 90 nm and about 110 nm. In embodiments, the nanoparticles of the present disclosure have a greatest dimension (e.g., a diameter) of about 100 nm. In aspects, the cell in accordance with the present disclosure is prepared via an in vivo genetic modification method. In embodiments, a genetic modification in accordance with the present disclosure is performed via an ex vivo method. In aspects, the cell in accordance with the present disclosure is prepared by contacting a cell with an enzyme capable of targeted genomic integration by transposition (e.g., without limitation, the transposase enzyme) in vivo. In embodiments, the cell is contacted with the enzyme ex vivo. In embodiments, the present method provides high specific targeting as compared to a method that does not use the transposase enzyme with a target selector. Therapeutic Applications In embodiments, the transgene of interest in accordance with embodiments of the present disclosure can encode various genes. In embodiments, the transposase enzyme and the transposon are included in the same pharmaceutical composition. In embodiments, the transposase enzyme and the transposon are included in different pharmaceutical compositions. In embodiments, the transposase enzyme and the transposon are co-transfected. In embodiments the transposase enzyme and the transposon are transfected separately. In embodiments, a transfected cell for gene therapy is provided, wherein the transfected cell is generated using the transposase enzyme in accordance with embodiments of the present disclosure. In embodiments, a method of delivering a cell therapy is provided, comprising administering to a patient in need thereof the transfected cell generated using the transposase enzyme in accordance with embodiments of the present disclosure. In embodiments, a method of treating a disease or condition using a cell therapy, comprising administering to a patient in need thereof the transfected cell generated using the transposase enzyme in accordance with embodiments of the present disclosure. In embodiments, there is provided a method for treating a disease or disorder ex vivo, comprising contacting a cell with the composition of the present disclosure and administering the cell to a subject in need thereof. In embodiments, there is provided a method for treating a disease or disorder in vivo, comprising administering the composition of the present disclosure, or host cell of the present disclosure to a subject in need thereof. In embodiments, the disease or condition may comprise cancer. In embodiments, the cancer is or comprises an adrenal cancer, a biliary track cancer, a bladder cancer, a bone / bone marrow cancer, a brain cancer, a breast cancer, a cervical cancer, a colorectal cancer, a cancer of the esophagus, a gastric cancer, a head / neck cancer, a hepatobiliary cancer, a kidney cancer, a liver cancer, a lung cancer, an ovarian cancer, a pancreatic cancer, a pelvis cancer, a pleura cancer, a prostate cancer, a renal cancer, a skin cancer, a stomach cancer, a testis cancer, a thymus cancer, a thyroid cancer, a uterine cancer, a lymphoma, a melanoma, a multiple myeloma, or a leukemia. In embodiments, the cancer is selected from one or more of the basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer; melanoma; myeloma; neuroblastoma; oral cavity cancer; ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; Hodgkin's lymphoma; non-Hodgkin's lymphoma; B-cell lymphoma; small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); and Hairy cell leukemia. In embodiments, the cancer is selected from one or more of basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (e.g., that associated with brain tumors), and Meigs syndrome. In embodiments, the disease or condition is or comprises an infectious disease. In embodiments, the infectious disease is a coronavirus infection, optionally selected from infection with SAR-CoV, MERS-CoV, and SARS-CoV-2, or variants thereof. In embodiments, the infectious disease is or comprises a disease comprising a viral infection, a parasitic infection, or a bacterial infection. In embodiments, the viral infection is caused by a virus of family Flaviviridae, a virus of family Picornaviridae, a virus of family Orthomyxoviridae, a virus of family Coronaviridae, a virus of family Retroviridae, a virus of family Paramyxoviridae, a virus of family Bunyaviridae, or a virus of family Reoviridae. In embodiments, the virus of family Coronaviridae comprises a betacoronavirus or an alphacoronavirus, optionally wherein the betacoronavirus is selected from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-HKU1, and HCoV-OC43, or the alphacoronavirus is selected from a HCoV-NL63 and HCoV-229E. In embodiments, the infectious disease comprises a coronavirus infection 2019 (COVID-19). In embodiments, the method requires a single administration. In embodiments, the method requires a plurality of administrations. Isolated Cell In aspects of the present disclosure, an isolated cell is provided that comprises the transfected cell in accordance with embodiments of the present disclosure. In aspects, the present disclosure provides an ex vivo gene therapy approach. Accordingly, in embodiments, the method that is used to treat an inherited or acquired disease in a patient in need thereof comprises (a) contacting a cell obtained from a patient (autologous) or another individual (allogeneic) with a transfected cell in accordance with embodiments of the present disclosure; and (b) administering the cell to a patient in need thereof. One of the advantages of ex vivo gene therapy is the ability to “sample” the transduced cells before patient administration. This facilitates efficacy and allows performing safety checks before introducing the cell(s) to the patient. For example, the transduction efficiency and / or the clonality of integration can be assessed before infusion of the product. The present disclosure provides transfected cells and methods that can be effectively used for ex vivo gene modification. In embodiments, a composition comprising transfected cells in accordance with the present disclosure comprises a pharmaceutically acceptable carrier, excipient, or diluent. Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, N.Y.). For example, pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile, and the fluid should be easy to draw up by a syringe. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Therapeutic compounds can be prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as collagen, ethylene vinyl acetate, polyanhydrides (e.g., poly[1,3-bis(carboxyphenoxy)propane-co-sebacic-acid] (PCPP-SA) matrix, fatty acid dimer- sebacic acid (FAD-SA) copolymer, poly(lactide-co-glycolide)), polyglycolic acid, collagen, polyorthoesters, polyethyleneglycol-coated liposomes, and polylactic acid. Such formulations can be prepared using standard techniques, or obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No.4,522,811. Semisolid, gelling, soft-gel, or other formulations (including controlled release) can be used, e.g., when administration to a surgical site is desired. Methods of making such formulations are known in the art and can include the use of biodegradable, biocompatible polymers. See, e.g., Sawyer et al., Yale J Biol Med.2006; 79(3-4): 141-152. In embodiments, there is provided a method of transforming a cell using the construct comprising the enzyme and / or transgene described herein in the presence of a transposase (e.g., without limitation, the transposase enzyme) to produce a stably transfected cell which results from the stable integration of a gene of interest into the cell. In embodiments, the stable integration comprises an introduction of a polynucleotide into a chromosome or mini- chromosome of the cell and, therefore, becomes a relatively permanent part of the cellular genome. In embodiments, there is provided a transgenic organism that may comprise cells which have been transformed by the methods of the present disclosure. In embodiments, the organism may be a mammal or an insect. When the organism is a mammal, the organism may include, but is not limited to, a mouse, a rat, a monkey, a panda, a dog, a rabbit, and the like. When the organism is an insect, the organism may include, but is not limited to, a fruit fly, a ladybug, a mosquito, a bollworm, and the like. Definitions The following definitions are used in connection with the disclosure disclosed herein. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of skill in the art to which this invention belongs. As used herein, “a,” “an,” or “the” can mean one or more than one. Further, the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication. For example, the language “about 50” covers the range of 45 to 55. An “effective amount,” when used in connection with medical uses is an amount that is effective for providing a measurable treatment, prevention, or reduction in the rate of pathogenesis of a disease of interest. The term “in vivo” refers to an event that takes place in a subject’s body. The term “ex vivo” refers to an event which involves treating or performing a procedure on a cell, tissue and / or organ which has been removed from a subject’s body. Aptly, the cell, tissue and / or organ may be returned to the subject’s body in a method of treatment or surgery. As used herein, the term “variant” encompasses but is not limited to nucleic acids or proteins which comprise a nucleic acid or amino acid sequence which differs from the nucleic acid or amino acid sequence of a reference by way of one or more substitutions, deletions and / or additions at certain positions. The variant may comprise one or more conservative substitutions. Conservative substitutions may involve, e.g., the substitution of similarly charged or uncharged amino acids. “Carrier” or “vehicle” as used herein refer to carrier materials suitable for drug administration. Carriers and vehicles useful herein include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, surfactant, lipid, or the like, which is nontoxic, and which does not interact with other components of the composition in a deleterious manner. The phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit / risk ratio. The terms “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and inert ingredients. The use of such pharmaceutically acceptable carriers or pharmaceutically acceptable excipients for active pharmaceutical ingredients is well known in the art. Except insofar as any conventional pharmaceutically acceptable carrier or pharmaceutically acceptable excipient is incompatible with the active pharmaceutical ingredient, its use in the therapeutic compositions of the disclosure is contemplated. Additional active pharmaceutical ingredients, such as other drugs, can also be incorporated into the described compositions and methods. As referred to herein, all compositional percentages are by weight of the total composition, unless otherwise specified. As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the compositions and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features. Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the invention, the present invention, or embodiments thereof, may alternatively be described using alternative terms such as “consisting of” or “consisting essentially of.” As used herein, the words “preferred” and “preferably” refer to embodiments of the technology that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful and is not intended to exclude other embodiments from the scope of the technology. The amount of compositions described herein needed for achieving a therapeutic effect may be determined empirically in accordance with conventional procedures for the particular purpose. Generally, for administering therapeutic agents for therapeutic purposes, the therapeutic agents are given at a pharmacologically effective dose. A “pharmacologically effective amount,” “pharmacologically effective dose,” “therapeutically effective amount,” or “effective amount” refers to an amount sufficient to produce the desired physiological effect or amount capable of achieving the desired result, particularly for treating the disorder or disease. An effective amount as used herein would include an amount sufficient to, for example, delay the development of a symptom of the disorder or disease, alter the course of a symptom of the disorder or disease (e.g., slow the progression of a symptom of the disease), reduce or eliminate one or more symptoms or manifestations of the disorder or disease, and reverse a symptom of a disorder or disease. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized. Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50(the dose lethal to about 50% of the population) and the ED50(the dose therapeutically effective in about 50% of the population). The dosage can vary depending upon the dosage form employed and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50 / ED50. In embodiments, compositions and methods that exhibit large therapeutic indices are preferred. A therapeutically effective dose can be estimated initially from in vitro assays, including, for example, cell culture assays. Also, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50as determined in cell culture, or in an appropriate animal model. Levels of the described compositions in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. As used herein, “methods of treatment” are equally applicable to use of a composition for treating the diseases or disorders described herein and / or compositions for use and / or uses in the manufacture of a medicaments for treating the diseases or disorders described herein. SELECTED SEQUENCES In embodiments, the present disclosure provides for any of the sequence provided herein, including the below, and a variant sequence having at least about 90%, or at least about 93%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99% identity thereto, or at least about 10 mutations, or at least about 9 mutations, or at least about 8 mutations, or at least about 7 mutations, or at least about 6 mutations, or at least about 5 mutations, or at least about 4 mutations, or at least about 3 mutations, or at least about 2 mutations, or at least about 1 mutation. SEQ ID NO: 1: amino acid sequence of piggyBac transposase (594 aa) 1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE 51 VHEVQPTSSG SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST 101 SKSTRRSRVS ALNIVRSQRG PTRMCRNIYD PLLCFKLFFT DEIISEIVKW 151 TNAEISLKRR ESMTGATFRD TNEDEIYAFF GILVMTAVRK DNHMSTDDLF 201 DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV FTPVRKIWDL 251 FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD 301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT 351 SIPLAKNLLQ EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP 401 LTLVSYKPKP AKMVYLLSSC DEDASINEST GKPQMVMYYN QTKGGVDTLD 451 QMCSVMTCSR KTNRWPMALL YGMINIACIN SFIIYSHNVS SKGEKVQSRK 501 KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV PGTSDDSTEE 551 PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF SEQ ID NO: 2: nucleotide sequence encoding the wild-type piggyBac transposase (2472 nt) 1 ccctagaaag atagtctgcg taaaattgac gcatgcattc ttgaaatatt gctctctctt 61 tctaaatagc gcgaatccgt cgctgtgcat ttaggacatc tcagtcgccg cttggagctc 121 ccgtgaggcg tgcttgtcaa tgcggtaagt gtcactgatt ttgaactata acgaccgcgt 181 gagtcaaaat gacgcatgat tatcttttac gtgactttta agatttaact catacgataa 241 ttatattgtt atttcatgtt ctacttacgt gataacttat tatatatata ttttcttgtt 301 atagatatcg tgactaatat ataataaaat gggtagttct ttagacgatg agcatatcct 361 ctctgctctt ctgcaaagcg atgacgagct tgttggtgag gattctgaca gtgaaatatc 421 agatcacgta agtgaagatg acgtccagag cgatacagaa gaagcgttta tagatgaggt 481 acatgaagtg cagccaacgt caagcggtag tgaaatatta gacgaacaaa atgttattga 541 acaaccaggt tcttcattgg cttctaacag aatcttgacc ttgccacaga ggactattag 601 aggtaagaat aaacattgtt ggtcaacttc aaagtccacg aggcgtagcc gagtctctgc 661 actgaacatt gtcagatctc aaagaggtcc gacgcgtatg tgccgcaata tatatgaccc 721 acttttatgc ttcaaactat tttttactga tgagataatt tcggaaattg taaaatggac 781 aaatgctgag atatcattga aacgtcggga atctatgaca ggtgctacat ttcgtgacac 841 gaatgaagat gaaatctatg ctttctttgg tattctggta atgacagcag tgagaaaaga 901 taaccacatg tccacagatg acctctttga tcgatctttg tcaatggtgt acgtctctgt 961 aatgagtcgt gatcgttttg attttttgat acgatgtctt agaatggatg acaaaagtat 1021 acggcccaca cttcgagaaa acgatgtatt tactcctgtt agaaaaatat gggatctctt 1081 tatccatcag tgcatacaaa attacactcc aggggctcat ttgaccatag atgaacagtt 1141 acttggtttt agaggacggt gtccgtttag gatgtatatc ccaaacaagc caagtaagta 1201 tggaataaaa atcctcatga tgtgtgacag tggtacgaag tatatgataa atggaatgcc 1261 ttatttggga agaggaacac agaccaacgg agtaccactc ggtgaatact acgtgaagga 1321 gttatcaaag cctgtgcacg gtagttgtcg taatattacg tgtgacaatt ggttcacctc 1381 aatccctttg gcaaaaaact tactacaaga accgtataag ttaaccattg tgggaaccgt 1441 gcgatcaaac aaacgcgaga taccggaagt actgaaaaac agtcgctcca ggccagtggg 1501 aacatcgatg ttttgttttg acggacccct tactctcgtc tcatataaac cgaagccagc 1561 taagatggta tacttattat catcttgtga tgaggatgct tctatcaacg aaagtaccgg 1621 taaaccgcaa atggttatgt attataatca aactaaaggc ggagtggaca cgctagacca 1681 aatgtgttct gtgatgacct gcagtaggaa gacgaatagg tggcctatgg cattattgta 1741 cggaatgata aacattgcct gcataaattc ttttattata tacagccata atgtcagtag 1801 caagggagaa aaggttcaaa gtcgcaaaaa atttatgaga aacctttaca tgagcctgac 1861 gtcatcgttt atgcgtaagc gtttagaagc tcctactttg aagagatatt tgcgcgataa 1921 tatctctaat attttgccaa atgaagtgcc tggtacatca gatgacagta ctgaagagcc 1981 agtaatgaaa aaacgtactt actgtactta ctgcccctct aaaataaggc gaaaggcaaa 2041 tgcatcgtgc aaaaaatgca aaaaagttat ttgtcgagag cataatattg atatgtgcca 2101 aagttgtttc tgactgacta ataagtataa tttgtttcta ttatgtataa gttaagctaa 2161 ttacttattt tataatacaa catgactgtt tttaaagtac aaaataagtt tatttttgta 2221 aaagagagaa tgtttaaaag ttttgttact ttatagaaga aattttgagt ttttgttttt 2281 ttttaataaa taaataaaca taaataaatt gtttgttgaa tttattatta gtatgtaagt 2341 gtaaatataa taaaacttaa tatctattca aattaataaa taaacctcga tatacagacc 2401 gataaaacac atgcgtcaat tttacgcatg attatcttta acgtacgtca caatatgatt 2461 atctttctag gg SEQ ID NO: 515: nucleotide sequence of E2C NbAlfa ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAA ATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAAT GCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGC CCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGC TAGCGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGAAGTCCAGCTCCAAGAAAGCGGCGGGGGCC TCGTGCAGCCAGGCGGGTCCCTGAGGCTGAGCTGTACCGCATCTGGAGTCACCATCTCTGCCCTTAACGCAATGGCT ATGGGGTGGTATCGGCAGGCGCCCGGCGAGAGGAGAGTCATGGTAGCAGCCGTTAGCGAAAGGGGGAATGCGATGTA CCGAGAGAGTGTTCAGGGACGATTTACTGTCACTCGGGATTTTACGAACAAAATGGTTTCATTGCAAATGGACAATT TGAAACCAGAGGACACCGCTGTTTACTACTGTCACGTCCTGGAAGATCGAGTAGATAGCTTCCATGACTATTGGGGC CAAGGAACACAAGTGACTGTCAGCTCC SEQ ID NO: 516: amino acid sequence of E2C NbAlfa MAPKKKRKVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTASGGSGGSGGSGGSLEEVQLQESGGGLVQPGGSLRLSCTASGVTISALNAMA MGWYRQAPGERRVMVAAVSERGNAMYRESVQGRFTVTRDFTNKMVSLQMDNLKPEDTAVYYCHVLEDRVDSFHDYWG QGTQVTVSS SEQ ID NO: 517: nucleotide sequence of Alfa Nterm R315 R372 ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCTCCAGACTGGAAGAGGAACTGAGAAGAAGGCTCACAGAAGCTAG CGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGGGTCTTCACTGGACGATGAGCATATTCTGAGCG CCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACGTGTCAGAGGACGAT GTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCCGGAAGCGAGATCCT GGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACTGCCACAGCGAACTA TTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCGCCCTGAACATCGTG AGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAGCTGTTCTTTACAGA TGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATCTATGACTAGTGCCA CCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAGTGAGGAAGGACAAC CATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGCAGAGACAGGTTCGA TTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGACGTGTTCACCCCAG TGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATCTGACTATCGACGAA CAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAATATGGCATCAAGAT TCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGGCACCCAGACAAATG GAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACCTGTGAC AATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAACCGTGGC CAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTCTATGTTCTGCTTTG ACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGAT GCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCT GAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCA ACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAG AAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAG GTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAG TGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGT AAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 518: amino acid sequence of Alfa Nterm R315 R372 MAPKKKRKVGGSRLEEELRRRLTEASGGSGGSGGSGGSLEGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDD VQSDTEEAFIDEVHEVQPTSSGSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIV RSQRGPTRMCRNIYDPLLCFKLFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDN HMSTDDLFDRSLSMVYVSVMSRDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDE QLLGFRGRCPFRVYIPNKPSKYGIKILMMCDSGTKYMINGMPYLGAGTQTNGVPLGEYYVKELSKPVHGSCRNITCD NWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDED ASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRK KFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKC KKVICREHNIDMCRSCF SEQ ID NO: 519: nucleotide sequence of Alfa E428 loop R315 R372 ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAATCCAGACTGGAAGAGGAACTGAGAAGAA GGCTCACAGAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGC AAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGAC CTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCA TCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATG GGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAA TATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCA CTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCAT AACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 520: amino acid sequence of Alfa E428 loop R315 R372 MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGAGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKSRLEEELRRRLTEPAKMVYLLSSCDEDASINESTG KPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYM GLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREH NIDMCRSCF* SEQ ID NO: 521: nucleotide sequence of E2C GCN4 ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGAGCCGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAATCCAGACTGGAAGAGGAACTGAGAAGAA GGCTCACAGAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGC AAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGAC CTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCA TCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATG GGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAA TATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCA CTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCAT AACATTGATATGTGCCGGTCCTGTTTT SEQ ID NO: 522: amino acid sequence of E2C GCN4 MAPKKKRKVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTASGGSGGSGGSGGSLEEELLSKNYHLENEVARLKK SEQ ID NO: 523: nucleotide sequence of E2C GCN4 (GCN4 underlined) ATGGCGCCTAAGAAGAAGAGAAAGGTCGGCGGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAA ATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAAT GCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGC CCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGC TAGCGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAGGAAGAACTTTTGAGCAAGAATTATCATCTTG AGAACGAAGTGGCTCGTCTTAAGAAA SEQ ID NO: 524: amino acid sequence of E2C GCN4 (GCN4 underlined) MAPKKKRKVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTASGGSGGSGGSGGSLEEELLSKNYHLENEVARLKK SEQ ID NO: 565: hyper pB – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGAGAAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTC TATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAA GCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGC GGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCT GTACGGGATGATCAACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAG TCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCA CCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTC TACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTT CTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTTTGA SEQ ID NO: 566: hyper pB – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVRSNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKG GVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEA PTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNIDMCRSCF SEQ ID NO: 567: E2C zinc finger (alone) – nucleotide sequence GGAGGTCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGT TAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCG ATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGAT TGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGAGGT SEQ ID NO: 568: E2C zinc finger (alone) – amino acid sequence GGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSD CRDLARHQRTHTGKKTGG SEQ ID NO: 569: E2C V390 R372A – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGAGGTCT CGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACC AGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGG AGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGA CCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGAGGTGGCACTTCTATGTTCTGCTTTGACGGGCCAC TGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATC AATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGAT GTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTT GCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATG CGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCG CGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGA AACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTG ATCTGTAGAGAGCATAACATTGATATGTGCCGGTCCTGTTTTTGA SEQ ID NO: 570: E2C V390 R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLR RHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASI NESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFM RNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKV ICREHNIDMCRSCF SEQ ID NO: 571: E2C GG V390 R372A – nucleotide sequence (has a shorter linker between the zinc finger and the transposase) ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGAGGTGA GAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATA CAGGGGAGAAACCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGA ACTCATACAGGCGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACA TCAAAGGACACATACAGGCGGAGGTGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGC CCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAAGCCC CAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCTGTAG TAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATCATCT ACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGGACTG ACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATATTCT GCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACTTATT GTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATT GATATGTGCCGGTCCTGTTTTTGA SEQ ID NO: 572: E2C GG V390 R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQR THTGEKPYKCPECGKSFSDCRDLARHQRTHTGGGGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASINESTGKP QMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYMGL TSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNI DMCRSCF* SEQ ID NO: 573: E2C LR V390 R372A – nucleotide sequence (has a 4x glycine-glycine-serine linker on the left and right (LR) side of the zinc finger) ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAA ACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATC GTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTGCTGAAGAACAGCCGGAGCAGACCTGTCGGTGGATC CGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAAATCCT TCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAATGCGGA AAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGCCCCGA GTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGGTGGTT CAGGTGGCAGCGGAGGGTCAGGAGGCTCTGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTAC AAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAA GCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCT GTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATC ATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGG ACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATA TTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACT TATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAA CATTGATATGTGCCGGTCCTGTTTTTGA SEQ ID NO: 574: E2C LR V390 R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTI VGTVASNKREIPEVLKNSRSRPVGGSGGSGGSGGSLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECG KSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGSGGSGGSGGSGTSMFCFDGPLTLVSY KPKPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFI IYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCT YCPSKIRRKASASCKKCKKVICREHNIDMCRSCF* SEQ ID NO: 575: del74 V390 E2C R372A – nucleotide sequence ATGTCTAGTCTGGCTTCCAATAGGAACCTGACACTGCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAG CACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCGCCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGT GCCGAAATATCTACGACCCCCTGCTGTGCTTTAAGCTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGG ACTAACGCAGAGATTTCACTGAAAAGGCGCGAATCTATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAAT CTACGCTTTCTTTGGCATTCTGGTCATGACCGCAGTGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATC GCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGCAGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGAC GATAAGAGCATTCGACCTACACTGCGGGAGAATGACGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCA CCAGTGTATTCAGAACTACACACCCGGAGCCCATCTGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCC CTTTTCGCGTATACATTCCAAATAAGCCCAGCAAATATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAA TACATGATCAACGGAATGCCATATCTGGGACGGGGCACCCAGACAAATGGAGTCCCCCTGGGCGAGTACTATGTGAA GGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGCCA AGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAGTG CTGAAGAACAGCCGGAGCAGACCTGTCGGAGGTCTCGAACCAGGCGAGAAGCCTTATGCCTGTCCTGAGTGTGGCAA ATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAACCCTATAAATGCCCCGAAT GCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGGCGAGAAACCATATAAGTGC CCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACACATACAGGCAAGAAGACCGG AGGTGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTACAAGCCCAAACCTGCTAAAATGGTGT ATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAAGCCCCAGATGGTCATGTACTATAAC CAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCTGTAGTAGAAAGACAAACAGGTGGCC TATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATCATCTACAGCCACAACGTGTCCTCTA AGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGGACTGACCAGTAGCTTCATGAGGAAG CGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATATTCTGCCTAAGGAAGTGCCAGGCAC TTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACTTATTGTCCCAGCAAGATCCGACGGA AAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAACATTGATATGTGCCAGTCCTGTTTT ACTAGCGATGATTCCACTGAAGAGCCTGTAATGAAGAAAAGAACTTACTGCACATACTGCCCTTCCAAGATAAGGCG AAAGGCGAGCGCATCCTGTAAGAAATGCAAGAAGGTTATTTGTAGAGAGCATAATATAGATATGTGCCAGAGCTGCT TCTGA SEQ ID NO: 576: del74 V390 E2C R372A – amino acid sequence MSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFKLFFTDEIISEIVKW TNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMSRDRFDFLIRCLRMD DKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSKYGIKILMMCDSGTK YMINGMPYLGRGTQTNGVPLGEYYVKELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEV LKNSRSRPVGGLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKC PECGKSFSDCRDLARHQRTHTGKKTGGGTSMFCFDGPLTLVSYKPKPAKMVYLLSSCDEDASINESTGKPQMVMYYN QTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFIIYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRK RLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNIDMCQSCF TSDDSTEEPVMKKRTYCTYCPSKIRRKASASCKKCKKVICREHNIDMCQSCF* SEQ ID NO: 577: G321 E2C LR R372A – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCTCTAGTCTGGCTTCCAATAGGAACCTGACACT GCCACAGCGAACTATTCGGGGCAAGAACAAGCACTGCTGGAGCACCTCCAAGCCTACACGGAGAAGCCGCGCGTCCG CCCTGAACATCGTGAGATCCCAGAGGGGGCCAACCCGCATGTGCCGAAATATCTACGACCCCCTGCTGTGCTTTAAG CTGTTCTTTACAGATGAGATCATTAGTGAAATCGTGAAGTGGACTAACGCAGAGATTTCACTGAAAAGGCGCGAATC TATGACTAGTGCCACCTTCAGAGACACAAATGAGGATGAAATCTACGCTTTCTTTGGCATTCTGGTCATGACCGCAG TGAGGAAGGACAACCATATGTCTACAGACGATCTGTTTGATCGCTCTCTGAGTATGGTGTATGTCTCAGTGATGAGC AGAGACAGGTTCGATTTTTTGATCCGGTGCCTGAGAATGGACGATAAGAGCATTCGACCTACACTGCGGGAGAATGA CGTGTTCACCCCAGTGAGGAAAATCTGGGATCTGTTTATCCACCAGTGTATTCAGAACTACACACCCGGAGCCCATC TGACTATCGACGAACAGCTGCTGGGCTTCCGCGGGCGATGCCCTTTTCGCGTATACATTCCAAATAAGCCCAGCAAA TATGGCATCAAGATTCTGATGATGTGCGATTCCGGGACCAAATACATGATCAACGGAATGCCATATCTGGGACGGGG CACCCAGACAAATGGAGGTGGATCCGGAGGGTCCGGAGGTAGTGGCGGCAGCCTCGAACCAGGCGAGAAGCCTTATG CCTGTCCTGAGTGTGGCAAATCCTTCTCAAGAAAAGACTCTCTGGTTAGACACCAGAGAACACATACAGGGGAGAAA CCCTATAAATGCCCCGAATGCGGAAAGTCCTTTTCCCAGAGCGGCGATCTCCGGAGGCATCAGAGAACTCATACAGG CGAGAAACCATATAAGTGCCCCGAGTGTGGGAAATCCTTTTCCGATTGTAGAGACCTGGCCAGACATCAAAGGACAC ATACAGGCAAGAAGACCGGTGGTTCAGGTGGCAGCGGAGGGTCAGGAGGCTCTGTCCCCCTGGGCGAGTACTATGTG AAGGAACTGTCCAAACCTGTCCACGGGTCTTGCAGAAACATCACCTGTGACAATTGGTTCACATCTATTCCCCTGGC CAAGAACCTGCTGCAGGAGCCTTATAAACTGACTATCGTCGGAACCGTGGCCAGCAACAAGAGGGAGATTCCCGAAG TGCTGAAGAACAGCCGGAGCAGACCTGTCGGCACTTCTATGTTCTGCTTTGACGGGCCACTGACCCTGGTGAGTTAC AAGCCCAAACCTGCTAAAATGGTGTATCTGCTGTCAAGCTGTGACGAGGATGCAAGCATCAATGAATCCACCGGCAA GCCCCAGATGGTCATGTACTATAACCAGACTAAAGGCGGGGTGGATACCCTGAATCAGATGTGCTCTGTCATGACCT GTAGTAGAAAGACAAACAGGTGGCCTATGGCCCTGCTGTACGGGATGATCAACATTGCTTGCATTAATTCATTCATC ATCTACAGCCACAACGTGTCCTCTAAGGGGGAGAAAGTCCAGTCCCGCAAGAAATTCATGCGAAATCTGTACATGGG ACTGACCAGTAGCTTCATGAGGAAGCGCCTGGAGGCACCCACACTGAAAAGGTATCTGCGCGACAACATCAGCAATA TTCTGCCTAAGGAAGTGCCAGGCACTTCCGACGATTCTACCGAGGAACCAGTGATGAAGAAACGGACATACTGCACT TATTGTCCCAGCAAGATCCGACGGAAAGCCTCCGCTTCTTGCAAGAAGTGTAAGAAAGTGATCTGTAGAGAGCATAA CATTGATATGTGCCGGTCCTGTTTTTGA SEQ ID NO: 578: G321 E2C LR R372A – amino acid sequence MPKKKRKVYPYDVPDYAGSGSSLDDEHILSALLQSDDELVGEDSDSEVSDHVSEDDVQSDTEEAFIDEVHEVQPTSS GSEILDEQNVIEQPGSSLASNRNLTLPQRTIRGKNKHCWSTSKPTRRSRASALNIVRSQRGPTRMCRNIYDPLLCFK LFFTDEIISEIVKWTNAEISLKRRESMTSATFRDTNEDEIYAFFGILVMTAVRKDNHMSTDDLFDRSLSMVYVSVMS RDRFDFLIRCLRMDDKSIRPTLRENDVFTPVRKIWDLFIHQCIQNYTPGAHLTIDEQLLGFRGRCPFRVYIPNKPSK YGIKILMMCDSGTKYMINGMPYLGRGTQTNGGGSGGSGGSGGSLEPGEKPYACPECGKSFSRKDSLVRHQRTHTGEK PYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGKKTGGSGGSGGSGGSVPLGEYYV KELSKPVHGSCRNITCDNWFTSIPLAKNLLQEPYKLTIVGTVASNKREIPEVLKNSRSRPVGTSMFCFDGPLTLVSY KPKPAKMVYLLSSCDEDASINESTGKPQMVMYYNQTKGGVDTLNQMCSVMTCSRKTNRWPMALLYGMINIACINSFI IYSHNVSSKGEKVQSRKKFMRNLYMGLTSSFMRKRLEAPTLKRYLRDNISNILPKEVPGTSDDSTEEPVMKKRTYCT YCPSKIRRKASASCKKCKKVICREHNIDMCRSCF* SEQ ID NO: 579: K409 E2C LR pB – nucleotide sequence ATGCCGAAAAAAAAACGAAAGGTGTACCCCTACGATGTACCGGACTATGCAGGAAGCGGGTCTTCACTGGACGATGA GCATATTCTGAGCGCCCTGCTGCAGAGCGATGACGAGCTGGTGGGAGAGGATTCCGATTCCGAGGTCAGTGACCACG TGTCAGAGGACGATGTGCAGAGCGACACTGAGGAAGCCTTCATCGATGAGGTCCATGAAGTGCAGCCAACAAGCTCC GGAAGCGAGATCCTGGATGAACAGAACGTGATTGAACAGCCTGGCT...
Claims
CLAIMS What is claimed is:
1. A composition comprising a transposase enzyme or a nucleic acid encoding the enzyme, wherein the enzyme comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions N374X, K375X, R315X, L324X, N347X, R372X, S373X, R376X, E377X, K409X, and K412X of SEQ ID NO: 1, or a substitution at a position corresponding thereto.
2. The composition of claim 1, wherein X is selected from a non-polar amino acid, optionally selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P), methionine (M), tryptophan (W), and phenylalanine (F), or a polar amino acid, optionally selected from serine (S), cysteine (C), asparagine (N), glutamine (Q), threonine (T), and tyrosine (Y), or a basic amino acid, optionally selected from arginine (R), and histidine (H), or an acidic amino acid, optionally selected from aspartic acid (D), and glutamic acid (E), or a positively charged hydrophilic amino acid, optionally selected from lysine (K), arginine (R), and histidine (H).
3. The composition of claims 1 or 2, wherein the enzyme comprises one, or two, or three, or four, or five substitutions selected from N374A, K375A, R274A, R274S, R274K, R274D, R315A, R315K, R315S, R315E, R315Q, R315G, R315L, R315H, R315F, R315Y, L324A, D346A, N347A, N347D, R372A, R372K, R372H, R372S, R372Q, S373A, S373K, S373H, S373E, S373D, S373Q, S373G S373F, S373Y, S373L, S373R, N374S, N374K, N374H, N374E, N374Q, N374G, N374F, N374Y, N374L, N374W, K375S, K375Q, K375H, K375L, K375W, K375G, K375E, K375F, K375Y, R376A, R376K, R376E, R376S, R376Q, R376G, R376A, R376L, R376H, E377A, K409A, K409R, K409S, A411D, A411K, A411R, A411S, K412R, R459A, R459S, R459K, R459D, K460A, K460S, K460K, K460D, N462A, N462S, N462K, N462D, or substitutions corresponding thereto relative to SEQ ID NO:
1.
4. The composition of any one of claims 1-3, wherein the enzyme further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten substitutions at positions 374, 375, 30, 82, 103, 109, 165, 189, 191, 198, 201, 274, 282, 312, 313, 314, 315, 316, 321, 324, 346, 347, 362, 369, 370, 371, 372, 373, 376, 377, 378, 379, 380, 387, 388, 390, 400, 409, 411, 412, 425, 428, 450, 459, 460, 462, 500, 504, 509, 538, 571, and / or 591 or substitutions at positions corresponding thereto relative to SEQ ID NO:
1.
5. The composition of any one of claims 1-4, wherein the enzyme further comprises at least one, two, three, four, five, six, seven, eight, nine, or ten, or eleven, or twelve substitutions selected from I30V, I82N, S103P, V109A, G165S, M282V, Y312A, D450N, S509G, N538K, N571S, and Q591R or substitutions corresponding thereto relative to SEQ ID NO: 1.
6. The composition of any one of claims 1-5, wherein the enzyme comprises a substitution selected from Table 3, 4, and / or 13 or a substitution corresponding thereto relative to SEQ ID NO:
1.
7. The composition of any one of claims 1-6, wherein the enzyme further comprises a SV40 nuclear localization signal.
8. The composition of claim 7, wherein the SV40 nuclear localization signal comprises an amino acid sequence of PKKKRKVYPYDVPDYAGS (SEQ ID NO: 656) or a variant thereof having a substitution or deletion.
9. The composition of claim 7 or 8, wherein the SV40 nuclear localization signal is inserted immediately after residue M1 relative to SEQ ID NO:
1.
10. The composition of any one of claims 1-8, wherein the enzyme further comprises an epitope tag, optionally wherein the epitope tag comprises a human influenza hemagglutinin (HA) tag or ALFA tag.
11. The composition of any one of claims 1-10, wherein the enzyme comprises a deletion of about 30, or about 40, or about 50, or about 60, or about 70, or about 80, or about 90, or about 100 amino acids from an N-terminus or a C-terminus.
12. The composition of claim 11, wherein the enzyme comprises a deletion of about 74 amino acids from the N- terminus.
13. The composition of any one of claims 1-12, wherein the enzyme comprises a deletion at positions about 1-35, or about 1-45, or about 1-55, or about 1-65, or about 1-75, or about 1-85, or about 1-95, or about 1-105 or positions corresponding thereto, wherein the positions are relative to SEQ ID NO:
1.
14. The composition of any one of claims 1-13, wherein the enzyme comprises a duplication of the C-terminal domain relative to SEQ ID NO:1, wherein the C-terminal domain comprises residues 542-594 relative to SEQ ID NO:
1.
15. The composition of any one of claims 1-14, wherein the enzyme is able to cause excision of a nucleic acid.
16. The composition of any one of claims 1-15, wherein the enzyme has increased excision activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof.
17. The composition of any one of claims 1-16, wherein the enzyme has reduced or ablated integration activity relative to an enzyme comprising an amino acid sequence of SEQ ID NO: 1 or functional equivalent thereof.
18. The composition of any one of claims 1-17, wherein the enzyme comprises a targeting element.
19. The composition of any one of claims 1-18, wherein the enzyme is capable of inserting a transposon, transgene and / or cargo nucleic acid comprising a transgene in a genomic safe harbor site (GSHS).
20. The composition of claims 18 or 19, wherein the targeting element is able to direct a transposition machinery to the GSHS of a nucleic acid molecule in a mammalian cell.
21. The composition of claims 19 or 20, wherein the GSHS is in an open chromatin location in a chromosome.
22. The composition of any one of claims 19-21, wherein the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus.
23. The composition of any one of claims 19-22, wherein the GSHS comprises one or more TTAA integration sites.
24. The composition of claim 23, wherein the targeting element directs the helper enzyme to either one or more nucleic acid binding sites that are upstream and / or downstream of the TTAA integration sites or to the TTAA integration sites.
25. The composition of claim 23, wherein the targeting element directs the helper enzyme to one or more nucleic acid binding sites that are upstream and / or downstream of the TTAA integration sites and within about 5 to about 30 base pairs of the TTAA integration sites or within about 11 to about 15 base pairs of the TTAA integration sites.
26. The composition of claim 23, wherein the targeting element directs the helper enzyme to two nucleic acid binding sites of the TTAA integration sites, wherein a first site is upstream of TTAA and within about 5 to about 30 base pairs or about 11 to about 15 base pairs of the TTAA and a second site is downstream of TTAA and within about 5 to about 30 base pairs or about 11 to about 15 base pairs of the TTAA.
27. The composition of any one of claims 19-22, wherein the GSHS is an adeno-associated virus site 1 (AAVS1).
28. The composition of any one of claims 19-22, wherein the GSHS is a human Rosa26 locus.
29. The composition of any one of claims 19-28, wherein the GSHS is located on human chromosome 2, 4, 6, 10, 11, 17, or 22.
30. The composition of any one of claims 19-29, wherein the GSHS is selected from TALC1, TALC2, TALC3, TALC4, TALC5, TALC7, TALC8, AVS1, AVS2, AVS3, ROSA1, ROSA2, TALER1, TALER2, TALER3, TALER4, TALER5, SHCHR2-1, SHCHR2-2, SHCHR2-3, SHCHR2-4, SHCHR4-1, SHCHR4-2, SHCHR4-3, SHCHR6-1, SHCHR6-2, SHCHR6-3, SHCHR6-4, SHCHR10-1, SHCHR10-2, SHCHR10-3, SHCHR10-4, SHCHR10-5, SHCHR11-1, SHCHR11-2, SHCHR11-3, SHCHR17-1, SHCHR17-2, SHCHR17-3, and SHCHR17-4.
31. The composition of any one of claims 19-30, wherein the targeting element comprises one or more of a Cas enzyme, which is optionally catalytically inactive and which is optionally associated with a guide RNA (gRNA), transcription activator-like effector (TALE) DNA binding domain (DBD), Zinc finger, catalytically inactive transcription factor, catalytically inactive nickase, a transcriptional activator, a transcriptional repressor, arecombinase, a DNA methyltransferase, a histone methyltransferase, and a paternally expressed gene 10 (PEG10).
32. The composition of claim 31, wherein the targeting element comprises a Zinc finger.
33. The composition of claim 32, wherein the Zinc finger comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 568 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 567 or a codon- optimized form thereof.
34. The composition of claim 31, wherein the targeting element comprises a TALE DBD.
35. The composition of claim 34, wherein the TALE DBD comprises one or more repeat sequences.
36. The composition of claim 35, wherein the TALE DBD comprises about 14, or about 15, or about, 16, or about 17, or about 18, or about 18.5 repeat sequences.
37. The composition of claim 35 or claim 36, wherein the repeat sequences each independently comprises about 33 or 34 amino acids.
38. The composition of claim 37, wherein the repeat sequences each independently comprises a repeat variable di- residue (RVD) at residue 12 or 13 of the 33 or 34 amino acids, respectively.
39. The composition of claim 38, wherein the RVD recognizes one base pair in a target nucleic acid sequence.
40. The composition of claim 38 or claim 39, wherein the RVD recognizes a C residue in the target nucleic acid sequence and is selected from HD, N(gap), HA, ND, and HI.
41. The composition of claim 38 or claim 39, wherein the RVD recognizes a G residue in the target nucleic acid sequence and is selected from NN, NH, NK, HN, and NA.
42. The composition of claim 38 or claim 39, wherein the RVD recognizes an A residue in the target nucleic acid sequence and is selected from NI and NS.
43. The composition of claim 38 or claim 39, wherein the RVD recognizes a T residue in the target nucleic acid sequence and is selected from NG, HG, H(gap), and IG.
44. The composition of claim 18, wherein the targeting element comprises a Cas9 enzyme associated with a gRNA or a CasX enzyme associated with a gRNA.
45. The composition of claim 44, wherein the Cas9 enzyme associated with a gRNA comprises a catalytically inactive dCas9 associated with a gRNA or the CasX enzyme associated with a gRNA comprises a catalytically inactive dCasX associated with a gRNA.
46. The composition of claim 45, wherein catalytically inactive dCas9 comprises at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identity to an amino acid sequence of SEQ ID NO: 9 or a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 10 or a codon-optimized form thereof.
47. The composition of claims 44 or 45, wherein the targeting element comprises a CasX enzyme associated with a gRNA, optionally wherein the catalytic inactive dCasX.
48. The composition of claim 14, wherein the targeting element comprises a Cas12 enzyme associated with a gRNA.
49. The composition of claim 48, wherein the targeting element comprises a catalytically inactive Cas12 associated with a gRNA, optionally wherein the catalytically inactive Cas12 is dCas12j or dCas12a.
50. The composition of any one of claims 18-49, wherein the targeting element comprises a nucleic acid binding component of a gene-editing system.
51. The composition of any one of claims 1-50, wherein the composition comprises a linker connecting the enzyme and the targeting element.
52. The composition of claim 51, wherein the linker is a covalent linker or a non-covalent linker.
53. The composition of claim 51, wherein the linker is a flexible linker.
54. The composition of claim 51, wherein the flexible linker is substantially comprised of glycine and serine residues, optionally wherein the flexible linker comprises (Gly4Ser)n, where n is an integer from 1-12.
55. The composition of claim 51, wherein the flexible linker is a glycine-glycine linker.
56. The composition of claim 51, wherein the flexible linker is or comprises about 20, or about 30, or about 40, or about 50, or about 60 amino acid residues.
57. The composition of claim 51, wherein the linker comprises an amino acid sequence of AKLAGGAPAVGGGPKAADKFAATGGS (SEQ ID NO: 3) or a variant thereof having a substitution or deletion.
58. The composition of any one of claims 51-57, wherein the linker connects the targeting element to the N-terminus of the helper enzyme or connects the targeting element within the helper enzyme.
59. The composition of claim 52, wherein the linker is a non-covalent linker.
60. The composition of claim 59, wherein the non-covalent linker comprises an epitope tag, optionally wherein the epitope tag comprises an ALFA tag.
61. The composition of claim 60, wherein the ALFA tag further comprises recombinant variable domains of heavy- chain-only antibodies (VHH) (NANOBODY).
62. The composition of any one of claims 51-61, wherein the linker is inserted after a residue selected from V390, R315, T319, N320, G321, V322, P323, L324, R376, K383, N384, S385, R386, S387, R388, P389, G391, T392, S393, K407, P408, K409, P410, A411, K412, M413, or E428 relative to SEQ ID NO:
1.
63. The composition of claim 45, wherein the enzyme is directly fused to the N-terminus of a dCas9 enzyme.
64. The composition of any one of claims 1-63, wherein the enzyme or variant thereof is able to directly or indirectly cause transposition of a target gene or nucleic acid cargo.
65. The composition of any one of claims 1-64, wherein the enzyme or variant thereof is able to directly or indirectly interact and / or form a complex with one or more proteins or nucleic acids.
66. The composition of any one of claims 1-65, further comprising a nucleic acid encoding a transposon or transgene to be integrated or inserted into a nucleic acid.
67. The composition of claim 66, wherein the transposon, transgene and / or cargo nucleic acid comprises a first and a second transposon end sequences.
68. The composition of claim 67, wherein the transposon, transgene and / or cargo nucleic acid is flanked by the first and the second transposon end sequences.
69. The composition of claims 67 or 68, wherein the transposon end sequences are selected from nucleotide sequences of SEQ ID NO: 5 and / or SEQ ID NO: 6, or a nucleotide sequence having at least about 90% identity thereto.
70. The composition of any one of claims 67-69, wherein the end sequences comprise at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO:
5.
71. The composition of claim 70, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 5 is positioned at the 5’ end of the transposon, transgene and / or nucleic acid.
72. The composition of any one of claims 67-71, wherein the end sequences further comprise at least one repeat from a nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO:
6.
73. The composition of any one of claims 70-72, wherein the at least one repeat from the nucleotide sequence having at least about 90% identity to the nucleotide sequence of SEQ ID NO: 6 is positioned at the 3’ end of the transposon, transgene and / or nucleic acid.
74. The composition of any one of claims 1-73, wherein the enzyme or variant thereof is incorporated into a vector or a vector-like particle.
75. The composition of any one of claims 1-74, wherein the vector or a vector-like particle comprises one or more expression cassettes.
76. The composition of claim 75, wherein the vector or a vector-like particle comprises one expression cassette.
77. The composition of claim 76, wherein the expression cassette further comprises the enzyme or variant thereof, the transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof.
78. The composition of claim 77, wherein the enzyme or variant thereof, the transposon, transgene and / or nucleic acid, the transposon end sequences, or a combination thereof are incorporated into one or more vectors or vector- like particles.
79. The composition of claim 77, wherein the enzyme or variant thereof, the transposon, transgene and / or nucleic acid, the transposon end sequences, or combination thereof are incorporated into a same vector or vector-like particle.
80. The composition of claim 77, wherein the enzyme or variant thereof, the transposon, transgene and / or nucleic acid, the transposon end sequences, or combination thereof is incorporated into different vectors vector-like particles.
81. The composition of claim of any one of claims 74-80, wherein the vector or vector-like particle is nonviral.
82. The composition of any one of claims 1-81, wherein the composition comprises DNA, RNA, or both.
83. The composition of any one of claims 1-82, wherein the enzyme or variant thereof is in the form of RNA.
84. The composition of claim 1-83, wherein the RNA is or comprises messenger RNA (mRNA).
85. The composition of claim 1-84, wherein the mRNA is or comprises modified mRNA (mmRNA).
86. The composition of claim 1-85, wherein the mmRNA comprises one or more of a 5’-m7G cap (cap0, cap1, or cap2), a pseudouridine or n-methyl-pseudouridine substitution, and a poly-A tail of about 30, or of about 50, or of about 100, or of about 150 nucleotides in length.
87. The composition of any one of claims 1-86, wherein the transposon, transgene and / or nucleic acid is in the form of DNA.
88. A host cell comprising the composition any one of claims 1-87.
89. The composition of any one of claims 1-87, wherein the composition is encapsulated in a lipid nanoparticle (LNP).
90. The composition of any one of claims 1-87, wherein the polynucleotide encoding the enzyme or variant thereof and the polynucleotide encoding the transposon are in the form of the same LNP, optionally in a co-formulation.
91. The composition of claim 89 or claim 90, wherein the LNP comprises one or more lipids selected from 1,2-dioleoyl- 3-trimethylammonium propane (DOTAP), a cationic cholesterol derivative mixed with dimethylaminoethane- carbamoyl (DC-Chol), phosphatidylcholine (PC), triolein (glyceryl trioleate), and 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG), 1,2-dimyristoyl-rac-glycero-3- methoxypolyethyleneglycol – 2000 (DMG-PEG 2K), and 1,2 distearol -sn-glycerol-3phosphocholine (DSPC) and / or comprising of one or more molecules selected from polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), and N-Acetylgalactosamine (GalNAc).
92. A method for inserting a gene into the genome of a cell, comprising contacting a cell with the composition of any one of claims 1-87, or 89-91, or host cell of claim 88.
93. The method of claim 92, further comprising contacting the cell with a polynucleotide encoding a transposon, transgene, and / or nucleic acid.
94. The method of claim 92 or claim 93, wherein the transposon, transgene, and / or nucleic acid comprises a gene encoding a complete polypeptide.
95. The method of any one of claims 92-94, wherein the transposon, transgene, and / or nucleic acid comprises a gene which is defective or substantially absent in a disease state.
96. A method for treating a disease or disorder ex vivo, comprising contacting a cell with the composition of any one of claims 1-87, or 89-91, or host cell of claim 88 and administering the cell to a subject in need thereof.
97. A method for treating a disease or disorder in vivo, comprising administering the composition of any one of claims 1-87, or 89-91, or host cell of claim 88 to a subject in need thereof.
98. A composition comprising a transposase enzyme or a nucleic acid encoding the enzyme, wherein the enzyme comprises an amino acid sequence having at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 85% or a sequence identity to SEQ ID NO: 1, and wherein the enzyme comprises at least one amino acid substitution at positions shown in any one of FIG.3, FIG.4, FIG.5, FIG.6, FIG.7, FIG.8, FIG.9, FIG.10, FIG.11, FIG.12, FIG. 13, FIG.14, FIG.15, FIG.16, FIG.17, FIG.18, FIG.19A, FIG.20, FIG.21, TABLE 3, TABLE 4, or TABLE 13 of SEQ ID NO: 1, or a substitution at a position corresponding thereto.
Citation Information
Patent Citations
Piggybac transposon variants and methods of use
US20170226531A1
Transposase with enhanced insertion site selection properties
US20220090142A1
Transposition-based therapies
US20220243227A1
Transposition-based therapies
WO2021226141A1
